Document:

EX-10.1

 Exhibit 10.1 

CREDIT, GUARANTY AND SECURITY AGREEMENT 

THIS CREDIT, GUARANTY AND SECURITY AGREEMENT (this “Agreement”), dated as of December 6, 2013 (the
“Closing Date”), by and among MIDCAP FUNDING V, LLC, a Delaware limited liability company (“MidCap”), as administrative agent (together with its successors and assigns, “Agent”), the
Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from time to time (each a “Lender”, and collectively the “Lenders”), QUOTIENT BIODIAGNOSTICS, INC., a Delaware
corporation (“Borrower”), the other Credit Parties listed on the signature pages hereof, provides the terms on which Lenders shall lend to Borrower and Borrower shall repay Lenders. The parties agree as follows: 

 

	 	1	ACCOUNTING AND OTHER TERMS 

 Accounting terms not defined in this Agreement shall
be construed in accordance with GAAP. Calculations and determinations must be made in accordance with GAAP. Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 16. All other terms contained in
this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein. All headings numbered without a decimal point are herein referred to as “Articles,” and all paragraphs
numbered with a decimal point (and all subparagraphs or subsections thereof) are herein referred to as “Sections.” 
  

	 	2	CREDIT FACILITIES AND TERMS 

 2.1 Promise to Pay. Borrower hereby
unconditionally promises to pay to each Lender in accordance with each Lender’s respective Pro Rata Share of each Credit Facility, the outstanding principal amount of all Credit Extensions made by the Lenders under such Credit Facility and
accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement. 
 2.2 Credit
Facilities. Subject to the terms and conditions hereof, each Lender, severally, but not jointly, agrees to make available to Borrower Credit Extensions in respect of each Credit Facility set forth opposite such Lender’s name on the Credit
Facility Schedule, in each case not to exceed such Lender’s commitment as identified on the Credit Facility Schedule (such commitment of each Lender, as it may be amended to reflect assignments made in accordance with this Agreement or
terminated or reduced in accordance with this Agreement, its “Applicable Commitment”, and the aggregate of all such commitments, the “Applicable Commitments”). 

2.3 Term Credit Facilities. 

(a) Nature of Credit Facility; Credit Extension Requests. For any Credit Facility identified on the Credit Facility Schedule as a term
facility (a “Term Credit Facility”), Credit Extensions in respect of a Term Credit Facility may be requested by Borrower during the Draw Period for such Term Credit Facility. For any Credit Extension requested under a Term Credit
Facility (other than a Credit Extension on the Closing Date), Agent must receive the completed Credit Extension Form by 12:00 noon (New York time) three (3) Business Days prior to the date of the Credit Extension is to be funded. To the extent
any Term Credit Facility proceeds are repaid for any reason, whether voluntarily or involuntarily (including repayments from insurance or condemnation proceeds), Agent and Lenders shall have no obligation to re-advance such sums to Borrower. 

(b) Principal Payments. Principal payable on account of a Term Credit Facility shall be payable by Borrower to Agent immediately upon
the earliest of (i) the date(s) set forth in the Amortization Schedule for such Term Credit Facility, or (ii) the Maturity Date. Except as this Agreement may specifically provide otherwise, all prepayments of Credit Extensions under Term
Credit Facilities shall be applied by Agent to the applicable Term Credit Facility in inverse order of maturity. The monthly payments required under the Amortization Schedule shall continue in the same amount (for so long as the applicable Term
Credit 
  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	
 1
	  	

 Facility shall remain outstanding) notwithstanding any partial prepayment, whether mandatory or optional, of the
applicable Term Credit Facility. 
 (c) Mandatory Prepayment. If a Term Credit Facility is accelerated following the occurrence of an
Event of Default, Borrower shall immediately pay to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of: (i) all outstanding principal of the Term Credit Facility and all other
Obligations, plus accrued and unpaid interest thereon, (ii) any fees payable under the Fee Letters by reason of such prepayment, (iii) the Applicable Prepayment Fee as specified in the Credit Facility Schedule for the Credit Facility being
prepaid, and (iv) all other sums that shall have become due and payable, including Protective Advances. Additionally, at the election of Agent, Borrower shall prepay the Term Credit Facilities (to be allocated pro rata among the outstanding
Credit Extensions under all Term Credit Facilities) in the following amounts: (A) on the date on which any Credit Party (or Agent as loss payee or assignee) receives any casualty proceeds in excess of One Hundred Thousand Dollars ($100,000) for
personal property, or in excess of One Hundred Fifty Thousand Dollars ($150,000) for real property, in respect of assets upon which Agent maintained a Lien, an amount equal to one hundred percent (100%) of such proceeds (net of out-of-pocket
expenses and, in the case of personal property, repayment of any permitted purchase money debt encumbering the personal property that suffered such casualty), or such lesser portion of such proceeds as Agent shall elect to apply to the Obligations;
and (B) upon receipt by any Credit Party of the proceeds of any asset disposition of personal property not made in the Ordinary Course of Business (other than transfers permitted by Section 7.1) and resulting in net cash proceeds in excess
of One Hundred Thousand Dollars ($100,000) an amount equal to one hundred percent (100%) of the net cash proceeds of such asset disposition (net of out-of-pocket expenses and repayment of any permitted purchase money debt encumbering such
asset), or such lesser portion as Agent shall elect to apply to the Obligations. Notwithstanding the foregoing, (a) so long as no Default or Event of Default has occurred and is continuing, Borrower shall have the option of applying the
proceeds of any casualty policy up to $500,000 in the aggregate with respect to any property loss in any one year, toward the replacement or repair of destroyed or damaged property; provided that any such replaced or repaired property (x) shall
be of equal or like value as the replaced or repaired Collateral and (y) shall be deemed Collateral in which Agent and Lenders have been granted a first priority security interest, and (b) after the occurrence and during the continuance of
a Default or Event of Default, all proceeds payable under such casualty policy shall, at the option of Agent, be payable to Agent, for the ratable benefit of the Lenders, on account of the Obligations. 

(d) Permitted Prepayment. Except as provided below, Borrower shall have no right to prepay the Credit Extensions made in respect of a
Term Credit Facility. Borrower shall have the option to prepay the Prepayable Amount (as defined below) of a Term Credit Facility advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Agent of its
election to prepay the Prepayable Amount at least fifteen (15) days prior to such prepayment, and (ii) pays to Agent, for payment to each Lender in accordance with its respective Pro Rata Share, on the date of such prepayment, an amount
equal to the sum of (A) the Prepayable Amount, plus accrued interest thereon, (B) any fees payable under the Fee Letters by reason of such prepayment, (C) the Applicable Prepayment Fee as specified in the Credit Facility Schedule for
the Credit Facility being prepaid, and (D) all Protective Advances. The term “Prepayable Amount” means all, but not less than all, of the Credit Extensions and all other Obligations under all Term Credit Facilities. 

2.4 Reserved. 
 2.5
Reserved. 
 2.6 Interest and Payments; Administration. 

(a) Interest; Computation of Interest. Each Credit Extension shall bear interest on the outstanding principal amount thereof from the
date when made until paid in full at a rate per annum equal to the Applicable Interest Rate. Each Lender may, upon the failure of Borrower to pay any fees or interest as required herein, capitalize such interest and fees and begin to accrue interest
thereon until paid in full, which 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	2	  	

 
such interest shall be at a rate per annum equal to the Applicable Interest Rate unless and until the Default Rate shall otherwise apply. All other Obligations shall bear interest on the
outstanding amount thereof from the date they first become payable by Borrower under the Financing Documents until paid in full at a rate per annum equal to the Applicable Interest Rate unless and until the Default Rate shall otherwise apply.
Interest on the Credit Extensions and all fees payable under the Financing Documents shall be computed on the basis of a 360-day year and the actual number of days elapsed in the period during which such interest accrues. In computing interest on
any Credit Extension or other advance, the date of the making of such Credit Extension or advance shall be included and the date of payment shall be excluded; provided, however, that if any Credit Extension or advance is repaid on the same day on
which it is made, such day shall be included in computing interest on such Credit Extension or advance. As of each Applicable Interest Rate Determination Date, Agent shall determine (which determination shall, absent manifest error in calculation,
be final, conclusive and binding upon all parties) the interest rate that shall apply to the Credit Extensions. 
 (b) Default Rate.
Upon the election of Agent following the occurrence and during the continuance of an Event of Default, Obligations shall bear interest at a rate per annum which is four hundred basis points (4.00%) above the rate that is otherwise applicable
thereto (the “Default Rate”). Payment or acceptance of the increased interest rate provided in this subsection is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default
or otherwise prejudice or limit any rights or remedies of Agent or Lenders. 
 (c) Payments Generally. All payments in respect of the
Obligations shall be made to Agent for the account of the applicable Lenders in accordance with their Pro Rata Share. All Obligations are payable upon demand of Agent in the absence of any other due date specified herein. All fees payable under the
Financing Documents shall be deemed non-refundable as of the date paid. Any payment required to be made to Agent or a Lender under this Agreement may be made by debit or automated clearing house payment initiated by Agent or such Lender from any of
Borrower’s deposit accounts, including the Designated Funding Account, and Borrower hereby authorizes Agent and each Lender to debit any such accounts for any amounts Borrower owes hereunder when due. Without limiting the foregoing, Borrower
shall tender to Agent and Lenders any authorization forms as Agent or any Lender may require to implement such debit or automated clearing house payment. These debits or automated clearing house payments shall not constitute a set-off. Payments of
principal and/or interest received after 12:00 noon New York time are considered received at the opening of business on the next Business Day. When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and
additional fees or interest, as applicable, shall continue to accrue until paid. All payments to be made by Borrower under any Financing Document shall be made without set-off, recoupment or counterclaim, in lawful money of the United States and in
immediately available funds. The balance of the Obligations, as recorded in Agent’s books and records at any time, shall be conclusive and binding evidence of the amounts due and owing to Agent and Lenders by Borrower absent manifest error;
provided, however, that any failure to so record or any error in so recording shall not limit or otherwise affect Borrower’s duty to pay all amounts owing hereunder or under any Financing Document. Agent shall endeavor to provide Borrower with
a monthly statement regarding the Credit Extensions (but neither Agent nor any Lender shall have any liability if Agent shall fail to provide any such statement). Unless Borrower notifies Agent of any objection to any such statement (specifically
describing the basis for such objection) within ninety (90) days after the date of receipt thereof, it shall be deemed final, binding and conclusive upon Borrower in all respects as to all matters reflected therein. 

(d) Interest Payments; Maturity Date. Commencing on the first (1st) Payment
Date following the funding of a Credit Extension, and continuing on the Payment Date of each successive month thereafter through and including the Maturity Date, Borrower shall make monthly payments of interest, in arrears, calculated as set forth
in this Section 2.6. All unpaid principal and accrued interest is due and payable in full on the Maturity Date or any earlier date specified herein. If the Obligations are not paid in full on or before the Maturity Date, all interest thereafter
accruing shall be payable immediately upon accrual. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	3	  	

 (e) Fees. Borrower shall pay, as and when due and payable under the terms of the Fee
Letters, to Agent and each Lender, for their own accounts and not for the benefit of any other Lenders, the fees set forth in the Fee Letters. 

(f) Protective Advances. Borrower shall pay to Agent for the account of Lenders all Protective Advances (including reasonable
attorneys’ fees and expenses for documentation and negotiation of this Agreement, the Warrants and the other Financing Documents) when due under any Financing Document (and in the absence of any other due date specified herein, such Protective
Advances shall be due upon demand). 
 (g) Maximum Lawful Rate. In no event shall the interest charged hereunder with respect to the
Obligations exceed the maximum amount permitted under the Laws of the State of Maryland. Notwithstanding anything to the contrary in any Financing Document, if at any time the rate of interest payable hereunder (the “Stated
Rate”) would exceed the highest rate of interest permitted under any applicable Law to be charged (the “Maximum Lawful Rate”), then for so long as the Maximum Lawful Rate would be so
exceeded, the rate of interest payable shall be equal to the Maximum Lawful Rate; provided, however, that if at any time thereafter the Stated Rate is less than the Maximum Lawful Rate, Borrower shall, to the extent permitted by Law, continue
to pay interest at the Maximum Lawful Rate until such time as the total interest received is equal to the total interest which would have been received had the Stated Rate been (but for the operation of this provision) the interest rate payable.
Thereafter, the interest rate payable shall be the Stated Rate unless and until the Stated Rate again would exceed the Maximum Lawful Rate, in which event this provision shall again apply. In no event shall the total interest received by any Lender
exceed the amount which it could lawfully have received, had the interest been calculated for the full term hereof at the Maximum Lawful Rate. If, notwithstanding the prior sentence, any Lender has received interest hereunder in excess of the
Maximum Lawful Rate, such excess amount shall be applied to the reduction of the principal balance of such Lender’s Credit Extensions or to other amounts (other than interest) payable hereunder, and if no such Credit Extensions or other amounts
are then outstanding, such excess or part thereof remaining shall be paid to Borrower. In computing interest payable with reference to the Maximum Lawful Rate applicable to any Lender, such interest shall be calculated at a daily rate equal to the
Maximum Lawful Rate divided by the number of days in the year in which such calculation is made. 
 (h) Taxes; Additional
Costs. 
 (i) All payments of principal and interest on the Obligations and all other amounts payable hereunder shall be made free and
clear of and without deduction for any present or future income, excise, stamp, documentary, payroll, employment, property or franchise taxes and other taxes, fees, duties, levies, assessments, withholdings or other charges of any nature whatsoever
(including interest and penalties thereon) imposed by any taxing authority, excluding taxes imposed on or measured by Agent’s, any Lender’s or any of their respective affiliates’ (including, without limitation, any direct or indirect
holders of equity therein) net income by the jurisdictions under which Agent, such Lender, or any of their respective affiliates (including, without limitation, any direct or indirect holders of equity therein) is organized or conducts business
(other than solely as the result of entering into any of the Financing Documents or taking any action thereunder) (all non-excluded items being called “Taxes”). If any withholding or deduction from any payment
to be made by any Credit Party hereunder is required in respect of any Taxes pursuant to any applicable Law, then such Credit Party will: (i) pay directly to the relevant authority the full amount required to be so withheld or deducted;
(ii) promptly forward to Agent an official receipt or other documentation satisfactory to Agent evidencing such payment to such authority; and (iii) pay to Agent for the account of Agent and Lenders such additional amount or amounts as is
necessary to ensure that the net amount actually received by Agent and each Lender will equal the full amount Agent and such Lender would have received had no such withholding or deduction been required. If any Taxes are directly asserted against
Agent, any Lender or any of their respective affiliates (including, without limitation, any direct or indirect holders of equity therein) with respect to any payment received by Agent or such Lender hereunder, Agent, such Lender or such affiliate
may pay such Taxes and Borrower will promptly pay such additional amounts (including any penalty, 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	4	  	

 
interest or expense) as is necessary in order that the net amount received by such Person after the payment of such Taxes (including any Taxes on such additional amount) shall equal the amount
such Person would have received had such Taxes not been asserted so long as such amounts have accrued on or after the day which is two hundred seventy (270) days prior to the date on which Agent or such Lender first made written demand
therefor. 
 (ii) If any Borrower fails to pay any Taxes when due to the appropriate taxing authority or fails to remit to Agent, for the
account of Agent and the respective Lenders, the required receipts or other required documentary evidence, Borrower shall indemnify Agent and Lenders for any incremental Taxes, interest or penalties that may become payable by Agent or any Lender as
a result of any such failure. 
 (iii) Each Lender that (A) is organized under the laws of a jurisdiction other than the United States,
and (B)(1) is a party hereto on the Closing Date or (2) purports to become an assignee of an interest as a Lender under this Agreement after the Closing Date (unless such Lender was already a Lender hereunder immediately prior to such
assignment) (each such Lender a “Foreign Lender”) shall execute and deliver to each of Borrower and Agent one or more (as Borrower or Agent may reasonably request) United States Internal Revenue Service Forms W-8ECI,
W-8BEN, W-8IMY (as applicable) and other applicable forms, certificates or documents prescribed by the United States Internal Revenue Service or reasonably requested by Agent certifying as to such Lender’s entitlement to a complete exemption
from withholding or deduction of Taxes. Borrower shall not be required to pay additional amounts to any Lender pursuant to this subsection (h) with respect to United States withholding and income Taxes to the extent that the obligation to pay
such additional amounts would not have arisen but for the failure of such Lender to comply with this paragraph other than as a result of a change in law. 

(iv) If any Lender shall determine in its commercially reasonable judgment that the adoption or taking effect of, or any change in, any
applicable Law regarding capital adequacy, in each instance, after the Closing Date, or any change after the Closing Date in the interpretation, administration or application thereof by any Governmental Authority, central bank or comparable agency
charged with the interpretation, administration or application thereof, or the compliance by any Lender or any Person controlling such Lender with any request, guideline or directive regarding capital adequacy (whether or not having the force of
law) of any such Governmental Authority, central bank or comparable agency adopted or otherwise taking effect after the Closing Date, has or would have the effect of reducing the rate of return on such Lender’s or such controlling Person’s
capital as a consequence of such Lender’s obligations hereunder to a level below that which such Lender or such controlling Person could have achieved but for such adoption, taking effect, change, interpretation, administration, application or
compliance (taking into consideration such Lender’s or such controlling Person’s policies with respect to capital adequacy) then from time to time, upon written demand by such Lender (which demand shall be accompanied by a statement
setting forth the basis for such demand and a calculation of the amount thereof in reasonable detail, a copy of which shall be furnished to Agent), Borrower shall promptly pay to such Lender such additional amount as will compensate such Lender or
such controlling Person for such reduction, so long as such amounts have accrued on or after the day which is two hundred seventy (270) days prior to the date on which such Lender first made demand therefor; provided, however, that
notwithstanding anything in this Agreement to the contrary, (A) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (B) all
requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case
pursuant to Basel III, shall in each case be deemed to be a “change in applicable Law”, regardless of the date enacted, adopted or issued. 

(v) (A) If any Lender requires compensation under this subsection (h), or requires Borrower to pay any additional amount to any Lender or any
Governmental Authority for the account of any Lender pursuant to this subsection (h), then, upon the written request of Borrower, such Lender shall use reasonable efforts to designate a different lending office for funding or booking its Credit
Extensions hereunder or to assign its rights and obligations hereunder (subject to the terms of this Agreement) to another 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	5	  	

 
of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (x) would eliminate or materially reduce amounts payable pursuant to any such
subsection, as the case may be, in the future, and (y) would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender (as determined in its sole discretion). Borrower hereby agrees to
pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment. 
 (B) If any Lender
(other than Midcap or its Affiliates) requires compensation under this subsection (h), or requires Borrower to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender (other than Midcap or its Affiliates)
pursuant to this subsection (h), and such Lender has declined or is unable to designate a different lending office in accordance with Section 2.6(h)(v)(A), then the Borrower may, at its sole expense and effort, upon notice to such Lender and
the Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 13.1), all of its interests, rights (other than its existing rights to
payments pursuant to this subsection (h)) and obligations under this Agreement and the related Financing Documents to an Eligible Assignee that shall assume such obligations; provided that: (x) such Lender shall have received payment of
an amount equal to the outstanding principal of its Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Financing Documents from the assignee (to the extent of such outstanding principal
and accrued interest and fees) or the Borrower (in the case of all other amounts), and (y) such assignment does not conflict with applicable law. A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a
result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply. 

(vi) If Borrower makes a Tax Payment and Lender determines: 

(A) a Tax Credit is attributable to an increased payment of which that Tax Payment forms part, to that Tax Payment or to a Tax Deduction in
consequence of which that Tax Payment was required; and 
 (B) Lender has obtained and utilized that Tax Credit. 

Lender shall pay an amount to Borrower which Lender determines will leave it (after that payment) in the same after Tax position as it would
have been in had the Tax Payment not been required to be made by Borrower. 
 (i) Administrative Fees and Charges. 

(i) Borrower shall pay to Agent, for its own account and not for the benefit of any other Lenders, all reasonable fees and expenses in
connection with audits and inspections of the books and records of the Credit Parties, audits, valuations or appraisals of the Collateral, audits of Borrower’s compliance with applicable Laws and such other matters as Agent shall deem
appropriate, which shall be due and payable on the first Business Day of the month following the date of issuance by Agent of a written request for payment thereof to any Borrower; provided, that, as long as no Default has occurred within the
preceding twelve (12) months, Agent shall be entitled to such reimbursement for no more than one audit and inspection per calendar year. 

(ii) If payments of principal or interest due on the Obligations, or any other amounts due hereunder or under the other Financing Documents,
are not timely made and remain overdue for a period of five (5) days, Borrower, without notice or demand by Agent, promptly shall pay to Agent, for its own 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	6	  	

 
account and not for the benefit of any other Lenders, as additional compensation to Agent in administering the Obligations, an amount equal to five percent (5.0%) of each delinquent payment.

 2.7 Secured Promissory Notes. At the election of any Lender made as to each Credit Facility for which it has made Credit
Extensions, each Credit Facility shall be evidenced by one or more secured promissory notes in form and substance satisfactory to Agent and Lenders (each a “Secured Promissory Note”). Upon receipt of an affidavit of an officer of a
Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note, Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor. 

 

	 	3	CONDITIONS OF CREDIT EXTENSIONS 

 3.1 Conditions Precedent to Initial Credit
Extension. Each Lender’s obligation to make an advance in respect of a Credit Facility is subject to the condition precedent that Agent shall consent to or shall have received, in form and substance satisfactory to Agent, such documents,
and completion of such other matters, as Agent may reasonably deem necessary or appropriate, including, without limitation, all items listed on the Closing Deliveries Schedule attached hereto. 

3.2 Conditions Precedent to all Credit Extensions. The obligation of each Lender to make each Credit Extension, including the initial
Credit Extension, is subject to the following conditions precedent: 
 (a) satisfaction of all Applicable Funding Conditions for the
applicable Credit Extension as set forth in the Credit Facility Schedule, each in form and substance satisfactory to Agent; 
 (b) timely
receipt by the Agent of an executed Credit Extension Form in the form attached hereto; 
 (c) the representations and warranties in Article 5
and elsewhere in the Financing Documents shall be true, correct and complete in all material respects on the date of the Credit Extension Form and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall
not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true,
accurate and complete in all material respects as of such date. Each Credit Extension is each Credit Party’s representation and warranty on that date that the representations and warranties in Article 5 and elsewhere in the Financing Documents
remain true, accurate and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof;
and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; 

(d) no Default or Event of Default shall have occurred and be continuing or result from the Credit Extension; 

(e) Agent shall be satisfied with the results of any searches conducted under Section 3.5; 

(f) receipt by Agent of such evidence as Agent shall request to confirm that the deliveries made in Section 3.1 remain current, accurate
and in full force and effect, or if not, updates thereto, each in form and substance satisfactory to Agent; and 
 (g) as determined in
Agent’s sole discretion, there has not been any Material Adverse Change or any material adverse deviation by Borrower or any Credit Party from the most recent business plan of the Credit Parties presented to and accepted by Agent. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	7	  	

 3.3 Method of Borrowing. Each Credit Extension in respect of each Credit Facility shall be
in an amount at least equal to the applicable Minimum Credit Extension Amount for such Credit Facility as set forth in the Credit Facility Schedule or such lesser amount as shall remain undisbursed under the Applicable Commitments for such Credit
Facility. The date of funding for any requested Credit Extension shall be a Business Day. To obtain a Credit Extension, Borrower shall deliver to Agent a completed Credit Extension Form executed by a Responsible Officer. Agent may rely on any notice
given by a person whom Agent reasonably believes is a Responsible Officer or designee thereof. Agent and Lenders shall have no duty to verify the authenticity of any such notice. 

3.4 Funding of Credit Facilities. Upon the terms and subject to the conditions set forth herein, each Lender, severally and not jointly,
shall make available to Agent its Pro Rata Share of the requested Credit Extension, in lawful money of the United States of America in immediately available funds, prior to 11:00 a.m. (New York time) on the specified date for the Credit Extension.
Agent shall, unless it shall have determined that one of the conditions set forth in Section 3.1 or 3.2, as applicable, has not been satisfied, by 2:00 p.m. (New York time) on such day, credit the amounts received by it in like funds to
Borrower by wire transfer to the Designated Funding Account (or to the account of Borrower in respect of the Obligations, if the Credit Extension is being made to pay an Obligation of Borrower). A Credit Extension made prior to the satisfaction of
any conditions set forth in Section 3.1 or 3.2 shall not constitute a waiver by Agent or Lenders of Borrower’s obligation to satisfy such conditions, and any such Credit Extension made in the absence of such satisfaction shall be made in
Agent’s discretion. 
 3.5 Searches. Before the Closing Date, and thereafter (as and when determined by Agent in its discretion),
Agent shall have the right to perform, all at the Credit Parties’ expense, the searches described in clauses (a), (b), and (c) below against Borrower and any other Credit Party, the results of which are to be consistent with the Credit
Parties’ representations and warranties under this Agreement and the reasonably satisfactory results of which shall be a condition precedent to all Credit Extensions requested by Borrower: (a) title investigations, UCC searches and fixture
filings searches; (b) judgment, pending litigation, federal tax lien, personal property tax lien, and corporate and partnership tax lien searches, in each jurisdiction searched under clause (a) above; and (c) searches of applicable
corporate, limited liability company, partnership and related records to confirm the continued existence, organization and good standing of the applicable Person and the exact legal name under which such Person is organized. 

 

	 	4	CREATION OF SECURITY INTEREST 

 4.1 Grant of Security Interest. Each Credit
Party hereby grants Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Agent, for the ratable benefit of the Lenders, the
Collateral (excluding that part of the Collateral which is otherwise subject to the security interest granted in the Foreign Security), wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. Each
Credit Party represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that may have
priority by operation of applicable Law or by the terms of a written intercreditor or subordination agreement entered into by Agent. 
 4.2
Representations and Covenants. 
 (a) As of the Closing Date, no Credit Party has ownership interest in any Chattel Paper, letter of
credit rights, commercial tort claims, Instruments, documents or investment property (other than equity interests in any Subsidiaries of any Credit Party disclosed on the Disclosure Schedule attached hereto). 

(b) Except for tangible Chattel Paper and Instruments in an aggregate amount of less than $50,000, each Credit Party shall deliver to Agent all
tangible Chattel Paper and all Instruments and documents (other than tangible Chattel Paper and Instruments located in the United Kingdom or Jersey and 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	8	  	

 
subject to the Scottish Security Documents or the Jersey Security Documents, as applicable, or located in another jurisdiction in which the Credit Parties have granted a perfected first priority
Lien on such Collateral (subject only to Permitted Liens) in favor of the Agent) owned by such Credit Party and constituting part of the Collateral duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and
substance satisfactory to Agent. Each Credit Party shall provide Agent with “control” (as in the Code) of all such electronic Chattel Paper owned by such Credit Party and constituting part of the Collateral by having Agent identified as
the assignee on the records pertaining to the single authoritative copy thereof and otherwise complying with the applicable elements of control set forth in the UCC. Each Credit Party also shall deliver to Agent all security agreements securing any
such Chattel Paper and securing any such Instruments. Each Credit Party will mark conspicuously all such Chattel Paper and all such Instruments and Documents with a legend, in form and substance satisfactory to Agent, indicating that such Chattel
Paper and such Instruments and Documents are subject to the security interests and Liens in favor of Agent created pursuant to this Agreement and the Financing Documents. 

(c) Except for letters of credit in an aggregate amount of less than $50,000, each Credit Party shall deliver to Agent all letters of credit
(other than letters of credit located in the United Kingdom or Jersey and subject to the Scottish Security Documents or the Jersey Security Documents, as applicable, or located in another jurisdiction in which the Credit Parties have granted a
perfected first priority Lien on such Collateral (subject only to Permitted Liens) in favor of the Agent) on which such Credit Party is the beneficiary and which give rise to letter of credit rights owned by such Credit Party which constitute part
of the Collateral in each case duly endorsed and accompanied by duly executed instruments of transfer or assignment, all in form and substance satisfactory to Agent. Each Credit Party shall take any and all actions as may be necessary or desirable,
or that Agent may request, from time to time, to cause Agent to obtain exclusive “control” (as defined in the Code) of any such letter of credit rights in a manner acceptable to Agent. 

(d) Each Credit Party shall promptly advise Agent upon such Credit Party becoming aware that it has any interests in any commercial tort claim
that constitutes part of the Collateral, which such notice shall include descriptions of the events and circumstances giving rise to such commercial tort claim and the dates such events and circumstances occurred, the potential defendants with
respect such commercial tort claim and any court proceedings that have been instituted with respect to such commercial tort claims, and each Credit Party shall, to the extent permitted by applicable law, with respect to any such commercial tort
claim, execute and deliver to Agent such documents as Agent shall request to perfect, preserve or protect the Liens, rights and remedies of Agent with respect to any such commercial tort claim. 

(e) Except for Accounts and Inventory in an aggregate amount of no more than Fifty Thousand Dollars ($50,000) and Accounts and Inventory
subject to the Scottish Security Documents or the Jersey Security Documents, as applicable, no Accounts or Inventory or other Collateral shall at any time be in the possession or control of any warehouse, consignee, bailee or any of the Credit
Parties’ agents or processors without prior written notice to Agent and the receipt by Agent, if Agent has so requested, of warehouse receipts, consignment agreements or bailee lien waivers (as applicable) satisfactory to Agent prior to the
commencement of such possession or control. Each Credit Party shall, upon the request of Agent, notify any such warehouse, consignee, bailee, agent or processor of the security interests and Liens in favor of Agent created pursuant to this Agreement
and the Financing Documents, instruct such Person to hold all such Collateral for Agent’s account subject to Agent’s instructions and shall obtain an acknowledgement from such Person that such Person holds the Collateral for Agent’s
benefit. 
 (f) Upon request of Agent, each Credit Party shall promptly deliver to Agent any and all certificates of title, applications for
title or similar evidence of ownership of all such tangible personal property (other than tangible personal property located in Scotland or Jersey and subject to the Scottish Security Documents or the Jersey Security Documents, as applicable, or
located in another jurisdiction in which the Credit Parties have granted a perfected first priority Lien on such tangible personal property (subject only to Permitted Liens) in favor of the Agent) and shall cause Agent to be named as lienholder on
any such certificate 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	9	  	

 
of title or other evidence of ownership. Each Credit Party shall not permit any such tangible personal property to become fixtures to real estate unless such real estate is subject to a Lien in
favor of Agent. 
 (g) Each Credit Party hereby authorizes Agent to file without the signature of such Credit Party one or more UCC financing
statements (and shall comply with all equivalent requirements in jurisdictions outside the United States) relating to all or any part of the Collateral, which financing statements may list Agent as the “secured party” and such Credit Party
as the “debtor” and which describe and indicate the collateral covered thereby as all or any part of the Collateral under the Financing Documents in such jurisdictions as Agent from time to time determines are appropriate, and to file
without the signature of such Credit Party any continuations of or corrective amendments to any such financing statements, in any such case in order for Agent to perfect, preserve or protect the Liens, rights and remedies of Agent with respect to
the Collateral. Each Credit Party also ratifies its authorization for Agent to have filed in each relevant jurisdiction initial financing statements or amendments thereto if filed prior to the date hereof. Any financing statement may include a
notice that any disposition of the Collateral, by such Credit Party or any other Person, shall be deemed to violate the rights of Agent and the Lenders under the UCC. 

(h) As of the Closing Date, no Credit Party holds, and after the Closing Date each Credit Party shall promptly notify Agent in writing upon
creation or acquisition by any Credit Party of, any Collateral which constitutes a claim against any Governmental Authority, including, without limitation, the federal government of the United States or any instrumentality or agency thereof, the
assignment of which claim is restricted by any applicable Law, including, without limitation, the federal Assignment of Claims Act and any other comparable Law. Upon the request of Agent, each Credit Party shall take such steps as may be necessary
or desirable, or that Agent may request, to comply with any such applicable Law. 
 (i) Each Credit Party shall furnish to Agent from time to
time any statements and schedules further identifying or describing the Collateral and any other information, reports or evidence concerning the Collateral as Agent may reasonably request from time to time. 

 

	 	5	REPRESENTATIONS AND WARRANTIES 

 Each Credit Party (in respect of itself only),
represents and warrants as follows on the Closing Date and the date of each Credit Extension: 
 5.1 Due Organization, Authorization:
Power and Authority. 
 (a) It is duly existing and in good standing, as a Registered Organization in its jurisdiction of formation or,
in the case of any Credit Party formed outside the United States or any political subdivision thereof, incorporated, existing and in good standing as a limited company under the laws of its jurisdiction of incorporation. It is qualified and licensed
to do business and is in good standing in any jurisdiction in which the conduct of its business or its ownership of property requires that it be qualified except where the failure to do so could not reasonably be expected to result in a Material
Adverse Change. The Financing Documents to which it is a party have been duly authorized, executed and delivered by it and constitute legal, valid and binding agreements enforceable in accordance with their terms except as the enforceability thereof
may be limited by bankruptcy, insolvency or other similar laws relating to the enforcement of creditors’ rights generally and by general equitable principles, and, for any Foreign Security, as the enforceability thereof may be limited by the
Reservations. The execution, delivery and performance by it of each Financing Document executed or to be executed by it is in each case within its powers. 

(b) The execution, delivery and performance by it of the Financing Documents to which it is a party do not (i) conflict with any of its
organizational documents; (ii) contravene, conflict with, constitute a default under or violate any Law applicable to it; (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or
award of any Governmental Authority by which it or any of its property or assets may be bound or affected; (iv) require any action by, filing, registration, or 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	10	  	

 
qualification with, or Required Permit from, any Governmental Authority (except such Required Permits which have already been obtained and are in full force and effect); or (v) constitute a
default under or conflict with any Material Agreement to which it is a party. It is not in default under any agreement to which it is a party or by which it is bound in which the default could reasonably be expected to result in a Material Adverse
Change. 
 5.2 Litigation. Except as disclosed on the Disclosure Schedule or, after the Closing Date, pursuant to
Section 6.7, there are no actions, suits, proceedings or investigations pending or, to the knowledge of the Responsible Officers, threatened in writing by or against it which involves the possibility of any judgment or liability of more than
One Hundred Fifty Thousand Dollars ($150,000.00) or that could result in a Material Adverse Change, or which questions the validity of the Financing Documents to which it is party, or the other documents required thereby or any action to be taken
pursuant to any of the foregoing, nor does it have reason to believe that any such actions, suits, proceedings or investigations are threatened. 

5.3 No Material Deterioration in Financial Condition; Financial Statements. All financial statements for the Credit Parties delivered to
Agent or any Lender fairly present, in conformity with GAAP, in all material respects the consolidated financial condition and consolidated results of operations of such Credit Party. There has been no material deterioration in the consolidated
financial condition of such Credit Party from the most recent financial statements and projections submitted to Agent or any Lender. There has been no adverse deviation from the most recent annual operating plan of Borrower delivered to Agent and
Lenders that constitutes or that could result in a Material Adverse Change. 
 5.4 Solvency. After giving effect to the transactions
contemplated hereby, the fair salable value of such Credit Party’s assets (including goodwill minus disposition costs) exceeds the fair value of its liabilities. After giving effect to the transactions described in this Agreement,
(a) it is not left with unreasonably small capital in relation to its business as presently conducted, and (b) it is able to pay its debts (including trade debts) as they mature. 

5.5 Subsidiaries; Investments. It does not own any stock, partnership interest or other equity securities, except for Permitted
Investments. 
 5.6 Tax Returns and Payments; Pension Contributions. It has timely filed all required tax returns and reports, and has
timely paid all foreign, federal, state and material local taxes, assessments, deposits and contributions owed by it. It is not aware of any claims or adjustments proposed for any of its prior tax years which could result in additional taxes
becoming due and payable by it. It has paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and it has not withdrawn from participation in, or has permitted partial or
complete termination of, or permitted the occurrence of any other event with respect to, any such plan which could reasonably be expected to result in any liability of it, including any liability to the Pension Benefit Guaranty Corporation or its
successors or any other Governmental Authority. 
 5.7 Disclosure Schedule. All information set forth in the Disclosure Schedule
is true, accurate and complete as of the date hereof. All information set forth in the Perfection Certificate is true, accurate and complete as of the date hereof. 
  

	 	6	AFFIRMATIVE COVENANTS 

 Each Credit Party covenants and agrees as follows: 

6.1 Organization and Existence; Government Compliance. 

(a) Each Credit Party shall maintain its legal existence and good standing in its respective jurisdiction of formation and maintain
qualification in each jurisdiction in which the failure to so 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	11	  	

 
qualify could reasonably be expected to result in a Material Adverse Change. If a Credit Party is not now a Registered Organization but later becomes one, Borrower shall promptly notify Agent of
such occurrence and provide Agent with such Credit Party’s organizational identification number. 
 (b) Each Credit Party shall comply
with all Laws, ordinances and regulations to which it or its business locations are subject, the noncompliance with which could reasonably be expected to result in a Material Adverse Change. Each Credit Party shall obtain and keep in full force and
effect and comply with all of the Required Permits, except where failure to have or maintain compliance with or effectiveness of such Required Permit could not reasonably be expected to result in a Material Adverse Change. Each Credit Party shall
promptly provide copies of any such obtained Required Permits to Agent. Borrower shall notify Agent within three (3) Business Days (but in any event prior to Borrower submitting any requests for Credit Extensions or release of any reserves) of
the occurrence of any facts, events or circumstances known to any Credit Party, whether threatened, existing or pending, that could cause any Required Permit to become limited, suspended or revoked or that makes any Credit Party subject to or
requires any Credit Party to file a plan of correction with respect to any accreditation survey. 
 6.2 Financial Statements, Reports,
Certificates. 
 (a) Borrower shall deliver, or shall cause Quotient Limited to deliver, to Agent and each Lender: (i) as soon as
available, but no later than forty-five (45) days after the last day of each month (or each quarter, if Borrower is subject to Section 6.2(b) below), a company prepared consolidated and consolidating balance sheet, income statement and
cash flow statement covering the Credit Parties’ consolidated operations for such month certified by a Responsible Officer and in a form acceptable to Agent; (ii) as soon as available, but no later than one hundred twenty (120) days
after the last day of the Borrower’s fiscal year, audited consolidated and consolidating financial statements prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements from an independent
certified public accounting firm acceptable to Agent in its reasonable discretion; (iii) as soon as available after approval thereof by such Credit Party’s governing board, but no later than sixty (60) days after the last day of such
Credit Party’s fiscal year, and as amended and/or updated, such Credit Party’s financial projections for current fiscal year; (iv) within five (5) days of delivery, copies of all statements, reports and notices made available to all
of such Credit Party’s security holders or to any holders of Subordinated Debt; (v) in the event that such Credit Party is or becomes subject to the reporting requirements under the Securities Exchange Act of 1934, as amended, within five
(5) days of filing, all reports on Form 10-K, 10-Q and 8-K, filed with the Securities and Exchange Commission (“SEC”) or a link thereto on such Credit Party’s or another website on the Internet; (vi) budgets, sales
projections, operating plans and other financial information reasonably requested by Agent or any Lender; (vii) as soon as available, but no later than forty-five (45) days after the last day of each month, copies of the month-end account
statements for each Collateral Account maintained by a Credit Party, which statements may be provided to Agent by Borrower or directly from the applicable institution(s); and (viii) such additional information, reports or statements regarding
the Credit Parties or their respective businesses, contractors and subcontractors as Agent or any Lender may from time to time reasonably request. 

(b) Notwithstanding the foregoing, in the event that the Borrower (or any direct or indirect parent thereof) is or becomes subject to the
reporting requirements under the Securities Exchange Act of 1934, as amended, the obligations in Section 6.2(a)(i) and (ii) may be satisfied by furnishing: (i) the Borrower’s (or such direct or indirect parent thereof) Form 10-K
or 10-Q, as applicable, filed with the SEC (or, if acceptable to the Agent in its reasonable discretion, equivalent public filing with the regulatory authorities of another jurisdiction where a Credit Party has registered a public offering of
securities), in each case within the time frames specified in Section 6.2(a) above and (ii) as soon as available, but no later than forty-five (45) days after the last day of each month, a company prepared calculation of the
consolidated cash and cash equivalents of the Credit Parties and a company prepared consolidated and consolidating income statement, provided that (x) to the extent such financial statements relate to a parent or indirect parent of Borrower,
such financial statements will be accompanied by consolidating information that describes Borrower standing alone, certified by a Responsible Officer, and (y) to the extent such financial statements are provided in lieu of statements

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	12	  	

 
required by clause (a)(ii) above, such statements will be accompanied by a report and opinion of an independent registered public accounting firm and be in form and content acceptable to the
Agent in its reasonable discretion. 
 (c) Within forty-five (45) days after the last day of each month, Borrower shall deliver, or
cause Quotient Limited to deliver, to Agent and each Lender with the monthly financial statements described above, a duly completed Compliance Certificate signed by a Responsible Officer. 

(d) Each Credit Party shall keep proper books of record and account in accordance with GAAP in which full, true and correct entries shall be
made of all dealings and transactions in relation to its business and activities. Upon prior written notice and during business hours (which such limitations shall not apply if a Default or Event of Default has occurred and is continuing), each
Credit Party shall allow Agent and Lenders to visit and inspect any properties of such Credit Party, to examine and make abstracts or copies from such Credit Party’s books, to conduct a collateral audit and analysis of its operations and the
Collateral to verify the amount and age of the accounts, the identity and credit of the respective account debtors, to review the billing practices of such Credit Party and to discuss its respective affairs, finances and accounts with their
respective officers, employees and independent public accountants as often as may reasonably be desired. The Credit Parties shall reimburse Agent and each Lender for all reasonable costs and expenses associated with such visits and inspections;
provided, however, that the Credit Parties shall be required to reimburse Agent and each Lender for such costs and expenses for no more than two (2) such visits and inspections per twelve (12) month period unless a Default or Event of
Default has occurred during such period. 
 (e) Each Credit Party shall deliver to Agent and each Lender, within five (5) days after the
same are sent or received, copies of all material correspondence, reports, documents and other filings with any Governmental Authority that could reasonably be expected to have a material effect on any of the Required Permits material to the Credit
Parties’ business or otherwise on the operations of the Credit Parties. 
 6.3 Maintenance of Property. Each Credit Party shall
cause all equipment and other tangible personal property other than Inventory to be maintained and preserved in the same condition, repair and in working order as of the date hereof, ordinary wear and tear excepted, and shall promptly make or cause
to be made all repairs, replacements and other improvements in connection therewith that are necessary or desirable to such end. Each Credit Party shall keep all Inventory in good and marketable condition, free from material defects. Returns and
allowances between any Credit Party and its Account Debtors shall follow such Credit Party’s customary practices as they exist at the Closing Date in all material respects. Borrower shall promptly notify Agent of all returns, recoveries,
disputes and claims that involve more than Two Hundred Thousand Dollars ($200,000) of Inventory collectively among all Credit Parties. 
 6.4
Taxes; Pensions. Each Credit Party shall timely file all required tax returns and reports and timely pay all foreign, federal, state, and local taxes, assessments, deposits and contributions owed, and shall deliver to Agent, on demand,
appropriate certificates attesting to such payments. Each Credit Party shall pay all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms. Notwithstanding the foregoing, any
Credit Party may defer payment of any contested taxes, provided, however, that such Credit Party (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and conducted,
(b) notifies Agent in writing of the commencement of, and any material development in, the proceedings, and (c) posts bonds or takes any other steps required to prevent the governmental authority levying such contested taxes from obtaining
a Lien upon any of the Collateral. 
 6.5 Insurance. Each Credit Party shall keep its business and the Collateral insured for risks
and in amounts standard for companies in such Credit Party’s industry and location and as Agent may reasonably request. Insurance policies shall be in a form, with companies, and in amounts that are satisfactory to Agent. All U.S. property
policies shall have a lender’s loss payable endorsement showing Agent as sole lender’s loss payee and waive subrogation against Agent, all U.S. liability policies shall show, or have endorsements

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	13	  	

 
showing, Agent as an additional insured, and all non-U.S. property or liability policies shall have Agent’s interest noted in the manner customary in the relevant jurisdiction. No other loss
payees may be shown on the policies unless Agent shall otherwise consent in writing. If required by Agent, all policies (or the loss payable and additional insured endorsements) shall provide that the insurer shall endeavor to give Agent at least
thirty (30) days’ notice before canceling, amending, or declining to renew its policy. At Agent’s request, each Credit Party shall deliver certified copies of all such Credit Party insurance policies and evidence of all premium
payments. If any Credit Party fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons and Agent, Agent may make all or part of such payment or obtain such
insurance policies required in this Section 6.5, and take any action under the policies Agent deems prudent. 
 6.6 Collateral
Accounts. Each Credit Party shall provide Agent five (5) days prior written notice before establishing any Collateral Account at or with any bank or financial institution. In addition, for each Collateral Account that any Credit Party at
any time maintains (other than the Citizens Account until the date that is 110 days following the Closing Date), each Credit Party shall cause the applicable bank or financial institution at or with which any Collateral Account is maintained to
execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Agent’s Lien in such Collateral Account in accordance with the terms hereunder, which Control Agreement may not be
terminated without prior written consent of Agent. The provisions of the previous sentence shall not apply to deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of a Credit
Party’s employees and identified to Agent by such Credit Party as such; provided, however, that at all times Borrower shall maintain one or more separate Deposit Accounts to hold any and all amounts to be used for payroll, payroll taxes and
other employee wage and benefit payments, and shall not commingle any monies allocated for such purposes with funds in any other Deposit Account. Immediately following the establishment of the Collateral Account at Wells Fargo Bank, N.A. (the
“Wells Account”), all funds on deposit in the Citizens Account shall be wired not later than three (3) Business Days after receipt thereof in such Citizens Account to the Wells Account, provided, however that from the Closing
Date through and including January 27, 2014, Borrower may maintain a balance of up to $100,000 in the Citizens Account. 
 6.7
Notices of Material Agreements, Litigation and Defaults; Cooperation in Litigation. Promptly (and in any event within three (3) Business Days), (a) upon any Credit Party becoming aware of the existence of any Event of Default or
event which, with the giving of notice or passage of time, or both, would constitute an Event of Default or (b) upon the execution and delivery of any Material Agreement and each material amendment, consent, waiver or other modification, and
each notice of termination or default or similar notice delivered to or by a Credit Party in connection with any Material Agreement, or (c) upon any Credit Party becoming aware of (or having reason to believe any of the following are pending or
threatened in writing) any action, suit, proceeding or investigation by or against Borrower or any Credit Party which involves the possibility of any judgment or liability of more than One Hundred Fifty Thousand Dollars ($150,000) or that could
result in a Material Adverse Change, or which questions the validity of any of the Financing Documents, or the other documents required thereby or any action to be taken pursuant to any of the foregoing, the Credit Parties shall give written notice
to Agent of such occurrence, and such further information (including copies of such documentation) as Agent shall reasonably request. From the date hereof and continuing through the termination of this Agreement, each Credit Party shall make
available to Agent and each Lender, without expense to Agent or any Lender, each Credit Party’s officers, employees and agents and books, to the extent that Agent or any Lender may deem them reasonably necessary to prosecute or defend any
third-party suit or proceeding instituted by or against Agent or any Lender with respect to any Collateral or relating to any Credit Party. 

6.8 Creation/Acquisition of Subsidiaries. In the event any Credit Party creates or, to the extent permitted hereunder, acquires any
Subsidiary, such Credit Party shall promptly (and in any event within five (5) Business Days of such creation or acquisition) notify Agent of the creation or acquisition of such new Subsidiary and take all such action as may be reasonably
required by Agent or the Required Lenders to cause each such Subsidiary to become a co-Borrower hereunder or to guarantee the Obligations of Borrower under 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	14	  	

 
the Financing Documents and, in each case, grant a continuing pledge and security interest in and to the assets of such Subsidiary (substantially as described on Exhibit A hereto or, in
the case of a Subsidiary formed outside of the United States or any political subdivision thereof, in such form as reasonably acceptable to the Agent and as appropriate for the relevant jurisdiction in which the Subsidiary is formed); and such
Credit Party shall grant and pledge to Agent, for the ratable benefit of the Lenders, a perfected security interest in the stock, units or other evidence of ownership of each Subsidiary (the foregoing collectively, the “Joinder
Requirements”); provided, that the Credit Parties shall not be permitted to make any Investment (other than Permitted Investments described in clause (a) of the definition thereof) in such Subsidiary until such time as the Joinder
Requirements of this Section 6.8 have been satisfied. 
 6.9 Use of Proceeds. Borrower shall use the proceeds of the Credit
Extensions solely for (a) transaction fees and other expenses incurred in connection with the Financing Documents, (b) for working capital needs of Borrower and its Subsidiaries and the other Credit Parties, and (c) any other
Permitted Purpose specified in the Credit Facility Schedule for such Credit Facility. No portion of the proceeds of the Credit Extensions will be used for family, personal, agricultural or household use. 

6.10 Hazardous Materials; Remediation. 

(a) If any release or disposal of Hazardous Materials shall occur or shall have occurred on any real property or any other assets of any Credit
Party, such Credit Party will cause the prompt containment and removal of such Hazardous Materials and the remediation of such real property or other assets as is necessary to comply with all Laws and to preserve the value of such real property or
other assets. Without limiting the generality of the foregoing, each Credit Party shall comply with each Law requiring the performance at any real property by such Credit Party of activities in response to the release or threatened release of a
Hazardous Material. 
 (b) The Credit Parties will provide Agent within thirty (30) days after written demand therefor with a bond,
letter of credit or similar financial assurance evidencing to the reasonable satisfaction of Agent that sufficient funds are available to pay the cost of removing, treating and disposing of any Hazardous Materials or Hazardous Materials
Contamination and discharging any assessment which may be established on any property as a result thereof, such demand to be made, if at all, upon Agent’s determination that the failure to remove, treat or dispose of any Hazardous Materials or
Hazardous Materials Contamination, or the failure to discharge any such assessment could reasonably be expected to have a Material Adverse Change. 

(c) If there is any conflict between this Section 6.10 and any environmental indemnity agreement which is a Financing Document, the
environmental indemnity agreement shall govern and control. 
 6.11 Power of Attorney. Each of the officers of Agent is hereby
irrevocably made, constituted and appointed the true and lawful attorney for each Credit Party (without requiring any of them to act as such) with full power of substitution to do the following: (a) pay, contest or settle any Lien, charge,
encumbrance, security interest, and adverse claim in or to the Collateral (in each case, so long as no Default or Event of Default has occurred, other than Permitted Liens), or any judgment based thereon, or otherwise take any action to terminate or
discharge the same; (b) so long as Agent has provided not less than three (3) Business Days’ prior written notice to the Credit Parties to perform the same and the Credit Parties have failed to take such action, (i) execute in
the name of any Person comprising any Credit Party any schedules, assignments, instruments, documents, and statements that such Credit Party is obligated to give Agent under this Agreement or that Agent or any Lender deems necessary to perfect or
better perfect Agent’s security interest or Lien in any Collateral, (ii) do such other and further acts and deeds in the name of such Credit Party that Agent may deem necessary or desirable to enforce, protect or preserve any Collateral or
its rights therein, including, but not limited to, to sign such Credit Party’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; and (iii) after the occurrence and during the continuance of an Event
of Default, (A) endorse the name of any Credit Party upon any and all checks, drafts, money orders, and other instruments for the payment of money that are payable to such Credit Party; (B) make, settle, and adjust all claims under the

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	15	  	

 
Credit Parties’ insurance policies; (C) take any action any Credit Party is required to take under this Agreement or any other Financing Document; (D) transfer the Collateral into
the name of Agent or a third party as the Code permits; (E) exercise any rights and remedies described in this Agreement or the other Financing Documents; and (F) do such other and further acts and deeds in the name of any Credit Party
that Agent may deem necessary or desirable to enforce its rights with regard to any Collateral. 
 6.12 Further Assurances. Each
Credit Party shall promptly execute any further instruments and take further action as Agent reasonably requests to perfect or better perfect or continue Agent’s Lien in the Collateral or to effect the purposes of this Agreement or any other
Financing Document. 
 6.13 Post-Closing Obligations. Each Credit Party shall complete each of the post-closing obligations and/or
deliver to Agent each of the documents, instruments, agreements and information listed on the Post-Closing Obligations Schedule attached hereto, on or before the date set forth for each such item thereon (as the same may be extended by Agent
in writing in its sole discretion), each of which shall be completed or provided in form and substance satisfactory to Agent and Lenders. 

6.14 Disclosure Schedule. Each Credit Party shall, on each date that it delivers a Compliance Certificate in accordance with
Section 8.2(c), deliver to Agent a proposed update to the Disclosure Schedule correcting all outdated, inaccurate, incomplete or misleading information, to the extent any information is outdated, inaccurate, incomplete or misleading.
With respect to any proposed updates to the Disclosure Schedule involving Permitted Liens, Permitted Indebtedness or Permitted Investments, Agent will replace the Disclosure Schedule attached hereto with such proposed update only if
such updated information is consistent with the definitions of and limitations herein pertaining to Permitted Liens, Permitted Indebtedness or Permitted Investments. With respect to any proposed updates to the Disclosure Schedule involving
other matters, Agent will replace the applicable portion of the Disclosure Schedule attached hereto with such proposed update upon Agent’s approval thereof. 
  

	 	7	NEGATIVE COVENANTS 

 No Credit Party shall do any of the following without the
prior written consent of Agent: 
 7.1 Dispositions. Convey, sell, abandon, lease, license, transfer, assign or otherwise dispose of
(collectively, “Transfer”) all or any part of its business or property, except for (a) sales, transfers or dispositions of Inventory in the Ordinary Course of Business; (b) sales or abandonment of worn-out or obsolete
Equipment; (c) Transfers of assets to another Credit Party in compliance with the covenants set forth in this Agreement, including without limitation Section 7.13; (d) Transfers of accounts receivable in connection with collection or
compromise thereof, or (e) Transfers in the Ordinary Course of Business consisting of the abandonment of Intellectual Property rights which, in the reasonable good faith determination of such Credit Party, are uneconomical, negligible, obsolete
or otherwise not useful in the conduct of its business. 
 7.2 Changes in Business, Management, Ownership or Business Locations.
(a) Engage in any business other than the businesses currently engaged in by such Credit Party, as applicable, or reasonably related thereto; (b) liquidate or dissolve; (c) (i) have a change in senior management where a suitable
permanent replacement, as approved by such Credit Party’s board of directors, has not been named and hired by not later than sixty (60) days after such change, or (ii) enter into any transaction or series of related transactions which
would result in a Change in Control; (d) add any new offices or business locations, or enter into any new leases with respect to existing offices or business locations (unless such new or existing offices or business locations contain less than
Fifty Thousand Dollars ($50,000) of such Credit Party’s assets or property and do not contain any of such Credit Party’s Books) without first delivering (i) in the case of leased premises located in jurisdictions in which such
documents are customary, including without limitation the United States, a fully-executed Access Agreement to Agent and (ii) any other documents which are necessary or advisable to maintain in favor of the Agent, Liens on the Collateral that
are duly perfected in accordance with all applicable 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	16	  	

 
Law; (e) change its jurisdiction of organization; (f) change its organizational structure or type; (g) change its legal name; or (h) change any organizational number (if any)
assigned by its jurisdiction of organization. 
 7.3 Mergers or Acquisitions. Merge or consolidate with any other Person, or acquire
all or substantially all of the capital stock or property of another Person; provided, however, that a Subsidiary of a Credit Party may merge or consolidate into another Subsidiary that is a Credit Party, so long as (a) Borrower
has provided Agent with prior written notice of such transaction, (b) a Person already comprising a Credit Party shall be the surviving legal entity, (c) if the Borrower is a party thereto, the Borrower shall be the surviving legal entity,
(d) the surviving Credit Party’s tangible net worth is not thereby reduced, (d) no Event of Default has occurred and is continuing prior thereto or arises as a result therefrom, and (e) the Credit Parties shall be in compliance
with the covenants set forth in this Agreement, including without limitation Section 7.13, both before and after giving effect to such transaction. 

7.4 Indebtedness. Create, incur, assume, or be liable for any Indebtedness other than Permitted Indebtedness. 

7.5 Encumbrance. (a) Create, incur, allow, or suffer any Lien on any of its property, except for Permitted Liens, (b) permit
any Collateral to fail to be subject to the first priority security interest granted herein except for Permitted Liens that may have priority by operation of applicable Law or by the terms of a written intercreditor or subordination agreement
entered into by Agent, or (c) enter into any agreement, document, instrument or other arrangement (except with or in favor of Agent) with any Person which directly or indirectly prohibits or has the effect of prohibiting any Credit Party or any
Subsidiary from assigning, mortgaging, pledging, granting a security interest in or upon, or encumbering any Credit Party’s or any Subsidiary’s Collateral or Intellectual Property, except as is otherwise permitted in the definition of
“Permitted Liens” herein. 
 7.6 Maintenance of Collateral Accounts. Maintain any Collateral Account, except in compliance
with the terms of Section 6.6 hereof. 
 7.7 Distributions; Investments. (a) Pay any dividends or make any distribution or
payment with respect to or redeem, retire or purchase or repurchase any of its equity interests (other than Permitted Distributions), or (b) directly or indirectly make any Investment (including, without limitation, any additional Investment in
any Subsidiary) other than Permitted Investments. 
 7.8 Transactions with Affiliates. Directly or indirectly enter into or permit to
exist any material transaction with any Affiliate of any Credit Party, except for (a) transactions that are upon fair and reasonable terms that are no less favorable to such Credit Party than would be obtained in an arm’s length
transaction with a non-affiliated Person, (b) transactions with Credit Parties hereunder and that are not otherwise prohibited by Article 7 of this Agreement, and (c) transactions permitted by Section 7.7 of this Agreement;. 

7.9 Subordinated Debt. (a) Make or permit any payment on any Subordinated Debt, except to the extent expressly permitted to be made
pursuant to the terms of the Subordination Agreement to which such Subordinated Debt is subject, or (b) amend any provision in any document relating to the Subordinated Debt other than as may be expressly permitted pursuant to the terms of any
applicable Subordination Agreement to which such Subordinated Debt is subject. 
 7.10 Compliance. Become an “investment
company” or a company controlled by an “investment company”, under the Investment Company Act of 1940, as amended or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in
Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as
defined in ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate any other Law or regulation, if the violation could reasonably be expected to result in a Material Adverse Change; withdraw

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	17	  	

 
from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan
which could reasonably be expected to result in any liability of such Credit Party, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other governmental agency. 

7.11 Amendments to Organization Documents and Material Agreements. Subject to applicable requirements of law, amend, modify or waive any
provision of (a) any Material Agreement in a manner that is materially adverse to any Credit Party, that is adverse to Agent or any Lender, that pertains to rights to assign or grant a security interest in such Material Agreement or that could
or could reasonably be expected to result in a Material Adverse Change, or (b) any of its organizational documents (other than a change in registered agents, or a change that could not adversely affect the rights of Agent or Lenders hereunder,
but, for the avoidance of doubt, under no circumstances a change of its name, type of organization or jurisdiction of organization), in each case, without the prior written consent of Agent, such consent not to be unreasonably withheld or delayed.
Each Credit Party shall provide to Agent copies of all amendments, waivers and modifications of any Material Agreement or organizational documents. 

7.12 Compliance with Anti-Terrorism Laws. Directly or indirectly, knowingly enter into any documents, instruments, agreements or
contracts with any Person listed on the OFAC Lists. Each Credit Party shall immediately notify Agent if such Credit Party has knowledge that any Credit Party or any Subsidiary or Affiliate is listed on the OFAC Lists or (a) is convicted on,
(b) pleads nolo contendere to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering. No Credit Party will, nor will any Credit Party permit any
Subsidiary or Affiliate to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services
to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224, any similar executive order or other
Anti-Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or
other Anti-Terrorism Law. Agent hereby notifies each Credit Party that pursuant to the requirements of Anti-Terrorism Laws, and Agent’s policies and practices, Agent is required to obtain, verify and record certain information and documentation
that identifies such Credit Party and its principals, which information includes the name and address of such Credit Party and its principals and such other information that will allow Agent to identify such party in accordance with Anti-Terrorism
Laws. 
 7.13 Holdings. (a) Quotient Limited will not incur or permit to exist any Indebtedness nor grant or permit to exist any
Liens upon any of its properties or assets nor engage in any operations, business or activity other than (i) owning 100% of the Equity Interests of the Borrower and the other Credit Parties and all operations incidental thereto,
(ii) granting a security interest in all its assets to the Agent, for the benefit of the Lenders, (iii) executing the Financing Documents to which it is a party, (iv) fulfilling its obligations under the Financing Documents to which
it is a party, (v) performing administrative, governance and supervisory functions in connection with the operation of the business of its Subsidiaries, and (vi) issuing equity interests, including without limitation pursuant to stock
option plans. 
 (b) Following the creation of the Luxembourg Holding Company, the Luxembourg Holding Company will not incur or permit to
exist any Indebtedness nor grant or permit to exist any Liens upon any of its properties or assets nor engage in any operations, business or activity other than (i) owning 100% of the Equity Interests of Quotient Suisse and all operations
incidental thereto, (ii) granting a security interest in all its assets to the Agent, for the benefit of the Lenders, (iii) executing the Financing Documents to which it is a party, (iv) fulfilling its obligations under the Financing
Documents to which it is a party, (v) performing administrative, governance and supervisory functions in connection with the operation of the business of its Subsidiaries, and (vi) issuing equity interests, including without limitation
pursuant to stock option plans. 
  

	 	8	ADDITIONAL COVENANTS 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	18	  	

 8.1 Life Sciences Covenants. 

(a) As used in this Agreement, the following terms have the following meanings: 

“DEA” means the Drug Enforcement Administration of the United States of America, and any successor agency thereof or any
foreign equivalent thereof. 
 “Drug Application” means a new drug application, an abbreviated drug application, or a
product license application for any Product, as appropriate, as those terms are defined in the FDCA. 
 “FDA” means the Food
and Drug Administration of the United States of America, or any successor entity thereto or foreign equivalent thereof. 

“FDCA” means the Federal Food, Drug and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq., and all regulations
promulgated thereunder and any foreign equivalent of the Federal Food, Drug and Cosmetic Act and all regulations promulgated thereunder. 

“Material Intellectual Property” means all of the Credit Parties’ Intellectual Property and license or sublicense
agreements or other agreements with respect to rights in Intellectual Property that are material to the condition (financial or other), business or operations of the Credit Parties, as reasonably determined by Agent. 

“Permitted License” means any non-exclusive license of patent rights of any Credit Party or its Subsidiaries granted to third
parties in the Ordinary Course of Business and that does not result in a legal transfer of title to the licensed property. 

“Products” means any products manufactured, sold, developed, tested or marketed by any Credit Party or any of its
Subsidiaries, including without limitation, those products set forth on the Products Schedule (as updated from time to time in accordance with Section 8.1(d)); provided, however, that if Borrower shall fail to comply with
the obligations under Section 8.1(d) to give notice to Agent and update the Products Schedule prior to manufacturing, selling, developing, testing or marketing any new Product, any such improperly undisclosed Product shall be deemed to
be included in this definition. 
 “Registered Intellectual Property” means any patent, registered trademark or servicemark,
registered copyright, registered mask work, or any pending application for any of the foregoing. 
 (b) Notwithstanding the terms of
Section 7.1 of this Agreement to the contrary, the Credit Parties shall be permitted to make Transfers in the form of Permitted Licenses. 

(c) Each Credit Party represents and warrants as follows at all times unless expressly provided below: 

(i) Intellectual Property and License Agreements. A list of all Intellectual Property of the Credit Parties and all license agreements,
sublicenses, or other rights of the Credit Parties to use Intellectual Property (including all in-bound license agreements, but excluding over-the-counter software that is commercially available to the public), as of the Closing Date and, as updated
pursuant to Section 8.1(d), is set forth on the Intellectual Property Schedule, which indicates, for each item of property: (A) the name of the Credit Party owning such Intellectual Property or licensee to such license agreement;
(B) whether such property is Intellectual Property (or application therefor) owned by a Credit Party or is property to which a Credit Party has rights pursuant to a license agreement, (C) the expiration date of such Intellectual Property
or license agreement, and (D) whether such property constitutes Material Intellectual Property. In the case of any Material Intellectual Property that is a license agreement, the Intellectual Property Schedule further indicates, for
each: (1) the name and address of the licensor, (2) the name and date of the agreement pursuant to which such item of Material Intellectual Property is licensed, (3) whether or not such license agreement

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	19	  	

 
grants an exclusive license to such Credit Party, (4) whether there are any purported restrictions in such license agreement as to the ability of such Credit Party to grant a security interest in
and/or to transfer any of its rights as a licensee under such license agreement, and (5) whether a default under or termination of such license agreement could interfere with Agent’s right to sell or assign such license or any other Collateral.
Except as noted on the Intellectual Property Schedule, each Credit Party is the sole owner of its Intellectual Property, except for licenses granted to its customers in the Ordinary Course of Business as identified on the Intellectual
Property Schedule. Each Patent is valid and enforceable and no part of the Material Intellectual Property has been judged invalid or unenforceable, in whole or in part, and to the best of the Credit Parties’ knowledge, no claim has been
made that any part of the Intellectual Property violates the rights of any third party. 
 (ii) Regulatory Status. 

(A) All Products and all Required Permits are listed on the Products Schedule and Required Permits Schedule (as updated from
time to time pursuant to Section 8.1(d)), and each Credit Party has delivered to Agent a copy of all Required Permits requested by Agent as of the date hereof or to the extent requested by Agent pursuant to Section 8.1(d). 

(B) Without limiting the generality of Section 8.1 above, with respect to any Product being tested or manufactured, each Credit Party and
its Subsidiaries have received, and such Product is the subject of, all Required Permits needed in connection with the testing or manufacture of such Product as such testing or manufacturing is currently being conducted by or on behalf of such
Credit Party, and no Credit Party or its Subsidiaries have received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an investigation or review of (1) such Credit
Party’s or such Subsidiary’s manufacturing facilities and processes for such Product which have disclosed any material deficiencies or violations of Laws and/or the Required Permits related to the manufacture of such Product, or
(2) any such Required Permit or that any such Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation stating that the development, testing and/or manufacturing of such Product
should cease. 
 (C) Without limiting the generality of Section 8.1 above, with respect to any Product marketed or sold by any Credit
Party or its Subsidiaries, the Credit Parties and their Subsidiaries have received, and such Product is the subject of, all Required Permits needed in connection with the marketing and sales of such Product as currently being marketed or sold by the
Credit Parties or their Subsidiaries, and the Credit Parties and their Subsidiaries have not received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an
investigation or review of any such Required Permit or approval or that any such Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation stating that such marketing or sales of such
Product cease or that such Product be withdrawn from the marketplace. 
 (D) Without limiting the generality of Section 8.1 above,
(i) there have been no adverse clinical test results which have or could reasonably be expected to result in a Material Adverse Change, and (ii) there have been no Product recalls or voluntary Product withdrawals from any market, other
than recalls or withdrawals that relate only to a specific lot or batch of a Product. 
 (E) The Credit Parties and their Subsidiaries have
not experienced any significant failures in its manufacturing of any Product material to the business of the Credit Parties such that the amount of such Product successfully manufactured by any Credit Party or its Subsidiaries in accordance with all
specifications thereof and the required payments related thereto shall decrease significantly. 
 (d) Each Credit Party covenants and agrees
as follows: 
 (i) [Reserved]. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	20	  	

 (ii) The Credit Parties shall own, or be licensed to use or otherwise have the right to use, all
Material Intellectual Property. All Material Intellectual Property of the Credit Parties is and shall be fully protected and/or duly and properly registered, filed or issued in the appropriate office and jurisdictions for such registrations, filings
or issuances, except where the failure to do so would not reasonably be expected to result in a Material Adverse Change. No Credit Party shall become a party to, nor become bound by, any material license or other agreement with respect to which such
Credit Party is the licensee that prohibits or otherwise restricts such Credit Party from granting a security interest in such Credit Party’s interest in such license or agreement or other property. Each Credit Party shall at all times conduct
its business without infringing (knowingly or when Borrower should have known) any Intellectual Property rights of others. Each Credit Party shall do the following, to the extent it determines, in the exercise of its reasonable business judgment,
that it is prudent to do so: (A) protect, defend and maintain the validity and enforceability of its Material Intellectual Property; (B) promptly advise Agent in writing of material infringements of its Material Intellectual Property; and
(C) not allow, without Agent’s prior written consent, any Material Intellectual Property to be abandoned, invalidated, forfeited or dedicated to the public or to become unenforceable. If any Credit Party (1) obtains any patent,
registered trademark or servicemark, registered copyright, registered mask work, or any pending application for any of the foregoing, whether as owner, licensee or otherwise, or (2) applies for any patent or the registration of any trademark or
servicemark, then such Credit Party shall concurrently provide written notice thereof to Agent and shall execute such documents and take such other actions as Agent shall request in its good faith business judgment to perfect and maintain a first
priority perfected security interest in favor of Agent, for the ratable benefit of Lenders, in the IP Proceeds (as defined in Exhibit A) pertaining thereto. Each Credit Party shall promptly provide to Agent copies of all applications that it
files for patents or for the registration of trademarks, servicemarks, copyrights or mask works. 
 (iii) In connection with the
development, testing, manufacture, marketing or sale of each and any Product by a Credit Party, such Credit Party shall comply fully and completely in all respects with all Required Permits at all times issued by any Governmental Authority the
noncompliance with which could reasonably be expected to result in a Material Adverse Change, specifically including the FDA, with respect to such development, testing, manufacture, marketing or sales of such Product by such Credit Party as such
activities are at any such time being conducted by such Credit Party. 
 (iv) Within ten (10) Business Days of (A) acquiring
and/or developing any new Registered Intellectual Property, or (B) entering or becoming bound by any additional license or sublicense agreement or other agreement with respect to rights in Intellectual Property (other than over-the-counter
software that is commercially available to the public), deliver to Agent an updated Intellectual Property Schedule reflecting same, and upon any other material change in any Credit Party’s Material Intellectual Property from that listed
on the Intellectual Property Schedule. Each Credit Party shall take such steps as Agent requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for (x) all licenses or agreements to be deemed
“Collateral” and for Agent to have a security interest in it that might otherwise be restricted or prohibited by Law or by the terms of any such license or agreement, whether now existing or entered into in the future, and (y) Agent
to have the ability in the event of a liquidation of any Collateral to dispose of such Collateral in accordance with Agent’s rights and remedies under this Agreement and the other Financing Documents. 

(v) If, after the Closing Date, any Credit Party determines to manufacture, sell, develop, test or market any new Product, such Credit Party
shall give prior written notice to Agent of such determination (which shall include a brief description of such Product, plus a list of all Required Permits relating to such new Product (and a copy of such Required Permits if requested by Agent)
and/or such Credit Party’s manufacture, sale, development, testing or marketing thereof issued or outstanding as of the date of such notice), along with a copy of an updated Intellectual Property Schedule, Products Schedule and
Required Permits Schedule; provided, however, that if any Credit Party shall at any time obtain any new or additional Required Permits from the FDA, DEA, or parallel state or local authorities, or foreign counterparts of the FDA, DEA,
or parallel state or local authorities, with respect to any Product which has previously been 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	21	  	

 
disclosed to Agent, such Credit Party shall promptly give written notice to Agent of such new or additional Required Permits (along with a copy thereof if requested by Agent). 

(e) In addition to the events listed in Article 10, any one of the following shall also constitute an Event of Default under this Agreement, in
each case, to the extent the following could reasonably be expected to result in a Material Adverse Change: (i) the institution of any proceeding by FDA or similar Governmental Authority to order the withdrawal of any Product or Product
category from the market or to enjoin any Credit Party, its Subsidiaries or any representative of such Credit Party or its Subsidiaries from manufacturing, marketing, selling or distributing any Product or Product category, (ii) the institution
of any action or proceeding by any DEA, FDA, or any other Governmental Authority to revoke, suspend, reject, withdraw, limit, or restrict any Required Permit held by any Credit Party, its Subsidiaries or any representative of such Credit Party or
its Subsidiaries, which, in each case, could result in Material Adverse Change, (iii) the commencement of any enforcement action against any Credit Party, its Subsidiaries or any representative of such Credit Party or its Subsidiaries (with
respect to the business of such Credit Party or its Subsidiaries) by DEA, FDA, or any other Governmental Authority, (iv) the recall of any Products from the market, the voluntary withdrawal of any Products from the market, or actions to
discontinue the sale of any Products, or (v) the occurrence of adverse test results in connection with a Product. 
 8.2 Financial
Covenants. 
 (a) As used in this Section, the following terms have the following meanings: 

(b) Borrower shall not permit its consolidated net product revenue as of any Testing Date to be less than the minimum amounts set forth on
Minimum Net Product Revenue Schedule, opposite such Testing Date set forth on such Minimum Net Product Revenue Schedule. For each period after December 31, 2016, the required minimum net product revenues shall be determined by
Agent, in consultation with the Borrower, annually based on the greater of (i) 80% of Borrower’s board-approved projections for the applicable trailing twelve month period and (ii) $23,500,000 for the applicable trailing twelve month
period. 
 (c) Borrower shall furnish to Agent, together with the monthly financial reporting required of Borrower in this Agreement, a
Compliance Certificate as evidence of Borrower’s compliance with the covenants in this Section. The Compliance Certificate shall include, without limitation, (a) a statement and report, on a form approved by Agent, detailing
Borrower’s calculations, and (b) if requested by Agent, back-up documentation (including, without limitation, invoices, receipts and other evidence of costs incurred during such quarter as Agent shall reasonably require) evidencing the
propriety of the calculations. 
  

	 	9	RESERVED 

  

	 	10	EVENTS OF DEFAULT 

 10.1 Events of Default. The occurrence of
any of the following conditions and/or events, whether voluntary or involuntary, by operation of law or otherwise, shall constitute an “Event of Default” and Credit Parties shall thereupon be in default under this Agreement and each
of the other Financing Documents: 
 (a) Borrower fails to (i) make any payment of principal or interest on any Credit Extension on its
due date, or (ii) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of
acceleration pursuant to Section 10.2 hereof). 
 (b) Any Credit Party defaults in the performance of or compliance with any term
contained in this Agreement or in any other Financing Document (other than occurrences described in other provisions of this Section 10.1 for which a different grace or cure period is specified or for which no grace or cure period is specified
and thereby constitute immediate Events of Default) and such default is not remedied 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	22	  	

 
by the Credit Party or waived by Agent within fifteen (15) days after the earlier of (i) the date of receipt by any Borrower of notice from Agent or Required Lenders of such default, or
(ii) the date a Responsible Officer of such Credit Party becomes aware, or through the exercise of reasonable diligence should have become aware, of such default; Any Credit Party defaults in the performance of or compliance with any term
contained in Section 6.2, 6.4, 6.5, 6.6, 6.8 or 6.10 or Article 7 or Article 8. 
 (c) Any representation, warranty, certification or
statement made by any Credit Party or any other Person in any Financing Document or in any certificate, financial statement or other document delivered pursuant to any Financing Document is incorrect in any respect (or in any material respect if
such representation, warranty, certification or statement is not by its terms already qualified as to materiality) when made (or deemed made); 

(d) (i) any Credit Party defaults under or breaches any Material Agreement (after any applicable grace period contained therein), or a Material
Agreement shall be terminated by a third party or parties party thereto prior to the expiration thereof, or there is a loss of a material right of a Credit Party under any Material Agreement to which it is a party, in each case, which could
reasonably be expected to result in a Material Adverse Change, (ii) (A) any Credit Party fails to make (after any applicable grace period) any payment when due (whether due because of scheduled maturity, required prepayment provisions,
acceleration, demand or otherwise) on any Indebtedness (other than the Obligations) of such Credit Party or such Subsidiary having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all
creditors under any combined or syndicated credit arrangement) of more than One Hundred Thousand Dollars ($100,000) (“Material Indebtedness”), (B) any other event shall occur or condition shall exist under any contractual
obligation relating to any such Material Indebtedness, if the effect of such event or condition is to accelerate, or to permit the acceleration of (without regard to any subordination terms with respect thereto), the maturity of such Material
Indebtedness or (C) any such Material Indebtedness shall become or be declared to be due and payable, or be required to be prepaid, redeemed, defeased or repurchased (other than by a regularly scheduled required prepayment), prior to the stated
maturity thereof, (iii) any Credit Party defaults (beyond any applicable grace period) under any obligation for payments due or otherwise under any lease agreement for such Credit Party’s principal place of business or any place of business
that meets the criteria for the requirement of an Access Agreement under Section 7.2 or for which an Access Agreement exists or was required to be delivered, (iv) the occurrence of any breach or default under any terms or provisions of any
Subordinated Debt Document or under any agreement subordinating the Subordinated Debt to all or any portion of the Obligations, or the occurrence of any event requiring the prepayment of any Subordinated Debt, or the delivery of any notice with
respect to any Subordinated Debt or pursuant to any Subordination Agreement that triggers the start of any standstill or similar period under any Subordination Agreement, or (v) any Borrower makes any payment on account of any Indebtedness that
has been subordinated to any of the Obligations, other than payments specifically permitted by the terms of such subordination; 
 (e) (i)
any Credit Party shall generally not pay its debts as such debts become due, shall admit in writing its inability to pay its debts generally, shall make a general assignment for the benefit of creditors, or shall cease doing business as a going
concern, (ii) any proceeding shall be instituted by or against any Credit Party seeking to adjudicate it a bankrupt or insolvent or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief, composition of it
or its debts or any similar order (including any proceeding set out in Article 8 of the Interpretation (Jersey) Law 1954 or an application is made to declare the property of any Credit Party en desastre), in each case under any law relating to
bankruptcy, insolvency or reorganization or relief of debtors or seeking the entry of an order for relief or the appointment of a custodian, receiver, trustee, conservator, liquidating agent, liquidator, other similar official or other official with
similar powers, in each case for it or for any substantial part of its property and, in the case of any such proceedings instituted against (but not by or with the consent of) such Credit Party, either such proceedings shall remain undismissed or
unstayed for a period of forty-five (45) days or more or any action sought in such proceedings shall occur or (iii) any Credit Party shall take any corporate or similar action or any other action to authorize any action described in
clause (i) or (ii) above; 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	23	  	

 (f) (i) The service of process seeking to attach, exercise diligence upon, execute or levy upon,
seize or confiscate any Collateral Account, any Intellectual Property, or any funds of any Credit Party on deposit with Agent, any Lender or any Affiliate of Agent or any Lender, or (ii) a notice of lien, levy, or assessment is filed against
any assets of a Credit Party by any government agency, and the same under subclauses (i) and (ii) hereof are not discharged or stayed (whether through the posting of a bond or otherwise) prior to the earlier to occur of ten (10) days
after the occurrence thereof or such action becoming effective; 
 (g) (i) any court order enjoins, restrains, or prevents Borrower from
conducting any material part of its business, (ii) the institution by any Governmental Authority of criminal proceedings against any Credit Party, or (iii) one or more judgments or orders for the payment of money (not paid or fully covered
by insurance and as to which the relevant insurance company has acknowledged coverage in writing) aggregating in excess of One Hundred Fifty Thousand Dollars $150,000 shall be rendered against any or all Credit Parties and either
(A) enforcement proceedings shall have been commenced by any creditor upon any such judgments or orders, or (B) there shall be any period of ten (10) consecutive days during which a stay of enforcement of any such judgments or orders,
by reason of a pending appeal, bond or otherwise, shall not be in effect, 
 (h) any Lien created by any of the Financing Documents shall at
any time fail to constitute a valid and perfected Lien on all of the Collateral purported to be encumbered thereby, subject to no prior or equal Lien except Permitted Liens, or any Credit Party shall so assert; any provision of any Financing
Document shall fail to be valid and binding on, or enforceable against, a Credit Party, or any Credit Party shall so assert; 
 (i) A Change
in Control occurs or any Credit Party or direct or indirect equity owner in a Credit Party shall enter into agreement which contemplates a Change in Control; 

(j) Any Required Permit shall have been (i) revoked, rescinded, suspended, modified in an adverse manner or not renewed in the Ordinary
Course of Business for a full term, or (ii) subject to any decision by a Governmental Authority that designates a hearing with respect to any applications for renewal of any of such Required Permit or that could result in the Governmental
Authority taking any of the actions described in clause (i) above, and such decision or such revocation, rescission, suspension, modification or non-renewal (A) results in, or could reasonably be expected to results in, a Material Adverse
Change, or (B) adversely affects the legal qualifications of any Credit Party to hold such Required Permit in any applicable jurisdiction and such revocation, rescission, suspension, modification or non-renewal could reasonably be expected to
affect the status of or legal qualifications of any Credit Party to hold any Required Permit in any other jurisdiction; 
 (k) If any
Borrower is or becomes an entity whose equity is registered with the SEC, and/or is publicly traded on and/or registered with a public securities exchange, such Borrower’s equity fails to remain registered with the SEC in good standing, and/or
such equity fails to remain publicly traded on and registered with a public securities exchange; 
 (1) Any Credit Party or any Person acting
for any Credit Party makes any representation, warranty, or other statement now or later in this Agreement, any Financing Document or in any writing delivered to Agent and/or the Lenders or to induce Agent and/or the Lenders to enter this Agreement
or any Financing Document, and such representation, warranty, or other statement is incorrect in any material respect when made; 
 (m) The
occurrence of any fact, event or circumstance that could reasonably be expected to result in a Material Adverse Change, if such default shall have continued unremedied for a period of ten (10) days after written notice from Agent; or 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	24	  	

 (n) Agent determines, based on information available to it and in its reasonable judgment, that
there is a reasonable likelihood that Borrower shall fail to comply with one or more financial covenants in this Agreement during the next succeeding financial reporting period. 

All cure periods provided for in this Section 10.1 shall run concurrently with any cure period provided for in any applicable Financing Documents under
which the default occurred. 
 10.2 Rights and Remedies. 

(a) Upon the occurrence and during the continuance of an Event of Default, Agent may, and at the written direction of any Lender shall, without
notice or demand, do any or all of the following: (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in
Section 10.1(f) occurs all Obligations shall be immediately due and payable without any action by Agent or the Lenders), or (iii) by notice to any Borrower suspend or terminate the obligations, if any, of the Lenders to advance money or
extend credit for Borrower’s benefit under this Agreement or under any other agreement between any Credit Party and Agent and/or the Lenders (but if an Event of Default described in Section 10.1(f) occurs all obligations, if any, of the
Lenders to advance money or extend credit for Borrower’s benefit under this Agreement or under any other agreement between Borrower and Agent and/or the Lenders shall be immediately terminated without any action by Agent or the Lenders). 

(b) Without limiting the rights of Agent and Lenders set forth in Section 10.2(a) above, upon the occurrence and during the continuance of
an Event of Default, Agent shall have the right, without notice or demand, to do any or all of the following: 
 (i) with or without legal
process, enter any premises where the Collateral may be and take possession of and remove the Collateral from the premises or store it on the premises, and foreclose upon and/or sell, lease or liquidate, the Collateral, in whole or in part; 

(ii) apply to the Obligations (A) any balances and deposits of any Credit Party that Agent or any Lender or any Affiliate of Agent or a
Lender holds or controls, or (B) any amount held or controlled by Agent or any Lender or any Affiliate of Agent or a Lender owing to or for the credit or the account of any Credit Party; 

(iii) settle, compromise or adjust and grant releases with respect to disputes and claims directly with Account Debtors for amounts on terms
and in any order that Agent considers advisable, notify any Person owing any Credit Party money of Agent’s security interest in such funds, and verify the amount of such Account; 

(iv) make any payments and do any acts it considers necessary or reasonable to protect the Collateral and/or its security interest in the
Collateral. Borrower shall assemble the Collateral if Agent requests and make it available as Agent designates. Agent may also, subject to applicable law, render any or all of the Collateral unusable at a Credit Party’s premises and may,
subject to applicable law, dispose of such Collateral on such premises without liability for rent or costs. Borrower, subject to applicable law, grants Agent a license to enter and occupy any of its premises, without charge, to exercise any of
Agent’s rights or remedies; 
 (v) pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security
interest and pay all expenses incurred; 
 (vi) subject to applicable law, ship, reclaim, recover, store, finish, maintain, repair, prepare
for sale, and/or advertise for sale, the Collateral. Agent is hereby granted a non-exclusive, royalty-free license or other right to use, without charge, Borrower’s labels, patents, copyrights, mask works,

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	25	  	

 
rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of,
advertising for sale, and selling any Collateral (and including in such license access to all media in which any of the licensed items may be recorded or stored and to all computer software and programs used for the compilation or printout thereof)
and, in connection with Agent’s exercise of its rights under this Article 10, Borrower’s rights under all licenses and all franchise agreements shall be deemed to inure to Agent for the benefit of the Lenders; 

(vii) place a “hold” on any account maintained with Agent or the Lenders or any Affiliate of Agent or a Lender and/or deliver a
notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral; 

(viii) demand and receive possession of the Books of Borrower and the other Credit Parties; and 

(ix) exercise all other rights and remedies available to Agent under the Financing Documents or at law or equity, including all remedies
provided under the Code (including disposal of the Collateral pursuant to the terms thereof). 
 10.3 Notices. Any notice that Agent
is required to give to a Credit Party under the UCC of the time and place of any public sale or the time after which any private sale or other intended disposition of the Collateral is to be made shall be deemed to constitute reasonable notice if
such notice is given in accordance with this Agreement at least five (5) days prior to such action. 
 10.4 Protective Payments.
If any Credit Party fails to pay or perform any covenant or obligation under this Agreement or any other Financing Document, Agent may pay or perform such covenant or obligation, and all amounts so paid by Agent are Protective Advances and
immediately due and payable, bearing interest at the then highest applicable rate for the Credit Facilities hereunder, and secured by the Collateral. No such payments or performance by Agent shall be construed as an agreement to make similar
payments or performance in the future or constitute Agent’s waiver of any Event of Default. 
 10.5 Liability for Collateral No
Waiver; Remedies Cumulative. So long as Agent and the Lenders comply with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Agent and the Lenders, Agent and the Lenders shall not
be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or
other Person. Borrower bears all risk of loss, damage or destruction of the Collateral. Agent’s failure, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Financing Document shall
not waive, affect, or diminish any right of Agent thereafter to demand strict performance and compliance herewith or therewith. No waiver hereunder shall be effective unless signed by Agent and then is only effective for the specific instance and
purpose for which it is given. Agent’s rights and remedies under this Agreement and the other Financing Documents are cumulative. Agent has all rights and remedies provided under the Code, by Law, or in equity. Agent’s exercise of one
right or remedy is not an election, and Agent’s waiver of any Event of Default is not a continuing waiver. Agent’s delay in exercising any remedy is not a waiver, election, or acquiescence. 

10.6 Application of Payments and Proceeds. Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and
during the continuance of an Event of Default, (i) Borrower, for itself and the other Credit Parties, irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Agent from or on
behalf of Borrower of all or any part of the Obligations, and, as between Borrower and the Credit Parties on the one hand and Agent and Lenders on the other, Agent shall have the continuing and exclusive right to apply and to reapply any and all
payments received against the Obligations in such manner as Agent may deem advisable notwithstanding any previous 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	26	  	

 
application by Agent, and (ii) unless the Agent and the Lenders shall agree otherwise, the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be
applied: first, to the Protective Advances; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts);
third, to the principal amount of the Obligations outstanding; and fourth, to any other indebtedness or obligations of the Credit Parties owing to Agent or any Lender under the Financing Documents. Borrower shall remain fully liable
for any deficiency. Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct. Unless the Agent and the Lenders shall agree otherwise, in
carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any
particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category. 

10.7 Waivers. 
 (a) Except
as otherwise provided for in this Agreement and to the fullest extent permitted by applicable law, Borrower waives: (i) presentment, demand and protest, and notice of presentment, dishonor, intent to accelerate, acceleration, protest, default,
nonpayment, maturity, release, compromise, settlement, extension or renewal of any or all Financing Documents and hereby ratifies and confirms whatever Agent or Lenders may do in this regard; (ii) all rights to notice and a hearing prior to
Agent’s or any Lender’s entry upon the premises of Borrower, the taking possession or control of, or to Agent’s or any Lender’s replevy, attachment or levy upon, any Collateral or any bond or security which might be required by
any court prior to allowing Agent or any Lender to exercise any of its remedies; and (iii) the benefit of all valuation, appraisal and exemption Laws. Borrower acknowledges that it has been advised by counsel of its choice and decision with
respect to this Agreement, the other Financing Documents and the transactions evidenced hereby and thereby. 
 (b) Borrower for itself and
all its successors and assigns, (i) agrees that its liability shall not be in any manner affected by any indulgence, extension of time, renewal, waiver, or modification granted or consented to by Lender; (ii) consents to any indulgences
and all extensions of time, renewals, waivers, or modifications that may be granted by Agent or any Lender with respect to the payment or other provisions of the Financing Documents, and to any substitution, exchange or release of the Collateral, or
any part thereof, with or without substitution, and agrees to the addition or release of Borrower, endorsers, guarantors, or sureties, or whether primarily or secondarily liable, without notice to any other Borrower and without affecting its
liability hereunder; (iii) agrees that its liability shall be unconditional and without regard to the liability of any other Credit Party, Agent or any Lender for any tax on the indebtedness; and (iv) to the fullest extent permitted by
law, expressly waives the benefit of any statute or rule of law or equity now provided, or which may hereafter be provided, which would produce a result contrary to or in conflict with the foregoing. 

(c) To the extent that Agent or any Lender may have acquiesced in any noncompliance with any requirements or conditions precedent to the
closing of the Credit Facilities or to any subsequent disbursement of Credit Extensions, such acquiescence shall not be deemed to constitute a waiver by Agent or any Lender of such requirements with respect to any future Credit Extensions and Agent
may at any time after such acquiescence require Borrower to comply with all such requirements. Any forbearance by Agent or a Lender in exercising any right or remedy under any of the Financing Documents, or otherwise afforded by applicable law,
including any failure to accelerate the maturity date of the Credit Facilities, shall not be a waiver of or preclude the exercise of any right or remedy nor shall it serve as a novation of the Financing Documents or as a reinstatement of the
Obligations or a waiver of such right of acceleration or the right to insist upon strict compliance of the terms of the Financing Documents. Agent’s or any Lender’s acceptance of payment of any sum secured by any of the Financing Documents
after the due date of such payment shall not be a waiver of Agent’s and such Lender’s right to either require prompt payment when due of all other sums so secured or to declare a default for failure to make prompt payment. The procurement
of insurance or the payment of taxes or other Liens or charges by Agent as the result of an Event of Default shall not be a waiver 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	27	  	

 
of Agent’s right to accelerate the maturity of the Obligations, nor shall Agent’s receipt of any condemnation awards, insurance proceeds, or damages under this Agreement operate to cure
or waive any Credit Party’s default in payment of sums secured by any of the Financing Documents. 
 (d) Without limiting the generality
of anything contained in this Agreement or the other Financing Documents, Borrower agrees that if an Event of Default is continuing (i) Agent and Lenders shall not be subject to any “one action” or “election of remedies” law
or rule, and (ii) all Liens and other rights, remedies or privileges provided to Agent or Lenders shall remain in full force and effect until Agent or Lenders have exhausted all remedies against the Collateral and any other properties owned by
Borrower and the Financing Documents and other security instruments or agreements securing the Obligations have been foreclosed, sold and/or otherwise realized upon in satisfaction of Borrower’s obligations under the Financing Documents. 

(e) Neither Agent nor any Lender shall be under any obligation to marshal any assets in payment of any or all of the Obligations. Nothing
contained herein or in any other Financing Document shall be construed as requiring Agent or any Lender to resort to any part of the Collateral for the satisfaction of any of Borrower’s obligations under the Financing Documents in preference or
priority to any other Collateral, and Agent may seek satisfaction out of all of the Collateral or any part thereof, in its absolute discretion in respect of Borrower’s obligations under the Financing Documents. To the fullest extent permitted
by law, Borrower, for itself and its successors and assigns, waives in the event of foreclosure of any or all of the Collateral any equitable right otherwise available to any Credit Party which would require the separate sale of any of the
Collateral or require Agent or Lenders to exhaust their remedies against any part of the Collateral before proceeding against any other part of the Collateral; and further in the event of such foreclosure Borrower does hereby expressly consent to
and authorize, at the option of Agent, the foreclosure and sale either separately or together of each part of the Collateral. 
 10.8
Injunctive Relief. The parties acknowledge and agree that, in the event of a breach or threatened breach of any Credit Party’s obligations under any Financing Documents, Agent and Lenders may have no adequate remedy in money damages and,
accordingly, shall be entitled to an injunction (including, without limitation, a temporary restraining order, preliminary injunction, writ of attachment, or order compelling an audit) against such breach or threatened breach, including, without
limitation, maintaining any cash management and collection procedure described herein. However, no specification in this Agreement of a specific legal or equitable remedy shall be construed as a waiver or prohibition against any other legal or
equitable remedies in the event of a breach or threatened breach of any provision of this Agreement. Each Credit Party waives, to the fullest extent permitted by law, the requirement of the posting of any bond in connection with such injunctive
relief. By joining in the Financing Documents as a Credit Party, each Credit Party specifically joins in this Section 10.8 as if this Section 10.8 were a part of each Financing Document executed by such Credit Party. 

 

	 	11	NOTICES 

 All notices, consents, requests, approvals, demands, or other
communication (collectively, “Communication”) by any party to this Agreement or any other Financing Document must be in writing and shall be deemed to have been validly served, given, or delivered: (a) if to Borrower or any
other U.S. Credit Party or U.S. Subsidiary of a Credit Party, upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage
prepaid; (b) if to any non-U.S. Credit Party or non-U.S. Subsidiary of a Credit Party, upon the earlier or actual receipt and seven (7) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt
requested, with proper postage prepaid; (c) upon transmission, when sent by electronic mail (if an email address is specified herein) or facsimile transmission; (d) if to Borrower or any U.S. Credit Party or U.S. Subsidiary of a Credit
Party, one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid and if to any non-U.S. Credit Party or non-U.S. Subsidiary of a Credit Party, three (3) Business Days after deposit with a reputable
overnight courier with all charges prepaid; or (e) when delivered, 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	28	  	

 
if hand-delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below. Any of Agent, Lender or
Borrower may change its mailing or electronic mail address or facsimile number by giving the other party written notice thereof in accordance with the terms of this Article 11. 

If to Borrower: 
 Quotient Biodiagnostics, Inc. 

Pentlands Science Park, Bush Loan 
 Penicuik, Midlothian, EH26
0PL, United Kingdom 
 Attention: Roland Boyd 
 Fax: +44 131 445
6184 
 E-Mail: roland.boyd@quotientbd.com 
 If to Quotient
Limited: 
 Quotient Limited 
 Pentlands Science Park, Bush
Loan 
 Penicuik, Midlothian, EH26 0PL, United Kingdom 

Attention: Roland Boyd 
 Fax: +44 131 445 6184 

E-Mail: roland.boyd@quotientbd.com 
 If to Alba Bioscience
Limited: 
 Alba Bioscience Limited 
 Pentlands Science
Park, Bush Loan 
 Penicuik, Midlothian, EH26 0PL, United Kingdom 

Attention: Roland Boyd 
 Fax: +44 131 445 6184 

E-Mail: roland.boyd@quotientbd.com 
 If to QBD (QSIP) Limited:

 QBD (QSIP) Limited 
 Pentlands Science Park, Bush Loan

 Penicuik, Midlothian, EH26 0PL, United Kingdom 
 Attention:
Roland Boyd 
 Fax: +44 131 445 6184 
 E-Mail:
roland.boyd@quotientbd.com 
 If to Agent or Lenders: 

MidCap Funding V, LLC 
 7255 Woodmont Avenue, Suite 200 

Bethesda, Maryland 20814 
 Attention: Portfolio Management-Life
Sciences 
 Fax: (301) 941-1450 
 E-Mail:
lviera@midcapfinancial.com 
 with a copy to: 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	29	  	

 MC Serviceco, LLC 

7255 Woodmont Avenue, Suite 200 
 Bethesda, Maryland 20814 

Attention: General Counsel 
 Fax: (301) 941-1450 

E-Mail: legalnotices@midcapfinancial.com 
  

	 	12	CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER 

 12.1 THIS AGREEMENT, EACH SECURED
PROMISSORY NOTE AND EACH OTHER FINANCING DOCUMENT, AND THE RIGHTS, REMEDIES AND OBLIGATIONS OF THE PARTIES HERETO AND THERETO, AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT OR SUCH FINANCING DOCUMENT, THE
RELATIONSHIP OF THE PARTIES, AND/OR THE INTERPRETATION AND ENFORCEMENT OF THE RIGHTS AND DUTIES OF THE PARTIES AND ALL OTHER MATTERS RELATING HERETO, THERETO OR ARISING THEREFROM (WHETHER SOUNDING IN CONTRACT LAW, TORT LAW OR OTHERWISE), SHALL BE
GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF MARYLAND, WITHOUT REFERENCE TO ITS CONFLICT OF LAW PROVISIONS. NOTWITHSTANDING THE FOREGOING, AGENT AND LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR
PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH AGENT AND LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 12.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE
AGENT’S AND LENDERS’ RIGHTS AGAINST BORROWER OR ITS PROPERTY. BORROWER EXPRESSLY SUBMITS AND CONSENTS IN ADVANCE TO SUCH JURISDICTION IN ANY ACTION OR SUIT COMMENCED IN ANY SUCH COURT, AND BORROWER HEREBY WAIVES ANY OBJECTION THAT IT MAY
HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE, OR FORUM NON CONVENIENS AND HEREBY CONSENTS TO THE GRANTING OF SUCH LEGAL OR EQUITABLE RELIEF AS IS DEEMED APPROPRIATE BY SUCH COURT. BORROWER HEREBY WAIVES PERSONAL SERVICE OF THE
SUMMONS, COMPLAINTS, AND OTHER PROCESS ISSUED IN SUCH ACTION OR SUIT AND AGREES THAT SERVICE OF SUCH SUMMONS, COMPLAINTS, AND OTHER PROCESS MAY BE MADE BY REGISTERED OR CERTIFIED MAIL ADDRESSED TO BORROWER AT THE ADDRESS SET FORTH IN ARTICLE 11 OF
THIS AGREEMENT AND THAT SERVICE SO MADE SHALL BE DEEMED COMPLETED UPON THE EARLIER TO OCCUR OF BORROWER’S ACTUAL RECEIPT THEREOF OR THREE (3) DAYS AFTER DEPOSIT IN THE U.S. MAIL, PROPER POSTAGE PREPAID. 

12.2 TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, AGENT AND LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR
CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE FINANCING DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO
THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL. 
 12.3 Borrower, Agent and each Lender agree that each Credit
Extension (including those made on the Closing Date) shall be deemed to be made in, and the transactions contemplated hereunder and in any other Financing Document shall be deemed to have been performed in, the State of Maryland. 

 

	 	13	GENERAL PROVISIONS 

 13.1 Successors and Assigns. 

 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	30	  	

 (a) This Agreement binds and is for the benefit of the successors and permitted assigns of each
party. Borrower may not assign this Agreement or any rights or obligations under it without Agent’s prior written consent (which may be granted or withheld in Agent’s discretion). Any Lender may at any time assign to one or more Eligible
Assignees all or any portion of such Lender’s Applicable Commitment and/or Credit Extensions, together with all related obligations of such Lender hereunder. Borrower and Agent shall be entitled to continue to deal solely and directly with such
Lender in connection with the interests so assigned until Agent shall have received and accepted an effective assignment agreement in form and substance acceptable to Agent, executed, delivered and fully completed by the applicable parties thereto,
and shall have received such other information regarding such Eligible Assignee as Agent reasonably shall require. Notwithstanding anything set forth in this Agreement to the contrary, any Lender may at any time pledge or assign a security interest
in all or any portion of its rights under this Agreement to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided, however, that no such pledge or assignment shall
release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto. If requested by Agent, Borrower agrees to (i) execute any documents reasonably required to effectuate and
acknowledge each assignment of an Applicable Commitment or Credit Extension to an assignee hereunder, (ii) make Borrower’s management available to meet with Agent and prospective participants and assignees of Applicable Commitments or
Credit Extensions and (iii) assist Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of an Applicable Commitment or Credit Extension reasonably may
request. 
 (b) From and after the date on which the conditions described above have been met, (i) such Eligible Assignee shall be
deemed automatically to have become a party hereto and, to the extent of the interests assigned to such Eligible Assignee pursuant to such assignment agreement, shall have the rights and obligations of a Lender hereunder, and (ii) the assigning
Lender, to the extent that rights and obligations hereunder have been assigned by it pursuant to such assignment agreement, shall be released from its rights and obligations hereunder (other than those that survive termination). Upon the request of
the Eligible Assignee (and, as applicable, the assigning Lender) pursuant to an effective assignment agreement, each Borrower shall execute and deliver to Agent for delivery to the Eligible Assignee (and, as applicable, the assigning Lender) secured
notes in the aggregate principal amount of the Eligible Assignee’s Credit Extensions or Applicable Commitments (and, as applicable, secured promissory notes in the principal amount of that portion of the principal amount of the Credit
Extensions or Applicable Commitments retained by the assigning Lender). 
 (c) Agent, acting solely for this purpose as an agent of Borrower,
shall maintain at its offices located in Bethesda, Maryland a copy of each assignment agreement delivered to it and a register for the recordation of the names and addresses of each Lender, and the commitments of, and principal amount of the Credit
Extensions owing to, such Lender pursuant to the terms hereof. The entries in such register shall be conclusive, and Borrower, Agent and Lenders may treat each Person whose name is recorded therein pursuant to the terms hereof as a Lender hereunder
for all purposes of this Agreement, notwithstanding notice to the contrary. Such register shall be available for inspection by Borrower and any Lender, at any reasonable time upon reasonable prior notice to Agent. 

13.2 Indemnification. 
 (a)
Borrower hereby agrees to promptly pay (i) all costs and expenses of Agent (including, without limitation, the fees, costs and expenses of counsel to, and independent appraisers and consultants retained by Agent) in connection with the
examination, review, due diligence investigation, documentation, negotiation, closing and syndication of the transactions contemplated by the Financing Documents, in connection with the performance by Agent of its rights and remedies under the
Financing Documents and in connection with the continued administration of the Financing Documents including (A) any amendments, modifications, consents and waivers to and/or under any and all Financing Documents, and (B) any periodic
public record searches conducted by or at the request of Agent (including, without limitation, 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	31	  	

 
title investigations, UCC searches, fixture filing searches, judgment, pending litigation and tax lien searches and searches of applicable corporate, limited liability, partnership and related
records concerning the continued existence, organization and good standing of certain Persons); (ii) without limitation of the preceding clause (i), all costs and expenses of Agent in connection with the creation, perfection and maintenance of
Liens pursuant to the Financing Documents; (iii) without limitation of the preceding clause (i), all costs and expenses of Agent in connection with (A) protecting, storing, insuring, handling, maintaining or selling any Collateral,
(B) any litigation, dispute, suit or proceeding relating to any Financing Document, and (C) any workout, collection, bankruptcy, insolvency and other enforcement proceedings under any and all of the Financing Documents; (iv) without
limitation of the preceding clause (i), all costs and expenses of Agent in connection with Agent’s reservation of funds in anticipation of the funding of the Credit Extensions to be made hereunder; and (v) all costs and expenses incurred
by Agent or Lenders (including penalties and interest) for which the Credit Parties are responsible under the Financing Documents (including, without limitation, section 2.6(h)) and in connection with any litigation, dispute, suit or proceeding
relating to any Financing Document and in connection with any workout, collection, bankruptcy, insolvency and other enforcement proceedings under any and all Financing Documents, whether or not Agent or Lenders are a party thereto. If Agent or any
Lender uses in-house counsel for any of these purposes, Borrower further agrees that the Obligations include reasonable charges for such work commensurate with the fees that would otherwise be charged by outside legal counsel selected by Agent or
such Lender for the work performed. 
 (b) Borrower hereby agrees to indemnify, pay and hold harmless Agent and Lenders and the officers,
directors, employees, trustees, agents, investment advisors, collateral managers, servicers, and counsel of Agent and Lenders (collectively called the “Indemnitees”) from and against any and all liabilities, obligations, losses,
damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnitee) in connection with any investigative, response, remedial,
administrative or judicial matter or proceeding, whether or not such Indemnitee shall be designated a party thereto and including any such proceeding initiated by or on behalf of a Credit Party, and the reasonable expenses of investigation by
engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Agent or Lenders) asserting any right to payment for the transactions contemplated
hereby, which may be imposed on, incurred by or asserted against such Indemnitee as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the Credit Facilities, except that Borrower
shall have no obligation hereunder to an Indemnitee with respect to any liability resulting from the gross negligence or willful misconduct of such Indemnitee, as determined by a final non-appealable judgment of a court of competent jurisdiction. To
the extent that the undertaking set forth in the immediately preceding sentence may be unenforceable, Borrower shall contribute the maximum portion which it is permitted to pay and satisfy under applicable Law to the payment and satisfaction of all
such indemnified liabilities incurred by the Indemnitees or any of them. No Indemnitee shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications,
electronic or other information transmission systems in connection with this Agreement or the other Financing Documents or the transactions contemplated hereby or thereby. 

(c) Notwithstanding any contrary provision in this Agreement, the obligations of Borrower under this Section 13.2 shall survive the
payment in full of the Obligations and the termination of this Agreement. NO INDEMNITEE SHALL BE RESPONSIBLE OR LIABLE TO ANY CREDIT PARTY OR TO ANY OTHER PARTY TO ANY FINANCING DOCUMENT, ANY SUCCESSOR, ASSIGNEE OR THIRD PARTY BENEFICIARY OR ANY
OTHER PERSON ASSERTING CLAIMS DERIVATIVELY THROUGH SUCH PARTY, FOR INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES WHICH MAY BE ALLEGED AS A RESULT OF CREDIT HAVING BEEN EXTENDED, SUSPENDED OR TERMINATED UNDER THIS AGREEMENT OR ANY OTHER
FINANCING DOCUMENT OR AS A RESULT OF ANY OTHER TRANSACTION CONTEMPLATED HEREUNDER OR THEREUNDER. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	32	  	

 13.3 Time of Essence. Time is of the essence for the payment and performance of the
Obligations in this Agreement. 
 13.4 Severability of Provisions. Each provision of this Agreement is severable from every other
provision in determining the enforceability of any provision. 
 13.5 Correction of Financing Documents. Agent and the Lenders may
correct patent errors and fill in any blanks in this Agreement and the other Financing Documents consistent with the agreement of the parties. 

13.6 Integration. This Agreement and the Financing Documents represent the entire agreement about this subject matter and supersede
prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Financing Documents merge into this Agreement and the
Financing Documents. 
 13.7 Counterparts. This Agreement may be executed in any number of counterparts and by different parties on
separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement. Delivery of an executed signature page of this Agreement by facsimile transmission or electronic transmission shall
be as effective as delivery of a manually executed counterpart hereof. 
 13.8 Survival. All covenants, representations and warranties
made in this Agreement continue in full force until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of
this Agreement) have been satisfied. The obligation of Borrower in Section 13.2 to indemnify each Lender and Agent shall survive until the statute of limitations with respect to such claim or cause of action shall have run. All powers of
attorney and appointments of Agent or any Lender as Borrower’s attorney in fact hereunder, and all of Agent’s and Lenders’ rights and powers in respect thereof, are coupled with an interest, are irrevocable until all Obligations
(other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been fully repaid and performed and Agent’s and the Lenders’ obligation to provide Credit
Extensions terminates. 
 13.9 Confidentiality. In handling any confidential information of Borrower, each of the Lenders and Agent
shall use all reasonable efforts to maintain, in accordance with its customary practices, the confidentiality of information obtained by it pursuant to any Financing Document, but disclosure of information may be made: (a) to the Lenders’
and Agent’s Subsidiaries or Affiliates for purposes reasonably related to this Agreement; (b) to prospective transferees or purchasers of any interest in the Credit Extensions that are advised of the confidential nature of such information
and are instructed to keep such information confidential; (c) as required by Law, regulation, subpoena, order or other legal, administrative, governmental or regulatory request; (d) to regulators or as otherwise required in connection with
an examination or audit, or to any nationally recognized rating agency; (e) as Agent or any Lender considers appropriate in exercising remedies under the Financing Documents; (f) to financing sources that are advised of the confidential
nature of such information and are instructed to keep such information confidential; (g) to third party service providers of the Lenders and/or Agent so long as such service providers are bound to such Lender or Agent by obligations of
confidentiality; and (h) in connection with any litigation or other proceeding to which such Lender or Agent or any of their Affiliates is a party or bound. Confidential information does not include information that either: (i) is in the
public domain or in the Lenders’ and/or Agent’s possession when disclosed to the Lenders and/or Agent, or becomes part of the public domain after disclosure to the Lenders and/or Agent; or (ii) is disclosed to the Lenders and/or Agent
by a third party, if the Lenders and/or Agent does not know that the third party is prohibited from disclosing the information. The agreements provided under this Section 13.9 supersede all prior agreements, understanding, representations,
warranties, and negotiations between the parties about the subject matter of this Section 13.9. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	33	  	

 13.10 Right of Set-off. Borrower hereby grants to Agent and to each Lender, a lien,
security interest and right of set-off as security for all Obligations to Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession,
custody, safekeeping or control of Agent or the Lenders or any entity under the control of Agent or the Lenders (including an Agent or Lender Affiliate) or in transit to any of them. At any time after the occurrence and during the continuance of an
Event of Default, without demand or notice, Agent or the Lenders may set-off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral
securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SET-OFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR
OTHER PROPERTY OF BORROWER, ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED. 
 13.11 Publicity. Borrower will not directly
or indirectly publish, disclose or otherwise use in any public disclosure, advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of Agent or any Lender or any of their Affiliates or
any reference to this Agreement or the financing evidenced hereby, in any case except as required by applicable Law, subpoena or judicial or similar order, in which case Borrower shall endeavor to give Agent prior written notice of such publication
or other disclosure. Each Lender and Borrower hereby authorizes each Lender to publish the name of such Lender and Borrower, the existence of the financing arrangements referenced under this Agreement, the primary purpose and/or structure of those
arrangements, the amount of credit extended under each facility, the title and role of each party to this Agreement, and the total amount of the financing evidenced hereby in any “tombstone”, comparable advertisement or press release which
such Lender elects to submit for publication. In addition, each Lender and Borrower agrees that each Lender may provide lending industry trade organizations with information necessary and customary for inclusion in league table measurements after
the Closing Date. With respect to any of the foregoing, such authorization shall be subject to such Lender providing Borrower and the other Lenders with an opportunity to review and confer with such Lender regarding, and approve, the contents of any
such tombstone, advertisement or information, as applicable, prior to its initial submission for publication, but subsequent publications of the same tombstone, advertisement or information shall not require Borrower’s approval. 

13.12 No Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the
authorship of any provisions of this Agreement. 
 13.13 Approvals. Unless expressly provided herein to the contrary, any approval,
consent, waiver or satisfaction of Agent or Lenders with respect to any matter that is the subject of this Agreement or the other Financing Documents may be granted or withheld by Agent and Lenders in their sole and absolute discretion and credit
judgment. 
 13.14 Amendments; Required Lenders; Inter-Lender Matters. 

(a) No amendment, modification, termination or waiver of any provision of this Agreement or any other Financing Document, no approval or
consent thereunder, or any consent to any departure by Borrower therefrom (in each case, other than amendments, waivers, approvals or consents deemed ministerial by Agent), shall in any event be effective unless the same shall be in writing and
signed by Borrower, the other Credit Parties if directly affected thereby, Agent and Required Lenders. Except as set forth in clause (b) below, all such amendments, modifications, terminations or waivers requiring the consent of the
“Lenders” shall require the written consent of Required Lenders. 
 (b) No amendment, modification, termination or waiver of any
provision of this Agreement or any other Financing Document shall, unless in writing and signed by Agent and by each Lender 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	34	  	

 
directly affected thereby: (i) increase or decrease the Applicable Commitment of any Lender (which shall be deemed to affect all Lenders), (ii) reduce the principal of or rate of
interest on any Obligation or the amount of any fees payable hereunder, (iii) postpone the date fixed for or waive any payment of principal of or interest on any Credit Extension, or any fees or reimbursement obligation hereunder,
(iv) release all or substantially all of the Collateral, or consent to a transfer of any of the Intellectual Property, in each case, except as otherwise expressly permitted in the Financing Documents (which shall be deemed to affect all
Lenders), (v) subordinate the lien granted in favor of Agent securing the Obligations (which shall be deemed to affect all Lenders, except as otherwise provided below), (vi) except as otherwise permitted under this Agreement release a
Credit Party from, or consent to a Credit Party’s assignment or delegation of, such Credit Party’s obligations hereunder and under the other Financing Documents or any Guarantor from its guarantee of the Obligations (which shall be deemed
to affect all Lenders); or (vii) amend, modify, terminate or waive this Section 13.14(b) or the definition of “Required Lenders” or “Pro Rata Share” or any other provision hereof specifying the number or percentage of
Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder, without the consent of each Lender. For purposes of the foregoing, no Lender shall be deemed affected by
(i) waiver of the imposition of the Default Rate or imposition of the Default Rate to only a portion of the Obligations, (ii) waiver of the accrual of late charges, (iii) waiver of any fee solely payable to Agent under the Financing
Documents, (iv) subordination of a lien granted in favor of Agent provided such subordination is limited to equipment being financed by a third party providing Permitted Indebtedness. Notwithstanding any provision in this Section 13.14 to
the contrary, no amendment, modification, termination or waiver affecting or modifying the rights or obligations of Agent hereunder shall be effective unless signed by Agent and Required Lenders. 

(c) Agent shall not grant its written consent to any deviation or departure by Borrower or any Credit Party from the provisions of Article 7
without the prior written consent of the Required Lenders. Required Lenders shall have the right to direct Agent to take any action described in Section 10.2(b). Upon the occurrence of any Event of Default, Agent shall have the right to
exercise any and all remedies referenced in Section 10.2 without the written consent of Required Lenders following the occurrence of an “Exigent Circumstance” (as defined below). All matters requiring the satisfaction or acceptance of
Agent in the definition of Subordinated Debt shall further require the satisfaction and acceptance of each Required Lender. Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation
“ratably,” “proportionally” or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise. As used in this Section, “Exigent Circumstance” means any event or circumstance that, in the
reasonable judgment of Agent, imminently threatens the ability of Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material
waste thereof, or failure of Borrower after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Agent, could result in a material diminution in value of the Collateral. 

13.15 Borrower Liability. If there is more than one entity comprising Borrower, then (a) any Borrower may, acting singly, request
Credit Extensions hereunder, (b) each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions hereunder, (c) each Borrower shall be jointly and severally
obligated to pay and perform all obligations under the Financing Documents, including, but not limited to, the obligation to repay all Credit Extensions made hereunder and all other Obligations, regardless of which Borrower actually receives said
Credit Extensions, as if each Borrower directly received all Credit Extensions, and (d) each Borrower waives (1) any suretyship defenses available to it under the Code or any other applicable law, and (2) any right to require the
Lenders or Agent to: (A) proceed against any Borrower or any other person; (B) proceed against or exhaust any security; or (C) pursue any other remedy. The Lenders or Agent may exercise or not exercise any right or remedy they have
against any Credit Party or any security (including the right to foreclose by judicial or non-judicial sale) without affecting any other Credit Party’s liability or any Lien against any other Credit Party’s assets. Notwithstanding any
other provision of this Agreement or other related document, until payment in full of the Obligations and termination of the Applicable Commitments, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without
limitation, any law subrogating Borrower to the 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	35	  	

 
rights of the Lenders and Agent under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Credit Party, or any other Person now or hereafter
primarily or secondarily liable for any of the Obligations, for any payment made by any Credit Party with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate
in, any security for the Obligations as a result of any payment made by a Credit Party with respect to the Obligations in connection with this Agreement or otherwise. Any agreement providing for indemnification, reimbursement or any other
arrangement prohibited under this Section shall be null and void. If any payment is made to a Credit Party in contravention of this Section, such Credit Party shall hold such payment in trust for the Lenders and Agent and such payment shall be
promptly delivered to Agent for application to the Obligations, whether matured or unmatured. 
 13.16 Reinstatement. This Agreement
shall remain in full force and effect and continue to be effective should any petition or other proceeding be filed by or against any Credit Party for liquidation or reorganization, should any Credit Party become insolvent or make an assignment for
the benefit of any creditor or creditors or should an interim receiver, receiver, receiver and manager or trustee be appointed for all or any significant part of any Credit Party’s assets, and shall continue to be effective or to be reinstated,
as the case may be, if at any time payment and performance of the Obligations, or any part thereof, is, pursuant to applicable law, rescinded or reduced in amount, or must otherwise be restored or returned by any obligee of the Obligations, whether
as a fraudulent preference reviewable transaction or otherwise, all as though such payment or performance had not been made. In the event that any payment, or any part thereof, is rescinded, reduced, restored or returned, the Obligations shall be
reinstated and deemed reduced only by such amount paid and not so rescinded, reduced, restored or returned. 
 13.17 USA PATRIOT Act
Notification. Agent (for itself and not on behalf of any Lender) and each Lender hereby notifies Borrower that pursuant to the requirements of the USA PATRIOT Act, it is required to obtain, verify and record certain information and documentation
that identifies Borrower, which information includes the name and address of Borrower and such other information that will allow Agent or such Lender, as applicable, to identify Borrower in accordance with the USA PATRIOT Act. 

13.18 Warrants. Notwithstanding anything to the contrary herein, any warrants issued to the Lenders by any Credit Party, the stock
issuable thereunder, any equity securities purchased by Lenders, any amounts paid thereunder, any dividends, and any other rights in connection therewith shall not be subject to the terms and conditions of this Agreement. Nothing herein shall affect
any Lender’s rights under any such warrants, stock, or other equity securities to administer, manage, transfer, assign, or exercise such warrants, stock, or other equity securities for its own account. 

 

	 	14	AGENT 

 14.1 Appointment and Authorization of Agent. Each Lender hereby
irrevocably appoints, designates and authorizes Agent to take such action on its behalf under the provisions of this Agreement and each other Financing Document and to exercise such powers and perform such duties as are expressly delegated to it by
the terms of this Agreement or any other Financing Document, together with such powers as are reasonably incidental thereto. The provisions of this Article are solely for the benefit of Agent and Lenders and none of Credit Parties nor any other
Person shall have any rights as a third party beneficiary of any of the provisions hereof. The duties of Agent shall be mechanical and administrative in nature. Notwithstanding any provision to the contrary contained elsewhere herein or in any other
Financing Document, Agent shall not have any duties or responsibilities, except those expressly set forth herein, nor shall Agent have or be deemed to have any fiduciary relationship with any Lender or participant, and no implied covenants,
functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Financing Document or otherwise exist against Agent. Without limiting the generality of the foregoing sentence, the use of the term
“agent” herein and in the other Financing Documents with reference to Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used
merely as a matter of market custom, and is intended to create or reflect only 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	36	  	

 
an administrative relationship between independent contracting parties. Without limiting the generality of the foregoing, Agent shall have the sole and exclusive right and authority (to the
exclusion of the Lenders), and is hereby authorized, to (a) act as collateral agent for Agent and each Lender for purposes of the perfection of all liens created by the Financing Documents and all other purposes stated therein, (b) manage,
supervise and otherwise deal with the Collateral, (c) take such other action as is necessary or desirable to maintain the perfection and priority of the liens created or purported to be created by the Financing Documents, (d) except as may
be otherwise specified in any Financing Document, exercise all remedies given to Agent and the other Lenders with respect to the Collateral, whether under the Financing Documents, applicable law or otherwise and (e) execute any amendment,
consent or waiver under the Financing Documents on behalf of any Lender that has consented in writing to such amendment, consent or waiver; provided, however, that Agent hereby appoints, authorizes and directs each Lender to act as collateral
sub-agent for Agent and the Lenders for purposes of the perfection of all liens with respect to the Collateral, including any deposit account maintained by a Credit Party with, and cash and cash equivalents held by, such Lender, and may further
authorize and direct the Lenders to take further actions as collateral sub-agents for purposes of enforcing such liens or otherwise to transfer the Collateral subject thereto to Agent, and each Lender hereby agrees to take such further actions to
the extent, and only to the extent, so authorized and directed. 
 14.2 Successor Agent. 

(a) Agent may at any time assign its rights, powers, privileges and duties hereunder to (i) another Lender, or (ii) any Person to
whom Agent, in its capacity as a Lender, has assigned (or will assign, in conjunction with such assignment of agency rights hereunder) fifty percent (50%) or more of the Credit Extensions or Applicable Commitments then held by Agent (in its
capacity as a Lender), in each case without the consent of the Lenders or Borrower. Following any such assignment, Agent shall give notice to the Lenders and Borrower. An assignment by Agent pursuant to this subsection (a) shall not be deemed a
resignation by Agent for purposes of subsection (b) below. 
 (b) Without limiting the rights of Agent to designate an assignee pursuant
to subsection (a) above, Agent may at any time give notice of its resignation to the Lenders and Borrower. Upon receipt of any such notice of resignation, Required Lenders shall have the right to appoint a successor Agent. If no such successor shall
have been so appointed by Required Lenders and shall have accepted such appointment within ten (10) Business Days after the retiring Agent gives notice of its resignation, then the retiring Agent may, on behalf of the Lenders, appoint a
successor Agent; provided, however, that if Agent shall notify Borrower and the Lenders that no Person has accepted such appointment, then such resignation shall nonetheless become effective in accordance with such notice from Agent that no
Person has accepted such appointment and, from and following delivery of such notice, (i) the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Financing Documents, and (ii) all payments,
communications and determinations provided to be made by, to or through Agent shall instead be made by or to each Lender directly, until such time as Required Lenders appoint a successor Agent as provided for above in this subsection (b). 

(c) Upon (i) an assignment permitted by subsection (a) above, or (ii) the acceptance of a successor’s appointment as Agent
pursuant to subsection (b) above, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Agent, and the retiring Agent shall be discharged from all of its duties and
obligations hereunder and under the other Financing Documents (if not already discharged therefrom as provided above in this subsection (c)). The fees payable by Borrower to a successor Agent shall be the same as those payable to its predecessor
unless otherwise agreed between Borrower and such successor. After the retiring Agent’s resignation hereunder and under the other Financing Documents, the provisions of this Article shall continue in effect for the benefit of such retiring
Agent and its sub-agents in respect of any actions taken or omitted to be taken by any of them while the retiring Agent was acting or was continuing to act as Agent. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	37	  	

 14.3 Delegation of Duties. Agent may execute any of its duties under this Agreement or any
other Financing Document by or through its, or its Affiliates’, agents, employees or attorneys-in-fact and shall be entitled to obtain and rely upon the advice of counsel and other consultants or experts concerning all matters pertaining to
such duties. Agent shall not be responsible for the negligence or misconduct of any agent or attorney-in-fact that it selects in the absence of gross negligence or willful misconduct. Any such Person to whom Agent delegates a duty shall benefit from
this Article 14 to the extent provided by Agent. 
 14.4 Liability of Agent. Except as otherwise provided herein, no
“Agent-Related Person” (as defined below) shall (a) be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other Financing Document or the transactions contemplated
hereby (except for its own gross negligence or willful misconduct in connection with its duties expressly set forth herein), or (b) be responsible in any manner to any Lender or participant for any recital, statement, representation or warranty
made by any Credit Party or any officer thereof, contained herein or in any other Financing Document, or in any certificate, report, statement or other document referred to or provided for in, or received by Agent under or in connection with, this
Agreement or any other Financing Document, or the validity, effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Financing Document, or for any failure of any Credit Party or any other party to any Financing
Document to perform its obligations hereunder or thereunder. No Agent-Related Person shall be under any obligation to any Lender or participant to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or
conditions of, this Agreement or any other Financing Document, or to inspect the Collateral, other properties or books or records of any Credit Party or any Affiliate thereof. The term “Agent-Related Person” means the Agent,
together with its Affiliates, and the officers, directors, employees, agents, advisors, auditors and attorneys-in-fact of such Persons; provided, however, that no Agent-Related Person shall be an Affiliate of Borrower. 

14.5 Reliance by Agent. Agent shall be entitled to rely, and shall be fully protected in relying, upon any writing, communication,
signature, resolution, representation, notice, consent, certificate, affidavit, letter, telegram, facsimile, telex or telephone message, electronic mail message, statement or other document or conversation believed by it to be genuine and correct
and to have been signed, sent or made by the proper Person or Persons, and upon advice and statements of legal counsel (including counsel to Borrower), independent accountants and other experts selected by Agent. Agent shall be fully justified in
failing or refusing to take any action under any Financing Document (a) if such action would, in the opinion of Agent, be contrary to law or any Financing Document, (b) if such action would, in the opinion of Agent, expose Agent to any
potential liability under any law, statute or regulation or (c) if Agent shall not first have received such advice or concurrence of all Lenders as it deems appropriate and, if it so requests, it shall first be indemnified to its satisfaction
by the Lenders against any and all liability and expense which may be incurred by it by reason of taking or continuing to take any such action. Agent shall in all cases be fully protected in acting, or in refraining from acting, under this Agreement
or any other Financing Document in accordance with a request or consent of all Lenders (or Required Lenders where authorized herein) and such request and any action taken or failure to act pursuant thereto shall be binding upon all the Lenders. 

14.6 Notice of Default. Agent shall not be deemed to have knowledge or notice of the occurrence of any Default and/or Event of Default,
unless Agent shall have received written notice from a Lender or Borrower, describing such default or Event of Default. Agent will notify the Lenders of its receipt of any such notice. While an Event of Default has occurred and is continuing, Agent
may (but shall not be obligated to) take such action, or refrain from taking such action, with respect to such Event of Default as Agent shall deem advisable or in the best interest of the Lenders, including without limitation, satisfaction of other
security interests, liens or encumbrances on the Collateral not permitted under the Financing Documents, payment of taxes on behalf of Borrower or any other Credit Party, payments to landlords, warehouseman, bailees and other Persons in possession
of the Collateral and other actions to protect and safeguard the Collateral, and actions with respect to insurance claims for casualty events affecting a Credit Party and/or the Collateral. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	38	  	

 14.7 Credit Decision; Disclosure of Information by Agent. Each Lender acknowledges that no
Agent-Related Person has made any representation or warranty to it, and that no act by Agent hereafter taken, including any consent to and acceptance of any assignment or review of the affairs of Borrower or any Affiliate thereof, shall be deemed to
constitute any representation or warranty by any Agent-Related Person to any Lender as to any matter, including whether Agent-Related Persons have disclosed material information in their possession. Each Lender represents to Agent that it has,
independently and without reliance upon any Agent-Related Person and based on such documents and information as it has deemed appropriate, made its own appraisal of, and investigation into, the business, prospects, operations, property, financial
and other condition and creditworthiness of the Credit Parties, and all applicable bank or other regulatory Laws relating to the transactions contemplated hereby, and made its own decision to enter into this Agreement and to extend credit to
Borrower hereunder. Each Lender also represents that it will, independently and without reliance upon any Agent-Related Person and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit
analysis, appraisals and decisions in taking or not taking action under this Agreement and the other Financing Documents, and to make such investigations as it deems necessary to inform itself as to the business, prospects, operations, property,
financial and other condition and creditworthiness of Borrower. Except for notices, reports and other documents expressly required to be furnished to the Lenders by Agent herein, Agent shall not have any duty or responsibility to provide any Lender
with any credit or other information concerning the business, prospects, operations, property, financial and other condition or creditworthiness of any Credit Party which may come into the possession of any Agent-Related Person. 

14.8 Indemnification of Agent. Whether or not the transactions contemplated hereby are consummated, each Lender shall, severally and pro
rata based on its respective Pro Rata Share, indemnify upon demand each Agent-Related Person (to the extent not reimbursed by or on behalf of Borrower and without limiting the obligation of Borrower to do so), and hold harmless each Agent-Related
Person from and against any and all Indemnified Liabilities (which shall not include legal expenses of Agent incurred in connection with the closing of the transactions contemplated by this Agreement) incurred by it; provided, however, that
no Lender shall be liable for the payment to any Agent-Related Person of any portion of such Indemnified Liabilities to the extent determined in a judgment by a court of competent jurisdiction to have resulted from such Agent-Related Person’s
own gross negligence or willful misconduct; provided, however, that no action taken in accordance with the directions of the Required Lenders shall be deemed to constitute gross negligence or willful misconduct for purposes of this Section.
Without limitation of the foregoing, each Lender shall, severally and pro rata based on its respective Pro Rata Share, reimburse Agent upon demand for its ratable share of any costs or out-of-pocket expenses (including Protective Advances incurred
after the closing of the transactions contemplated by this Agreement) incurred by Agent (in its capacity as Agent, and not as a Lender) in connection with the preparation, execution, delivery, administration, modification, amendment or enforcement
(whether through negotiations, legal proceedings or otherwise) of, or legal advice in respect of rights or responsibilities under, this Agreement, any other Financing Document, or any document contemplated by or referred to herein, to the extent
that Agent is not reimbursed for such expenses by or on behalf of Borrower. The undertaking in this Section shall survive the payment in full of the Obligations, the termination of this Agreement and the resignation of Agent. 

14.9 Agent in its Individual Capacity. With respect to its Credit Extensions, MidCap shall have the same rights and powers under this
Agreement as any other Lender and may exercise such rights and powers as though it were not Agent, and the terms “Lender” and “Lenders” include MidCap in its individual capacity. MidCap and its Affiliates may lend money to,
invest in, and generally engage in any kind of business with, any Credit Party and any of their Affiliates and any person who may do business with or own securities of any Credit Party or any of their Affiliates, all as if MidCap were not Agent and
without any duty to account therefor to Lenders. MidCap and its Affiliates may accept fees and other consideration from a Credit Party for services in connection with this Agreement or otherwise without having to account for the same to Lenders.
Each Lender acknowledges the potential conflict of interest between MidCap as a Lender holding disproportionate interests in the Credit Extensions and MidCap as Agent, and expressly consents to, and waives, any claim based upon, such conflict of
interest. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	39	  	

 14.10 Agent May File Proofs of Claim. In case of the pendency of any receivership,
insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to any Credit Party, Agent (irrespective of whether the principal of any Credit Extension, shall then be due and payable
as herein expressed or by declaration or otherwise and irrespective of whether Agent shall have made any demand on such Credit Party) shall be entitled and empowered, by intervention in such proceeding or otherwise: 

(a) to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Credit Extensions and all
other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and Agent (including any claim for the reasonable compensation, expenses, disbursements and
advances of the Lenders and Agent and their respective agents and counsel and all other amounts due the Lenders and Agent allowed in such judicial proceeding); and 

(b) to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; 

and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by
each Lender to make such payments to Agent and, in the event that Agent shall consent to the making of such payments directly to the Lenders, to pay to Agent any amount due for the reasonable compensation, expenses, disbursements and advances of
Agent and its agents and counsel, including Protective Advances. To the extent that Agent fails timely to do so, each Lender may file a claim relating to such Lender’s claim. 

14.11 Collateral and Guaranty Matters. The Lenders irrevocably authorize Agent, at its option and in its discretion, to release
(a) any Credit Party and any Lien on any Collateral granted to or held by Agent under any Financing Document upon the date that all Obligations due hereunder have been fully and indefeasibly paid in full and no Applicable Commitments or other
obligations of any Lender to provide funds to Borrower under this Agreement remain outstanding, and (b) any Lien on any Collateral that is transferred or to be transferred as part of or in connection with any transfer permitted hereunder or
under any other Financing Document. Upon request by Agent at any time, all Lenders will confirm in writing Agent’s authority to release its interest in particular types or items of Collateral pursuant to this Section 14.11. 

14.12 Advances; Payments; Non-Funding Lenders. 

(a) Advances; Payments. If Agent receives any payment for the account of Lenders on or prior to 11:00 a.m. (New York time) on any
Business Day, Agent shall pay to each applicable Lender such Lender’s Pro Rata Share of such payment on such Business Day. If Agent receives any payment for the account of Lenders after 11:00 a.m. (New York time) on any Business Day, Agent
shall pay to each applicable Lender such Lender’s Pro Rata Share of such payment on the next Business Day. To the extent that any Lender has failed to fund any Credit Extension (a “Non-Funding Lender”),
Agent shall be entitled to set-off the funding short-fall against that Non-Funding Lender’s Pro Rata Share of all payments received from Borrower. 

(b) Return of Payments. 

(i) If Agent pays an amount to a Lender under this Agreement in the belief or expectation that a related payment has been or will be received
by Agent from a Credit Party and such related payment is not received by Agent, then Agent will be entitled to recover such amount (including interest accruing on such amount at the Federal Funds Rate for the first Business Day and thereafter, at
the rate otherwise applicable to such Obligation) from such Lender on demand without set-off, counterclaim or deduction of any kind. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	40	  	

 (ii) If Agent determines at any time that any amount received by Agent under this Agreement must
be returned to a Credit Party or paid to any other person pursuant to any insolvency law or otherwise, then, notwithstanding any other term or condition of this Agreement or any other Financing Document, Agent will not be required to distribute any
portion thereof to any Lender. In addition, each Lender will repay to Agent on demand any portion of such amount that Agent has distributed to such Lender, together with interest at such rate, if any, as Agent is required to pay to a Credit Party or
such other person, without set-off, counterclaim or deduction of any kind. 
 14.13 Miscellaneous. 

(a) Neither Agent nor any Lender shall be responsible for the failure of any Non-Funding Lender to make a Credit Extension or make any other
advance required hereunder. The failure of any Non-Funding Lender to make any Credit Extension or any payment required by it hereunder shall not relieve any other Lender (each such other Lender, an “Other Lender”) of
its obligations to make the Credit Extension or payment required by it, but neither any Other Lender nor Agent shall be responsible for the failure of any Non-Funding Lender to make a Credit Extension or make any other payment required hereunder.
Notwithstanding anything set forth herein to the contrary, a Non-Funding Lender shall not have any voting or consent rights under or with respect to any Financing Document or constitute a “Lender” (or be included in the calculation of
“Required Lender” hereunder) for any voting or consent rights under or with respect to any Financing Document. At Borrower’s request, Agent or a person reasonably acceptable to Agent shall have the right with Agent’s consent and
in Agent’s sole discretion (but shall have no obligation) to purchase from any Non-Funding Lender, and each Non-Funding Lender agrees that it shall, at Agent’s request, sell and assign to Agent or such person, all of the Applicable
Commitments and all of the outstanding Credit Extensions of that Non-Funding Lender for an amount equal to the principal balance of the Credit Extensions held by such Non-Funding Lender and all accrued interest and fees with respect thereto through
the date of sale, such purchase and sale to be consummated pursuant to an executed assignment agreement reasonably acceptable to Agent. 

(b) Each Lender shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender’s
portion of any Credit Extension and the ratable distribution of interest, fees and reimbursements paid or made by any Credit Party. Notwithstanding the foregoing, if this Agreement requires payments of principal and interest to be made directly to
the Lenders, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date; provided, however, if it is determined that a Lender received more than
its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to the Agent (for Agent to redistribute to itself and the Lenders in a manner to ensure the payment to Agent of any sums due Agent hereunder and the
ratable repayment of each Lender’s portion of any Credit Extension and the ratable distribution of interest, fees and reimbursements) such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by
Agent. If any payment or distribution of any kind or character, whether in cash, properties or securities and whether voluntary, involuntary, through the exercise of any right of set-off, or otherwise, shall be received by a Lender in excess of its
ratable share, then (i) the portion of such payment or distribution in excess of such Lender’s ratable share shall be received by such Lender in trust for application to the payments of amounts due on the other Lender’s claims, or, in
the case of Collateral, shall hold such Collateral for itself and as agent and bailee for the Agent and other Lenders and (ii) such Lender shall promptly advise the Agent of the receipt of such payment, and, within five (5) Business Days
of such receipt and, in the case of payments and distributions, such Lender shall purchase (for cash at face value) from the other Lenders (through the Agent), without recourse, such participations in the Credit Extension made by the other Lenders
as shall be necessary to cause such purchasing Lender to share the excess payment ratably with each of them in accordance with the respective Pro Rata Shares of the Lenders; provided, however, that if all or any portion of such excess payment
is thereafter recovered by or on behalf of a Credit Party from such purchasing Lender, the purchase shall be rescinded and the purchase price restored to the extent of such recovery, but without interest; provided, further, that the
provisions of this Section shall not be construed to apply to (x) any payment made by a Credit Party pursuant to and in accordance with the express terms of this Agreement or the other Financing Documents, or (y) any payment obtained by a
Lender 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	41	  	

 
as consideration for the assignment of or sale of a participation in any of its Applicable Commitment pursuant to Section 13.1. Borrower agrees that any Lender so purchasing a participation
from another Lender pursuant to this Section may exercise all its rights of payment (including the right of set-off) with respect to such participation as fully as if such Lender were the direct creditor of the Borrower in the amount of such
participation. No documentation other than notices and the like shall be required to implement the terms of this Section. The Agent shall keep records (which shall be conclusive and binding in the absence of manifest error) of participations
purchased pursuant to this Section and shall in each case notify the Lenders following any such purchases. 
  

	 	15	GUARANTY 

 15.1 Guaranty. Each Guarantor hereby unconditionally
(a) guarantees, as a primary obligor and not merely as a surety, jointly and severally with each other Guarantor when and as due, whether at maturity, by acceleration, by notice of prepayment or otherwise, the due and punctual performance of
all of the Obligations, including payment in full of the principal, accrued but unpaid interest and all other amounts due and owing to the Agent and Lenders under the Term Credit Facility and (b) indemnifies each Lender immediately on demand
against any cost, loss or liability suffered by such Lender if any obligations guaranteed by it are or become unenforceable, invalid, voided, avoid or illegal, the amount of which such cost, loss or liability shall be equal to the amount which such
Lender would otherwise be entitled to recover. Each payment made by any Guarantor pursuant to this Section 15 shall be made in lawful money of the United States in immediately available funds. 

15.2 Payment of Amounts Owed. The Guarantee hereunder is an absolute, unconditional and continuing guarantee of the full and punctual
payment and performance of all of the Obligations and not of their collectability only and is in no way conditioned upon any requirement that the Agent or any Lender first attempt to collect any of the Obligations from Borrower or resort to any
collateral security or other means of obtaining payment. In the event of any default by Borrower in the payment of the Obligations, after the expiration of any applicable cure or grace period, each Guarantor agrees, on demand by Agent (which demand
may be made concurrently with notice to Borrower that Borrower is in default of its obligations), to pay the Obligations, regardless of any defense, right of set-off or recoupment or claims which Borrower or Guarantor may have against Agent or
Lenders or the holder of the Notes. All of the remedies set forth in this Agreement, in any other Financing Document or at law or equity shall be equally available to Agent and Lenders, and the choice by Agent or Lenders of one such alternative over
another shall not be subject to question or challenge by any Guarantor or any other person, nor shall any such choice be asserted as a defense, setoff, recoupment or failure to mitigate damages in any action, proceeding, or counteraction by Agent or
Lenders to recover or seeking any other remedy under this Guarantee, nor shall such choice preclude Agent or Lenders from subsequently electing to exercise a different remedy. 

15.3 Certain Waivers by Guarantor. To the fullest extent permitted by law, each Guarantor does hereby: 

(a) waive notice of acceptance of this Agreement by Agent and Lenders and any and all notices and demands of every kind which may be required
to be given by any statute, rule or law; 
 (b) agree to refrain from asserting, until after repayment in full of the Obligations, any
defense, right of set-off, right of recoupment or other claim which such Guarantor may have against Borrower; 
 (c) waive any defense, right
of set-off, right of recoupment or other claim which such Guarantor may have against Agent, Lenders or the holder of the Notes; 
 (d) waive
any and all rights such Guarantor may have under any anti-deficiency statute or other similar protections; 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	42	  	

 (e) waive all rights at law or in equity to seek subrogation, contribution, indemnification or
any other form of reimbursement or repayment from Borrower, any other Guarantor or any other person or entity now or hereafter primarily or secondarily liable for any of the Obligations until the Obligations have been paid in full; 

(f) waive presentment for payment, demand for payment, notice of nonpayment or dishonor, protest and notice of protest, diligence in collection
and any and all formalities which otherwise might be legally required to charge such Guarantor with liability; 
 (g) waive the benefit of
all appraisement, valuation, marshalling, forbearance, stay, extension, redemption, homestead, exemption and moratorium laws now or hereafter in effect; 

(h) waive any defense based on the incapacity, lack of authority, death or disability of any other person or entity or the failure of Agent or
Lenders to file or enforce a claim against the estate of any other person or entity in any administrative, bankruptcy or other proceeding; 

(i) waive any defense based on an election of remedies by Agent or Lenders, whether or not such election may affect in any way the recourse,
subrogation or other rights of such Guarantor against Borrower, any other Guarantor or any other person in connection with the Obligations; 

(j) waive any defense based on the failure of the Agent or Lenders to (i) provide notice to such Guarantor of a sale or other disposition
of any of the security for any of the Obligations, or (ii) conduct such a sale or disposition in a commercially reasonable manner; 

(k) waive any defense based on the negligence of Agent or Lenders in administering this Agreement or the other Financing Documents (including,
but not limited to, the failure to perfect any security interest in any Collateral), or taking or failing to take any action in connection therewith, provided, however, that such waiver shall not apply to the gross negligence or willful
misconduct of the Agent or Lenders, as determined by the final, non-appealable decision of a court having proper jurisdiction; 
 (l) waive
the defense of expiration of any statute of limitations affecting the liability of such Guarantor hereunder or the enforcement hereof; 
 (m)
waive any right to file any Claim (as defined below) as part of, and any right to request consolidation of any action or proceeding relating to a Claim with, any action or proceeding filed or maintained by Agent or Lenders to collect any Obligations
of such Guarantor to Agent or Lenders hereunder or to exercise any rights or remedies available to Agent or Lenders under the Financing Documents, at law, in equity or otherwise; 

(n) agree that neither Agent nor Lenders shall have any obligation to obtain, perfect or retain a security interest in any property to secure
any of the Obligations (including any mortgage or security interest contemplated by the Financing Documents), or to protect or insure any such property; 

(o) waive any obligation Agent or Lenders may have to disclose to such Guarantor any facts the Agent or Lenders now or hereafter may know or
have reasonably available to it regarding Borrower or Borrower’s financial condition, whether or not the Agent or Lenders have a reasonable opportunity to communicate such facts or have reason to believe that any such facts are unknown to such
Guarantor or materially increase the risk to such Guarantor beyond the risk such Guarantor intends to assume hereunder; 
 (p) agree that
neither Agent nor Lenders shall be liable in any way for any decrease in the value or marketability of any property securing any of the Obligations which may result from any action or omission of the Agent or Lenders in enforcing any part of this
Agreement; 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	43	  	

 (q) waive any defense based on any invalidity, irregularity or unenforceability, in whole or in
part, of any one or more of the Financing Documents; 
 (r) waive any defense based on any change in the composition of Borrower, and 

(s) waive any defense based on any representations and warranties made by such Guarantor herein or by Borrower herein or in any of the
Financing Documents. 
 Each Guarantor hereby abandons any right it may have under the existing or future laws of Jersey, whether by virtue of (a) the
“droit de discussion” or otherwise to require that recourse be had to the assets of any other person before any claim is enforced against such Guarantor in respect of the obligations assumed by it under the guarantee; and (b) the
“droit de division” or otherwise to require that any liability be apportioned or divided with any other person or be reduced in any manner whatsoever. 

For purposes of this section, the term “Claim” shall mean any claim, action or cause of action, defense, counterclaim,
retention, set-off or right of recoupment of any kind or nature against the Agent or Lenders, its officers, directors, employees, agents, members, actuaries, accountants, trustees or attorneys, or any affiliate of the Agent or Lenders in connection
with the making, closing, administration, collection or enforcement by the Agent or Lenders of the Obligations. 
 15.4 Guarantor’s
Obligations Not Affected by Modifications of Financing Documents. Each Guarantor further agrees that such Guarantor’s liability as guarantor shall not be impaired or affected by any renewals or extensions which may be made from time to
time, with or without the knowledge or consent of Guarantor for the time for payment of interest or principal or by any forbearance or delay in collecting interest or principal hereunder, or by any waiver by Agent or Lenders under this Agreement or
any other Financing Documents, or by Agent’s or Lenders’ failure or election not to pursue any other remedies it may have against Borrower or Guarantor, or by any change or modification in the Secured Promissory Notes, this Agreement or
any other Financing Document, or by the acceptance by Agent or Lenders of any additional security or any increase, substitution or change therein, or by the release by Agent or Lenders of any security or any withdrawal thereof or decrease therein,
or by the application of payments received from any source to the payment of any obligation other than the Obligations even though Agent or Lenders might lawfully have elected to apply such payments to any part or all of the Obligations, it being
the intent hereof that, subject to Agent’s or Lenders’ compliance with the terms of this Section 13 and the Financing Documents, each Guarantor shall remain liable for the payment of the Obligations, until the Obligations have been
paid in full, notwithstanding any act or thing which might otherwise operate as a legal or equitable discharge of a surety. Each Guarantor further understands and agrees that Agent or Lenders may at any time enter into agreements with Borrower to
amend, modify and/or increase the principal amount of, interest rate applicable to or other economic and non-economic terms of this Agreement or the other Financing Documents, and may waive or release any provision or provisions of this Agreement or
the other Financing Documents, and, with reference to such instruments, may make and enter into any such agreement or agreements as Agent, Lenders and Borrower may deem proper and desirable, without in any manner impairing this Guarantee or any of
Agent’s or Lenders’ rights hereunder or each Guarantor’s obligations hereunder, and each Guarantor’s obligations hereunder shall apply to the this Agreement and other Financing Documents as so amended, modified, extended, renewed
or increased. 
 15.5 Reinstatement; Deficiency. This guaranty shall continue to be effective or be reinstated (as the case may be) if
at any time payment of all or any part of any sum payable pursuant to this Agreement or any other Financing Document is rescinded or otherwise required to be returned by Agent or Lenders upon the insolvency, bankruptcy, dissolution, liquidation, or
reorganization of Borrower, or upon or as a result of the appointment of a receiver, intervenor, custodian or conservator of or trustee or similar officer for, Borrower or any substantial part of its property, or otherwise, all as though such
payment to Agent or Lenders had not been made, regardless of whether Agent or Lenders contested the order requiring the return of such payment. In the event of the foreclosure of the Financing Documents and of a deficiency, each Guarantor hereby
promises and 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	44	  	

 
agrees forthwith to pay the amount of such deficiency notwithstanding the fact that recovery of said deficiency against Borrower would not be allowed by applicable law; however, the foregoing
shall not be deemed to require that Agent or Lenders institute foreclosure proceedings or otherwise resort to or exhaust any other collateral or security prior to or concurrently with enforcing this guaranty. 

15.6 Subordination of Borrower’s Obligations to Guarantors; Claims in Bankruptcy. 

(a) Any indebtedness of Borrower to any Guarantor (including, but not limited to, any right of such Guarantor to a return of any capital
contributed to Borrower), whether now or hereafter existing, is hereby subordinated to the payment of the Obligations. Each Guarantor agrees that, until the Obligations have been paid in full, such Guarantor will not seek, accept, or retain for its
own account, any payment from Borrower on account of such subordinated debt. Any payments to any Guarantor on account of such subordinated debt shall be collected and received by such Guarantor in trust for Agent and Lenders and shall be immediately
paid over to Agent, for the benefit of Agent and Lenders, on account of the Obligations without impairing or releasing the obligations of such Guarantor hereunder. 

(b) Each Guarantor shall promptly file in any bankruptcy or other proceeding in which the filing of claims is required by law, all claims and
proofs of claims that such Guarantor may have against Borrower or any other Guarantor and does hereby assign to Agent or its nominee (and will, upon request of Agent, reconfirm in writing the assignment to Agent or its nominee of) all rights of such
Guarantor under such claims. If such Guarantor does not file any such claim, Agent, as attorney-in-fact for such Guarantor, is hereby irrevocably authorized to do so in the name of such Guarantor, or in Agent’s discretion, to assign the claim
to a designee and cause proof of claim to be filed in the name of Agent’s designee. In all such cases, whether in administration, bankruptcy or otherwise, the person or persons authorized to pay such claim shall pay to Agent, for the benefit of
Agent and Lenders, the full amount thereof and, to the full extent necessary for that purpose, each Guarantor hereby assigns to the Lenders all of such Guarantor’s rights to any such payments or distributions to which such Guarantor would
otherwise be entitled, such assignment being a present and irrevocable assignment of all such rights. 
 15.7 Maximum Liability. The
provisions of this Section 15 are severable, and in any action or proceeding involving any state corporate law, or any state, federal or foreign bankruptcy, insolvency, reorganization or other law affecting the rights of creditors generally, if
the obligations of any Guarantor under this Section 15 would otherwise be held or determined to be avoidable, invalid or unenforceable on account of the amount of such Guarantor’s liability under this Section 15, then, notwithstanding
any other provision of this Section 15 to the contrary, the amount of such liability shall, without any further action by the Guarantors or the Agent or any Lender, be automatically limited and reduced to the highest amount that is valid and
enforceable as determined in such action or proceeding (such highest amount determined hereunder being the relevant Guarantor’s “Maximum Liability”). This Section 15.7 with respect to the Maximum Liability of each
Guarantor is intended solely to preserve the rights of the Agent and the Lenders to the maximum extent not subject to avoidance under applicable law, and no Guarantor nor any other Person shall have any right or claim under this Section 15.7
with respect to such Maximum Liability, except to the extent necessary so that the obligations of any Guarantor hereunder shall not be rendered voidable under applicable law. Each Guarantor agrees that the Obligations may at any time and from time
to time exceed the Maximum Liability of each Guarantor without impairing this guaranty or affecting the rights and remedies of the Agent or the Lenders hereunder, provided that, nothing in this sentence shall be construed to increase any
Guarantor’s obligations hereunder beyond its Maximum Liability. 
 15.8 Guarantor’s Investigation. Each Guarantor
acknowledges receipt of a copy of each of this Agreement and the other Financing Documents. Each Guarantor has made an independent investigation of the other Credit Parties and of the financial condition of the other Credit Parties. Neither Agent
nor any Lender has made and neither Agent nor any Lender does make any representations or warranties as to the income, expense, operation, finances or any other matter or thing affecting any Credit Party nor has Agent or any Lender made any
representations or warranties as to the amount or nature of the Obligations of any Credit 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	45	  	

 
Party to which this Section 15 applies as specifically herein set forth, nor has Agent or any Lender or any officer, agent or employee of Agent or any Lender or any representative thereof,
made any other oral representations, agreements or commitments of any kind or nature, and each Guarantor hereby expressly acknowledges that no such representations or warranties have been made and such Guarantor expressly disclaims reliance on any
such representations or warranties 
 15.9  Termination. The provisions of this Section 15 shall remain in effect
until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied. 

15.10  Representative. Each Guarantor hereby designates Borrower and its representatives and agents on its behalf for the
purpose of giving and receiving all notices and other consents hereunder or under any other Financing Document and taking all other actions on behalf of such Guarantor under the Financing Documents. Borrower hereby accepts such appointment. 

 

	 	16	DEFINITIONS 

 In addition to any terms defined elsewhere in this Agreement, or in
any schedule or exhibit attached hereto, as used in this Agreement, the following terms have the following meanings: 
 “Access
Agreement” means a landlord consent, bailee letter or warehouseman’s letter, in form and substance reasonably satisfactory to Agent, in favor of Agent executed by such landlord, bailee or warehouseman, as applicable, for any third
party location. 
 “Account” means any “account”, as defined in the Code, with such additions to such term as may
hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower. 
 “Account
Debtor” means any “account debtor”, as defined in the Code, with such additions to such term as may hereafter be made. 

“Affiliate” means, with respect to any Person, a Person that owns or controls directly or indirectly the Person, any Person
that controls or is controlled by or is under common control with the Person, and each of that Person’s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person’s managers and
members. 
 “Agent” means, MidCap, not in its individual capacity, but solely in its capacity as agent on behalf of and for
the benefit of the Lenders. 
 “Agreement” has the meaning given it in the preamble of this Agreement. 

“Alba Bioscience Limited” means Alba Bioscience Limited, a company incorporated in Scotland with registration number
SC310584. 
 “Anti-Terrorism Laws” means any Laws relating to terrorism or money laundering, including Executive Order
No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the Laws comprising or implementing the Bank Secrecy Act, and the Laws administered by OFAC. 

“Applicable Commitment” has the meaning given it in Section 2.2 

“Applicable Floor” means for each Credit Facility the per annum rate of interest specified on the Credit Facility Schedule;
provided, however, that for the Applicable Prime Rate, the Applicable Floor is a per annum rate that is two hundred basis points above the Applicable Floor for the Applicable Libor Rate. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	46	  	

 “Applicable Index Rate” means, for any Applicable Interest Period, the rate per
annum determined by Agent equal to the Applicable Libor Rate; provided, however, that in the event that any change in market conditions or any law, regulation, treaty, or directive, or any change therein or in the interpretation of application
thereof, shall at any time after the date hereof, in the reasonable opinion of Agent or any Lender, make it unlawful or impractical for Agent or such Lender to fund or maintain Obligations bearing interest based upon the Applicable Libor Rate, Agent
or such Lender shall give notice of such changed circumstances to Agent and Borrower and the Applicable Index Rate for Obligations outstanding or thereafter extended or made by Agent or such Lender shall thereafter be the Applicable Prime Rate until
Agent or such Lender determines (as to the portion of the Credit Extensions or Obligations owed to it) that it would no longer be unlawful or impractical to fund or maintain such Obligations or Credit Extensions at the Applicable Libor Rate. In the
event that Agent shall have determined (which determination shall be final and conclusive absent manifest error and binding upon all parties hereto), as of any Applicable Interest Rate Determination Date, that adequate and fair means do not exist
for ascertaining the interest rate applicable to any Credit Facility on the basis provided for herein, then Agent may select a comparable replacement index and corresponding margin. 

“Applicable Interest Period” for each Credit Facility has the meaning specified for that Credit Facility in the Credit
Facility Schedule; provided, however, that at any time that the Applicable Prime Rate is the Applicable Index Rate, Applicable Interest Period shall mean the period commencing as of the most recent Applicable Interest Rate Determination Date and
continuing until the next Applicable Interest Rate Determination Date or such earlier date as the Applicable Prime Rate shall no longer be the Applicable Index Rate; and provided, further, that at any time the Libor Rate Index is adjusted as set
forth in the definition thereof, or re-implemented following invocation of the Applicable Prime Rate as permitted herein, the Applicable Interest Period shall mean the period of as of such adjustment or re-implementation and continuing until the
next Applicable Interest Rate Determination Date, if any. 
 “Applicable Interest Rate” means a per annum rate of interest
equal to the Applicable Index Rate plus the Applicable Margin. 
 “Applicable Interest Rate Determination Date” means the
second (2nd) Business Day prior to the first (1st) day of the related Applicable Interest Period; provided, however, that at any time that the Applicable Prime Rate is the Applicable Index Rate, Applicable Interest Rate Determination Date
means the date of any change in the Base Rate Index; and provided, further, that at any time the Libor Rate Index is adjusted as set forth in the definition thereof, the Applicable Interest Rate Determination Date shall mean the date of such
adjustment or the second (2nd) Business Day prior to the first (1st) day of the related Applicable Interest Period, as elected by Agent. 

“Applicable Libor Rate” means, for any Applicable Interest Period, the rate per annum, determined by Agent (rounded upwards,
if necessary, to the next 1/100th%), equal to the greater of (a) the Applicable Floor and (b) the Libor Rate Index. 

“Applicable Margin” for each Credit Facility has the meaning specified for that Credit Facility in the Credit Facility
Schedule. 
 “Applicable Prepayment Fee”, for each Credit Facility, has the meaning given it in the Credit Facility
Schedule for such Credit Facility. 
 “Applicable Prime Rate” means, for any Applicable Interest Period, the rate per
annum, determined by Agent (rounded upwards, if necessary, to the next 1/100th%), equal to the greater of (a) the Applicable Floor and (b) the Base Rate Index. 

“Approved Fund” means any (a) investment company, fund, trust, securitization vehicle or conduit that is (or will be)
engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the Ordinary Course of Business, or (b) any Person (other than a natural person)

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	47	  	

 
which temporarily warehouses loans for any Lender or any entity described in the preceding clause (a) and that, with respect to each of the preceding clauses (a) and (b), is
administered or managed by (i) a Lender, (ii) an Affiliate of a Lender or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender. 

“Base Rate Index” means, for any Applicable Interest Period, the rate per annum, determined by Agent (rounded upwards, if
necessary, to the next 1/100th%) as being the rate of interest announced, from time to time, within Wells Fargo Bank, N.A. (“Wells Fargo”) at its principal office in San Francisco as its “prime rate,” with the
understanding that the “prime rate” is one of Wells Fargo’s base rates (not necessarily the lowest of such rates) and serves as the basis upon which effective rates of interest are calculated for those loans making reference thereto
and is evidenced by the recording thereof after its announcement in such internal publications as Wells Fargo may designate; provided, however, that Agent may, upon prior written notice to any Borrower, choose a reasonably comparable index or source
to use as the basis for the Base Rate Index. 
 “Blocked Person” means: (a) any Person listed in the annex to, or is
otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order
No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti-Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports “terrorism”
as defined in Executive Order No. 13224, or (e) a Person that is named a “specially designated national” or “blocked person” on the most current list published by OFAC or other similar list. 

“Borrower” mean the entity(ies) described in the first paragraph of this Agreement and each of their successors and permitted
assigns. The term “each Borrower” shall refer to each Person comprising the Borrower if there is more than one such Person, or the sole Borrower if there is only one such Person. The term “any Borrower” shall refer to any Person
comprising the Borrower if there is more than one such Person, or the sole Borrower if there is only one such Person. 
 “Borrowing
Resolutions” means, with respect to any Person, those resolutions, in form and substance satisfactory to Agent, adopted by such Person’s Board of Directors or other appropriate governing body and delivered by such Person to Agent
approving the Financing Documents to which such Person is a party and the transactions contemplated thereby, as well as any other approvals as may be necessary or desired to approve the entering into the Financing Documents or the consummation of
the transactions contemplated thereby or in connection therewith. 
 “Books” means all of books and records of a Person,
including ledgers, federal and state tax returns, records regarding the Person’s assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such
information. 
 “Business Day” means any day (other than Saturday or Sunday) on which banks are open for general business
in Maryland. 
 “Change in Control” means any event, transaction, or occurrence as a result of which (a) prior to an
IPO, the Cowan Family and Galen Partners cease to own and control all of the economic and voting rights associated with ownership of at least fifty-one percent (51%) of the outstanding securities of all classes of Quotient Limited on a fully
diluted basis; (b) Quotient Limited ceases to own and control, directly or indirectly, all of the economic and voting rights associated with the outstanding securities of each of its Subsidiaries; (c) the occurrence of any “change in
control” or any term of similar effect under any Subordinated Debt Document; (d) Borrower ceases to own and control, directly or indirectly, all of the economic and voting rights associated with the outstanding voting capital stock (or
other voting equity interest) of each of its Subsidiaries; (e) the chief executive officer of Borrower as of the date hereof shall cease to be involved in the day to day operations (including research and development) or management of the
business of Borrower, and a successor of such officer reasonably acceptable to Agent is not appointed on terms 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	48	  	

 
reasonably acceptable to Agent within 90 days of such cessation or involvement, or (f) after an IPO, a “person” or “group” (within the meaning of the Securities Exchange
Act of 1934 and the rules of the SEC thereunder as in effect on the date hereof) becomes, directly or indirectly, the beneficial owner of equity interests in Quotient Limited representing more than 35% of the aggregate ordinary voting power
represented by the issued and outstanding equity interests of Quotient Limited or a majority of the seats (other than vacant seats) on the board of directors of Quotient Limited shall at any time be occupied by persons who were neither
(x) nominated by the board of directors of Quotient Limited nor (y) appointed by directors so nominated. An IPO shall not constitute a Change in Control. 

“Citizens Account” means that certain checking account number 6222 736142 of the Borrower and that certain money market
account number 6233834116, each held at Citizens Bank of Pennsylvania, 31 Cambridge Lane, 19B – 0250, Newtown, PA 18940. 

“Closing Date” has the meaning given it in the preamble of this Agreement. 

“Code” means the Uniform Commercial Code in effect on the date hereof, as the same may, from time to time, be enacted and in
effect in the State of Maryland; provided, however, that to the extent that the Code is used to define any term herein or in any Financing Document and such term is defined differently in different Articles or Divisions of the Code, the
definition of such term contained in Article or Division 9 shall govern; and provided, further, that in the event that, by reason of mandatory provisions of Law, any or all of the attachment, perfection, or priority of, or remedies with
respect to, Agent’s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of Maryland, the term “Code” shall mean the Uniform Commercial Code as enacted and in effect
in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions. 

“Collateral” means all property, now existing or hereafter acquired, mortgaged or pledged to, or purported to be subjected to
a Lien in favor of, Agent, for the benefit of Agent and Lenders, pursuant to this Agreement and the other Financing Documents, including, without limitation, all of the property described in Exhibit A hereto. 

“Collateral Account” means any Deposit Account, Securities Account or Commodity Account. 

“Commitment Commencement Date” has the meaning given it in the Credit Facility Schedule. 

“Commitment Termination Date” has the meaning given it in the Credit Facility Schedule. 

“Commodity Account” means any “commodity account”, as defined in the Code, with such additions to such term as may
hereafter be made. 
 “Communication” has the meaning given it in Article 11. 

“Compliance Certificate” means a certificate, duly executed by an authorized officer of Borrower, appropriately completed and
substantially in the form of Exhibit B. 
 “Contingent Obligation” means, for any Person, any direct or indirect
liability, contingent or not, of that Person for (a) any indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse
by that Person, or for which that Person is directly or indirectly liable; (b) any obligations for undrawn letters of credit for the account of that Person; and (c) all obligations from any interest rate, currency or commodity swap
agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices; but “Contingent Obligation” does not
include endorsements in the Ordinary Course of Business. The amount of a Contingent 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	49	  	

 
Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it
determined by the Person in good faith; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement. 

“Control Agreement” means any control agreement entered into among the depository institution at which Borrower maintains a
Deposit Account or the securities intermediary or commodity intermediary at which Borrower maintains a Securities Account or a Commodity Account, Borrower, and Agent pursuant to which Agent obtains control (within the meaning of the Code) for the
benefit of the Lenders over such Deposit Account, Securities Account or Commodity Account. 
 “Credit Extension” means an
advance or disbursement of proceeds to or for the account of Borrower in respect of a Credit Facility. 
 “Credit Extension
Form” means that certain form attached hereto as Exhibit C, as the same may be from time to time revised by Agent. 

“Credit Facility” means a credit facility specified on the Credit Facility Schedule. 

“Credit Party” means Borrower, any Guarantor under a guarantee of the Obligations or any part thereof, and any other Person
(other than Agent, a Lender or a participant of a Lender), whether now existing or hereafter acquired or formed, that becomes obligated as a borrower, guarantor, surety, indemnitor, pledgor, assignor or other obligor under any Financing Document,
and any Person whose equity interests or portion thereof have been pledged or hypothecated to Agent under any Financing Document; and “Credit Parties” means all such Persons, collectively. 

“Default” means any fact, event or circumstance which with notice or passage of time or both, could constitute an Event of
Default. 
 “Default Rate” has the meaning given it in Section 2.6(b). 

“Deposit Account” means any “deposit account” as defined in the Code with such additions to such term as may
hereafter be made. 
 “Designated Funding Account” is (i) prior to the opening of the Wells Account, the Citizens
Account and (ii) thereafter, the Wells Account. 
 “Dollars,” “dollars” and “$” each
means lawful money of the United States. 
 “Draw Period” means, for each Credit Facility, the period commencing on the
Commitment Commencement Date and ending on the Commitment Termination Date. 
 “Eligible Assignee” means (a) a Lender,
(b) an Affiliate of a Lender, (c) an Approved Fund, and (d) any other Person (other than a natural person) approved by Agent; provided, however, that notwithstanding the foregoing, “Eligible Assignee” shall not
include any Credit Party or any Subsidiary of a Credit Party. Notwithstanding the foregoing, in connection with assignments by a Lender due to a forced divestiture at the request of any regulatory agency, the restrictions set forth herein shall not
apply and Eligible Assignee shall mean any Person or party becoming an assignee incident to such forced divestiture. 

“Environmental Law” means all present and future any law (statutory or common), ordinance, treaty, rule, regulation, order,
policy, other legal requirement or determination of an arbitrator or of a Governmental Authority and/or Required Permits imposing liability or standards of conduct for or relating to the regulation 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	50	  	

 
and protection of human health, safety, the workplace, the environment and natural resources, and including public notification requirements and environmental transfer of ownership, notification
or approval statutes. 
 “Equipment” means all “equipment”, as defined in the Code, with such additions to such
term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing. 

“ERISA” means the Employee Retirement Income Security Act of 1974, and all regulations promulgated thereunder. 

“Event of Default” has the meaning given it in Section 10.1. 

“Exigent Circumstance” has the meaning given it in Section 13.14. 

“Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on overnight Federal
funds transactions with members of the Federal Reserve System arranged by Federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day, provided that if no such rate is so
published on such next succeeding Business Day, the Federal Funds Rate for such day shall be the average rate quoted to Agent on such day on such transactions as determined by Agent in a commercially reasonable manner. 

“Fee Letters” means, collectively, the fee letter agreements among Borrower and Agent and Borrower and each Lender. 

“Financing Documents” means, collectively, this Agreement, the Perfection Certificate, the Security Documents, the Fee
Letter(s), each note and guarantee executed by one or more Credit Parties in connection with the indebtedness governed by this Agreement, and each other present or future agreement executed by one or more Credit Parties and, or for the benefit of,
the Lenders and/or Agent in connection with this Agreement, all as amended, restated, or otherwise modified from time to time. 

“Foreign Lender” has the meaning given it in Section 2.6(h)(iii). 

“Funding Date” means any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.

 “GAAP” means (i) with respect to Borrower and any U.S. Subsidiaries and, after an IPO, Quotient Limited, Alba
Bioscience Limited and QBD (QSIP) Limited, generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and
pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as
of the date of determination and (ii) prior to an IPO, with respect to Quotient Limited, Alba Bioscience Limited and QBD (QSIP) Limited,, the generally accepted accounting standards and practices of the United Kingdom. 

“General Intangibles” means all “general intangibles”, as defined in the Code, with such additions to such term as
may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents,
trademarks, service marks and, to the extent permitted under applicable Law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract
rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights
in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including, without 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	51	  	

 
limitation, key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind. 

“Governmental Authority” means any nation or government, any state or other political subdivision thereof, any agency,
authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any
self-regulatory organization. 
 “Guarantor” means each Person that is or hereafter becomes a party to this Agreement as a
guarantor of the Obligations. As of the Closing Date, the Guarantors are Quotient Limited, Alba Bioscience Limited and QBD (QSIP) Limited. 

“Hazardous Materials” means petroleum and petroleum products and compounds containing them, including gasoline, diesel fuel
and oil; explosives, flammable materials; radioactive materials; polychlorinated biphenyls and compounds containing them; lead and lead-based paint; asbestos or asbestos-containing materials; underground or above-ground storage tanks, whether empty
or containing any substance; any substance the presence of which is prohibited by any Laws; toxic mold, any substance that requires special handling; and any other material or substance now or in the future defined as a “hazardous
substance,” “hazardous material,” “hazardous waste,” “toxic substance,” “toxic pollutant,” “contaminant,” “pollutant” or other words of similar import within the meaning of any
Environmental Law, including: (a) any “hazardous substance” defined as such in (or for purposes of) CERCLA, or any so-called “superfund” or “superlien” Law, including the judicial interpretation thereof;
(b) any “pollutant or contaminant” as defined in 42 U.S.C.A. § 9601(33); (c) any material now defined as “hazardous waste” pursuant to 40 C.F.R. Part 260; (d) any petroleum or petroleum by-products, including
crude oil or any fraction thereof; (e) natural gas, natural gas liquids, liquefied natural gas, or synthetic gas usable for fuel; (f) any “hazardous chemical” as defined pursuant to 29 C.F.R. Part 1910; (g) any toxic or
harmful substances, wastes, materials, pollutants or contaminants (including, without limitation, asbestos, polychlorinated biphenyls (“PCB’s”), flammable explosives, radioactive materials, infectious substances, materials containing
lead-based paint or raw materials which include hazardous constituents); and (h) any other toxic substance or contaminant that is subject to any Environmental Laws or other past or present requirement of any Governmental Authority. 

“Hazardous Materials Contamination” means contamination (whether now existing or hereafter occurring) of the improvements,
buildings, facilities, personalty, soil, groundwater, air or other elements on or of the relevant property by Hazardous Materials, or any derivatives thereof, or on or of any other property as a result of Hazardous Materials, or any derivatives
thereof, generated on, emanating from or disposed of in connection with the relevant property. 
 “Indebtedness” means,
without duplication of amounts described by more than one of the following, (a) indebtedness for borrowed money (including the Obligations) or the deferred price of property or services, such as reimbursement and other obligations for surety bonds
and letters of credit (other than trade accounts payable in the Ordinary Course of Business and liabilities associated with customer prepayments and deposits), (b) obligations evidenced by notes, bonds, debentures or similar instruments,
(c) capital lease obligations, (d) non-contingent obligations of such Person to reimburse any bank or other Person in respect of amounts paid under a letter of credit, banker’s acceptance or similar instrument, (e) equity
securities of such Person subject to repurchase or redemption other than at the sole option of such Person, (f) obligations secured by a Lien on any asset of such Person, whether or not such obligation is otherwise an obligation of such Person,
(g) “earnouts”, purchase price adjustments, profit sharing arrangements, deferred purchase money amounts and similar payment obligations or continuing obligations of any nature of such Person arising out of purchase and sale
contracts, (h) all Indebtedness of others guaranteed by such Person, (i) off-balance sheet liabilities and/or pension plan or multiemployer plan liabilities of such Person, (j) obligations arising under non-compete agreements,
(k) obligations arising under bonus, deferred compensation, incentive compensation or similar arrangements, other than those arising in the Ordinary Course of Business, and (1) Contingent Obligations. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	52	  	

 “Indemnitee” has the meaning given it in Section 13.2. 

“Insolvency Proceeding” means any proceeding by or against any Person under the United States Bankruptcy Code, or any other
bankruptcy or insolvency Law, including (i) any procedures set out in Article 8 of the Interpretation (Jersey) Law 1954 or an application is made to declare that the property is en desastre, and (ii) assignments for the benefit of
creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

“Intellectual Property” includes without limitation, all copyright rights, copyright applications, copyright registrations
and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, patent applications and like protections, including improvements, divisions, continuations, renewals, reissues, extensions, and
continuations-in-part of the same, trademarks, trade names, service marks, mask works, rights of use of any name, domain names, or any other similar rights, any applications therefor, whether registered or not, know-how, operating manuals, trade
secret rights, clinical and non-clinical data, rights to unpatented inventions, and any claims for damage by way of any past, present, or future infringement of any of the foregoing. 

“Intellectual Property Security Agreement” means that certain Intellectual Property Security Agreement, dated as of the date
hereof, by and among Agent, Borrower, QBD (QSIP) Limited and Alba Bioscience Limited. 
 “Inventory” means all
“inventory”, as defined in the Code, with such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished
products, including without limitation such inventory as is temporarily out of Borrower’s custody or possession or in transit and including any returned goods and any documents of title representing any of the above. 

“Investment” means, with respect to any Person, directly or indirectly, (a) to purchase or acquire any stock or stock
equivalents, or any obligations or other securities of, or any interest in, any Person, including the establishment or creation of a Subsidiary, (b) to make or commit to make any acquisition of all or substantially all of the assets of another
Person, or of any business, Product, business line or product line, division or other unit operation of any Person or (c) make or purchase any advance, loan, extension of credit or capital contribution to, or any other investment in, any
Person. 
 “IPO” means an underwritten public offering of common stock of Quotient Ltd. or any of its Subsidiaries
(i) pursuant to an effective registration statement filed with the SEC in accordance with the Securities Act of 1933, as amended, and results in the listing of the common stock of Quotient Ltd. or any such Subsidiary on a national securities
exchange or the NASDAQ Global Market quotation system, or (ii) pursuant to an effective registration statement or equivalent document on any other recognized exchange in the United Kingdom or any other member of the European Union. 

“Jersey Security Documents” means the Jersey Security Interest Agreements in relation to the shares in QBD (QS IP) Limited
and any other security document as may be executed from time to time in favor of the Agent which is governed by the laws of Jersey and grants a Lien to secure the Obligations. 

“Joinder Requirements” has the meaning set forth in Section 6.8. 

“Laws” means any and all federal, state, provincial, territorial, local and foreign statutes, laws, judicial decisions,
regulations, guidance, guidelines, ordinances, rules, judgments, orders, decrees, codes, plans, injunctions, permits, concessions, grants, franchises, governmental agreements and governmental restrictions, whether now or hereafter in effect, which
are applicable to any Credit Party in any particular circumstance. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	53	  	

 “Lender” means any one of the Lenders. 

“Lenders” means the Persons identified on the Credit Facility Schedule as amended from time to time to reflect assignments
made in accordance with this Agreement. 
 “Libor Rate Index” means, for any Applicable Interest Period, the rate per
annum, determined by Agent (rounded upwards, if necessary, to the next 1/100th%) by dividing (a) the rate per annum, determined by Agent in accordance with its customary procedures, and utilizing such electronic or other quotation sources as it
considers appropriate (rounded upwards, if necessary, to the next 1/100%), to be the rate at which Dollar deposits (for delivery on the first day of such Applicable Interest Period or, if such day is not a Business Day, on the preceding Business
Day) in the amount of One Million Dollars ($1,000,000) are offered to major banks in the London interbank market on or about 11:00 a.m. (New York time) on the Applicable Interest Rate Determination Date, for a period of thirty (30) days, which
determination shall be conclusive in the absence of manifest error, by (b) 100% minus the Reserve Percentage; provided, however, that Agent may, upon prior written notice to any Borrower, choose a reasonably comparable index or source to use as
the basis for the Libor Rate Index. The Libor Rate Index may be adjusted by Agent with respect to any Lender on a prospective basis to take into account any additional or increased costs to such Lender of maintaining or obtaining any eurodollar
deposits or increased costs, in each case, due to changes in applicable Law occurring subsequent to the commencement of the then Applicable Interest Period, including changes in tax laws (except changes of general applicability in corporate income
tax laws) and changes in the reserve requirements imposed by the Board of Governors of the Federal Reserve System (or any successor), which additional or increased costs would increase the cost of funding loans bearing interest based upon the Libor
Rate Index; provided, however, that notwithstanding anything in this Agreement to the contrary, (i) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in
connection therewith and (ii) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or
foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a “change in applicable Law”, regardless of the date enacted, adopted or issued. In any such event, the affected Lender shall give
Borrower and Agent notice of such a determination and adjustment and Agent promptly shall transmit the notice to each other Lender and, upon its receipt of the notice from the affected Lender, Borrower may, by notice to such affected Lender require
such Lender to furnish to Borrower a statement setting forth the basis for adjusting such Libor Rate Index and the method for determining the amount of such adjustment. 

“Lien” means a claim, mortgage, deed of trust, lien, levy, charge, pledge, security interest or other encumbrance of any
kind, whether voluntarily incurred or arising by operation of Law or otherwise against any property. 
 “Luxembourg Holding
Company” means that certain company to be formed under the laws of Luxembourg for the purpose of owning 100% of the equity of Quotient Suisse. 

“Material Adverse Change” means (a) a material impairment in the perfection or priority of the Agent’s Lien (or any
Lender’s Lien therein to the extent provided for in the Financing Documents) in the Collateral; (b) a material impairment in the value of the Collateral; (c) a material adverse change in the business, operations, or condition
(financial or otherwise) of the Credit Parties, taken as a whole; or (d) a material impairment of the prospect of repayment of any portion of the Obligations. 

“Material Agreement” means (a) the agreements listed in the Disclosure Schedule, (b) each agreement or
contract to which a Credit Party is a party relating to licensure of Material Intellectual Property or development of Products which are material to the business of the Credit Parties or Material Intellectual Property, and (c) any agreement or
contract to which such Credit Party or its Subsidiaries is a party the termination of which could reasonably be expected to result in a Material Adverse Change. 

“Material Indebtedness” has the meaning given it in Section 10.1. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	54	  	

 “Maturity Date” means December 6, 2017. 

“Maximum Lawful Rate” has the meaning given it in Section 2.6(g). 

“MidCap” has the meaning given it in the preamble of this Agreement. 

“Obligations” means all of Borrower’s obligations to pay when due any debts, principal, interest, Protective Advances,
fees, indemnities and other amounts Borrower owes the Agent or Lenders now or later, under this Agreement or the other Financing Documents, including, without limitation, interest accruing after Insolvency Proceedings begin (whether or not allowed)
and debts, liabilities, or obligations of Borrower assigned to the Lenders and/or Agent, and the payment and performance of each other Credit Party’s covenants and obligations under the Financing Documents. “Obligations” does not
include obligations under any warrants issued to Agent or a Lender. 
 “OFAC” means the U.S. Department of Treasury Office
of Foreign Assets Control. 
 “OFAC Lists” means, collectively, the Specially Designated Nationals and Blocked Persons List
maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and/or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any
other applicable Executive Orders. 
 “Operating Documents” means, for any Person, such Person’s formation documents,
and with respect to the Borrower, shall be certified with the Secretary of State of such Person’s state of formation on a date that is no earlier than thirty (30) days prior to the Closing Date, and (a) if such Person is a
corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar
agreement), each of the foregoing with all current amendments or modifications thereto. 
 “Ordinary Course of Business”
means, in respect of any transaction involving any Credit Party, the ordinary course of business of such Credit Party, as conducted by such Credit Party in accordance with past practices, which shall in any event be at arms-length. 

“Payment Date” means the first calendar day of each calendar month. 

“Perfection Certificate” means the Perfection Certificate delivered to Agent as of the Closing Date, together with any
amendments thereto required under this Agreement. 
 “Permitted Contingent Obligations” means (a) Contingent
Obligations resulting from endorsements for collection or deposit in the Ordinary Course of Business; (b) Contingent Obligations incurred in the Ordinary Course of Business with respect to surety and appeal bonds, performance bonds and other
similar obligations not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate at any time outstanding; (c) Contingent Obligations arising under indemnity agreements with title insurers; (d) Contingent Obligations arising with
respect to customary indemnification obligations in favor of purchasers in connection with dispositions of personal property assets permitted under Article 7; (e) so long as there exists no Event of Default both immediately before and
immediately after giving effect to any such transaction, Contingent Obligations existing or arising under any swap contract, provided, however, that such obligations are (or were) entered into by Borrower or an Affiliate in the Ordinary Course of
Business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person and not for purposes of speculation; and (f) other Contingent
Obligations not permitted by clauses (a) through (e) above, not to exceed One Hundred Thousand Dollars ($100,000) in the aggregate at any time outstanding. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	55	  	

 “Permitted Distributions” means the following Restricted Distributions:
(a) dividends by any Credit Party or Subsidiary of any Credit Party to another Credit Party provided that the Agent, for the benefit of the Lenders under this Agreement and the other Financing Documents, has a first priority, perfected security
interest in all or substantially all of the assets of the Credit Party to which such dividend is made; (b) dividends payable solely in common stock and (c) repurchases pursuant to the terms of employee stock purchase plans, employee
restricted stock agreements or similar plans. 
 “Permitted Indebtedness” means: (a) Borrower’s Indebtedness to
the Lenders and Agent under this Agreement and the other Financing Documents; (b) Indebtedness existing on the Closing Date and described on the Disclosure Schedule; (c) Indebtedness secured by Permitted Liens; (d) Subordinated
Debt; (e) unsecured Indebtedness to trade creditors incurred in the Ordinary Course of Business; (f) Permitted Contingent Obligations; (g) extensions, refinancings, modifications, amendments and restatements of any items of Permitted
Indebtedness (b) and (c) above, provided, however, that the principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon the obligors thereunder; and (h) Indebtedness
consisting of intercompany loans and advances made by any Credit Party to any other Credit Party, provided that (1) the obligations of the Credit Parties under such intercompany loan shall be subordinated at all times to the Obligations of the
Credit Parties hereunder or under the other Financing Documents in a manner satisfactory to Agent and (2) to the extent that such Indebtedness is evidenced by a promissory note or other written instrument, Borrower shall pledge and deliver to
Agent, for the benefit of itself and the Lenders, the original promissory note or instrument, as applicable, along with an endorsement in blank in form and substance satisfactory to Agent. 

“Permitted Investments” means: (a) Investments existing on the Closing Date and described on the Disclosure
Schedule; (b) Investments consisting of cash equivalents; (c) any Investments in liquid assets permitted by Borrower’s investment policy, as amended from time to time, provided that such investment policy (and any such amendment
thereto) has been approved in writing by Agent; (d) Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of any Credit Party’s business;
(e) Investments consisting of deposit accounts or securities accounts in which the Agent has a first priority perfected security interest except as otherwise provided by Section 6.6; (f) Investments by any Credit Party in any other
Credit Party (following compliance with Section 6.8); (g) Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the Ordinary Course of Business, and (ii) loans to
employees, officers or directors relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower’s board of directors; (h) Investments (including
debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the Ordinary Course of Business,
(i) Investments consisting of intercompany Indebtedness in accordance with and to the extent permitted by clause (h) of the definition of “Permitted Indebtedness” and (j) Investments in Quotient Suisse in an aggregate amount
not to exceed 250,000 Swiss Francs outstanding at any time. 
 “Permitted Liens” means: (a) Liens existing on the
Closing Date and shown on the Disclosure Schedule or arising under this Agreement and the other Financing Documents; (b) purchase money Liens (i) on Equipment acquired or held by a Credit Party incurred for financing the acquisition
of the Equipment securing no more than Two Hundred Thousand Dollars ($200,000) in the aggregate amount outstanding, or (ii) existing on Equipment when acquired, if the Lien is confined to the property and improvements and the proceeds of
the Equipment; (c) Liens for taxes, fees, assessments or other government charges or levies, either not delinquent or being contested in good faith and for which adequate reserves are maintained on the Books of the Credit Party against whose
asset such Lien exists, provided that no notice of any such Lien has been filed or recorded under the Internal Revenue Code of 1986, as amended, and the treasury regulations adopted thereunder; (d) statutory Liens securing claims or
demands of materialmen, mechanics, carriers, warehousemen, landlords and other Persons imposed without action of such parties, provided that they have no priority over any of Agent’s Lien and the aggregate amount of such Liens for all
Credit Parties does not any time exceed Fifty Thousand Dollars ($50,000); (e) leases or subleases of real property granted in the Ordinary 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	56	  	

 
Course of Business, and leases, subleases, non-exclusive licenses or sublicenses of property (other than real property or Intellectual Property) granted in the Ordinary Course of Business, if the
leases, subleases, licenses and sublicenses do not prohibit granting Agent a security interest; (f) banker’s liens, rights of set-off and Liens in favor of financial institutions incurred made in the Ordinary Course of Business arising in
connection with a Credit Party’s Collateral Accounts provided that such Collateral Accounts are subject to a Control Agreement to the extent required hereunder; (g) Liens to secure payment of workers’ compensation, employment
insurance, old-age pensions, social security and other like obligations incurred in the Ordinary Course of Business (other than Liens imposed by ERISA); (h) Liens arising from judgments, decrees or attachments in circumstances not constituting
an Event of Default; (i) easements, reservations, rights-of-way, restrictions, minor defects or irregularities in title and similar charges or encumbrances affecting real property not constituting a Material Adverse Change; and (j) Liens
incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) and (b) above, but any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the
principal amount of the Indebtedness may not increase. 
 “Person” means any individual, sole proprietorship, partnership,
limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

“Pro Rata Share” means, as determined by Agent, with respect to each Credit Facility and Lender holding an Applicable
Commitment or Credit Extensions in respect of such Credit Facility, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing (a) in the case of fully-funded Credit Facilities, the amount of Credit
Extensions held by such Lender in such Credit Facility by the aggregate amount of all outstanding Credit Extensions for such Credit Facility, and (b) in the case of Credit Facilities that are not fully-funded, the amount of Credit
Extensions and unfunded Applicable Commitments held by such Lender in such Credit Facility by the aggregate amount of all outstanding Credit Extensions and unfunded Applicable Commitments for such Credit Facility. 

“Protective Advances” means all audit fees and expenses, costs, and expenses (including reasonable attorneys’ fees and
expenses) of Agent and Lenders for preparing, amending, negotiating, administering, defending and enforcing the Financing Documents and the Warrants (including, without limitation, those incurred in connection with appeals or Insolvency Proceedings)
or otherwise incurred by Agent or the Lenders in connection with the Financing Documents and the Warrants. 
 “Quotient
Limited” means Quotient Limited, a company incorporated under the laws of Jersey with registered number 109886. 

“Quotient Suisse” means Quotient Suisse S.A., a company to be formed under the laws of Switzerland. 

“Registered Organization” means any “registered organization” as defined in the Code, with such additions to such
term as may hereafter be made. 
 “Required Lenders” means, unless all of the Lenders and Agent agree otherwise in writing,
Lenders having (a) more than sixty percent (60%) of the Applicable Commitments of all Lenders, or (b) if such Applicable Commitments have expired or been terminated, more than sixty percent (60%) of the aggregate outstanding
principal amount of the Credit Extensions. 
 “Required Permit” means all licenses, certificates, accreditations, product
clearances or approvals, provider numbers or provider authorizations, supplier numbers, provider numbers, marketing authorizations, other authorizations, registrations, permits, consents and approvals of a Credit Party (a) issued or required
under Laws applicable to the business of Borrower or any of its Subsidiaries or necessary in the manufacturing, importing, exporting, possession, ownership, warehousing, marketing, promoting, sale, 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	57	  	

 
labeling, furnishing, distribution or delivery of goods or services under Laws applicable to the business of Borrower or any of its Subsidiaries, or (b) issued by any Person from which
Borrower or any of its Subsidiaries have received an accreditation. Without limiting the generality of the foregoing, “Required Permits” includes any Drug Application (including without limitation, at any point in time, all
licenses, approvals and permits issued by the FDA or any other applicable Governmental Authority necessary for the testing, manufacture, marketing or sale of any Product by Borrower as such activities are being conducted by Borrower with respect to
such Product at such time) and any drug listings and drug establishment registrations under 21 U.S.C. Section 510, registrations issued by DEA under 21 U.S.C. Section 823 (if applicable to any Product), and those issued by State
governments for the conduct of Borrower’s or any Subsidiary’s business. 
 “Reservations” means: 

 

	 	(a)	the principle that equitable remedies may be granted or refused at the discretion of a court and the limitation of enforcement by laws relating to insolvency, reorganization and other laws generally affecting the rights
of creditors; 

  

	 	(b)	the time barring of claims under Laws relating to the limitation of claims, the possibility that an undertaking to assume liability for or indemnify a person against non-payment of UK stamp duty or other equivalent
Taxes in any relevant jurisdiction may be void and defenses of set-off or counterclaim; 

  

	 	(c)	similar principles, rights and defenses under the Laws of any relevant jurisdiction; and 

  

	 	(d)	any other matters which are set out as qualifications or reservations as to matters of law of general application in any legal opinions delivered to the Agent or the Lenders pursuant to the provisions of this Agreement.

 “Reserve Percentage” means, on any day, for any Lender, the maximum percentage prescribed by the Board of
Governors of the Federal Reserve System (or any successor Governmental Authority) for determining the reserve requirements (including any basic, supplemental, marginal, or emergency reserves) that are in effect on such date with respect to
eurocurrency funding (currently referred to as “eurocurrency liabilities”) of that Lender, but so long as such Lender is not required or directed under applicable regulations to maintain such reserves, the Reserve Percentage shall be zero.

 “Responsible Officer” means any of the President and Chief Executive Officer or Chief Financial Officer of Borrower or
Quotient Limited, as the context may require. 
 “Scottish Security Documents” means (i) the bond and floating charge
dated on or about the date hereof by Alba Bioscience Limited in favor of the Agent and (ii) the pledge of shares dated on or about the date hereof by Quotient Limited in favor of the Agent. 

“Secretary’s Certificate” means, with respect to any Person, a certificate, in form and substance satisfactory to Agent,
executed by such Person’s secretary on behalf of such Person certifying that (a) such Person has the authority to execute, deliver, and perform its obligations under each of the Financing Documents to which it is a party, (b) that
attached as Exhibit A to such certificate is a true, correct, and complete copy of the Borrower Resolutions then in full force and effect authorizing and ratifying the execution, delivery, and performance by such Person of the Financing Documents to
which it is a party, (c) the name(s) of the Person(s) authorized to execute the Financing Documents on behalf of such Person, together with a sample of the true signature(s) of such Person(s), and (d) that Agent and the Lenders may
conclusively rely on such certificate unless and until such Person shall have delivered to Agent a further certificate canceling or amending such prior certificate. 

“Secured Promissory Note” has the meaning given it in Section 2.7. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	58	  	

 “Security Documents” means the Scottish Security Documents and the Jersey
Security Documents. 
 “Securities Account” means any “securities account”, as defined in the Code, with such
additions to such term as may hereafter be made. 
 “Stated Rate” has the meaning given it in Section 2.6(g). 

“Subordinated Debt” means indebtedness incurred by any Credit Party which shall be (a) in an amount satisfactory to
Agent, (b) made pursuant to documents in form and substance satisfactory to Agent (the “Subordinated Debt Documents”), and (c) subordinated to all of such Credit Party’s now or hereafter indebtedness to the Agent and
Lenders pursuant to a Subordination Agreement. 
 “Subordination Agreement” means a subordination, intercreditor, or other
similar agreement in form and substance, and on terms, approved by Agent in writing. 
 “Subsidiary” means, with respect to
any Person, any Person of which more than fifty percent (50.0%) of the voting stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person. 

“Tax Credit” means a credit against, relief or remission for, or repayment of, any Tax. 

“Tax Payment” means either the increase in a payment made by a Credit Party to the Agent or a Lender under
Section 2.6(h)(i) or a payment under Section 2.6(h)(ii). 
 “Taxes” has the meaning given it in Section 2.6(h). 

“Testing Date” means each date identified as a “Testing Date” on the Minimum Net Product Revenue Schedule.

 “Transfer” has the meaning given it in Section 7.1. 

“Warrants” means warrants to purchase 200,000 shares of Quotient Limited’s Series C Preferred Stock. 

“Wells Account” has the meaning given it in Section 6.6. 

[SIGNATURES APPEAR ON FOLLOWING PAGE(S)] 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	Quotient Credit Agreement	  	59	  	

 IN WITNESS WHEREOF, intending that this instrument constitute an instrument executed and
delivered under seal, the parties hereto have caused this Agreement to be executed as of the Closing Date. 
 BORROWER: 

 

					
	QUOTIENT BIODIAGNOSTICS, INC.	 	
			
	By:	 	 /s/ Paul Cowan
	 	(SEAL)
	Name:	 	Paul Cowan	 	
	Title:	 	Chairman and Chief Executive Officer	 	
		
	GUARANTORS:	 	
		
	QUOTIENT BRANDED	 	
			
	By:	 	 /s/ Paul Cowan
	 	(SEAL)
	Name:	 	Paul Cowan	 	
	Title:	 	Chairman and Chief Executive Officer	 	
		
	ALBA BIOSCIENCE LIMITED	 	
			
	By:	 	 /s/ Paul Cowan
	 	(SEAL)
	Name:	 	Paul Cowan	 	
	Title:	 	Chairman and Chief Executive Officer	 	
		
	QBD (QSIP) LIMITED	 	
			
	By:	 	 /s/ Paul Cowan
	 	(SEAL)
	Name:	 	Paul Cowan	 	
	Title:	 	Chairman and Chief Executive Officer	 	

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Midcap / Quotient / Credit, Guaranty and Security Agreement 
	  	

					
	AGENT:	 	
		
	 MIDCAP FUNDING V, LLC,
 as
Agent for Lenders
	 	
			
	By:	 	 /s/ Colleen S. Kovas
	 	(SEAL)
		 	  
	 	
	Name:	 	 Colleen S. Kovas
	 	
	Title:	 	Its Authorized Signatory	 	

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Midcap / Quotient / Credit, Guaranty and Security Agreement
	  	

 EXHIBITS AND SCHEDULES 

EXHIBITS 
  

			
	Exhibit A	  	Collateral
	Exhibit B	  	Form of Compliance Certificate
	Exhibit C	  	Credit Extension Form

 SCHEDULES 
 Credit
Facility Schedule 
 Amortization Schedule (for each Credit Facility) 

Post-Closing Obligations Schedule 
 Closing Deliveries Schedule

 Disclosure Schedule 
 Intellectual Property Schedule 

Products Schedule 
 Required Permits Schedule 

Minimum Net Product Revenue Schedule 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	1	  	

 EXHIBIT A 

COLLATERAL 
 The
Collateral consists of all assets of Borrower, including all of Borrower’s right, title and interest in and to the following personal property: 

(a) all goods, Accounts (including health-care insurance receivables), Equipment, Inventory, contract rights or rights to payment of money,
leases, license agreements, franchise agreements, General Intangibles, commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, investment accounts,
commodity accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations,
and financial assets, whether now owned or hereafter acquired, wherever located; and 
 (b) all Borrower’s Books relating to the
foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of
the foregoing. 
 Notwithstanding the foregoing, except as provided below, the Collateral shall not include any Intellectual Property of any
Credit Party, whether now owned or hereafter acquired, except to the extent that it is necessary under applicable law to have a Lien and security interest in any such Intellectual Property in order to have a perfected Lien and security interest in
and to IP Proceeds (defined below), and for the avoidance of any doubt, the Collateral shall include, and Agent shall have a Lien and security interest in, (i) all IP Proceeds, and (ii) all payments with respect to IP Proceeds that are
received after the commencement of a bankruptcy or insolvency proceeding. The term “IP Proceeds” means, collectively, all cash, Accounts, license and royalty fees, claims, products, awards, judgments, insurance claims, and other
revenues, proceeds or income, arising out of, derived from or relating to any Intellectual Property of any Credit Party, and any claims for damage by way of any past, present or future infringement of any Intellectual Property of any Credit Party
(including, without limitation, all cash, royalty fees, other proceeds, Accounts and General Intangibles that consist of rights of payment to or on behalf of a Credit Party and the proceeds from the sale, licensing or other disposition of all or any
part of, or rights in, any Intellectual Property by or on behalf of a Credit Party). 
 Pursuant to the terms of a certain negative pledge
arrangement with Agent and Lenders, Borrower has agreed not to encumber any of its Intellectual Property without Agent’s and Lenders’ prior written consent. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	2	  	

 EXHIBIT B 

COMPLIANCE CERTIFICATE 
  

			
	TO:	  	MidCap Funding V, LLC, as Agent
	FROM:	  	
	DATE:	  	            , 201    

 The undersigned authorized officer of Quotient Biodiagnostics, Inc. (“Borrower”) certifies
that under the terms and conditions of the Credit, Guaranty and Security Agreement between Borrower, Agent and the Lenders (as amended, restated, supplemented, replaced or otherwise modified from time to time, the “Agreement”): 

(1) Borrower is in complete compliance with all required covenants for the month ending
            , 201    , except as noted below; 
 (2) there
are no Events of Default; 
 (3) all representations and warranties in the Agreement are true and correct in all material respects on this
date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided,
further, that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; 

(4) Each of Borrower and the other Credit Parties has timely filed all required tax returns and reports, and has timely paid all foreign,
federal, state and local taxes, assessments, deposits and contributions owed except as otherwise permitted pursuant to the terms of the Agreement; and 

(5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of
which Borrower has not previously provided written notification to Agent. 
 Attached are the required documents supporting the
certifications set forth in this Compliance Certificate. The undersigned certifies, in his/her capacity as an officer of the Borrower, that these are prepared in accordance with GAAP consistently applied from one period to the next except as
explained in an accompanying letter or footnotes. The undersigned acknowledges, in his/her capacity as an officer of Borrower, that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of
the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement. 

Please indicate compliance status by circling Yes/No under “Complies” column. 

 

					
	 Reporting Covenant
	  	 Required
	  	 Complies

	Monthly Financial Statements	  	Monthly within 45 days	  	Yes    No
	Audited Financial Statements	  	Annually within 120 days after FYE	  	Yes    No
	Board Approved Projections	  	Annually within 60 days after FYE	  	Yes    No
	Compliance Certificate	  	Monthly within 45 days	  	Yes    No

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	3	  	

							
	 Financial Covenant
	  	 Required
	  	 Actual
	  	 Complies

	Pursuant to Section 8.2, maintain at all times (tested monthly, unless otherwise noted) Minimum Net Product Revenue for the trailing twelve month period of:	  	$            1	  	$            	  	Yes    No

 The following are the exceptions with respect to the certification above: (If no exceptions exist, state
“No exceptions to note.”) 
  

	
	  

	  

	  

  

									
	QUOTIENT BIODIAGNOSTICS, INC.	 		 	AGENT USE ONLY
					
	By:	 	  
	 		 	Received by:	 	  

	Name:	 	  
	 		 	AUTHORIZED SIGNER
	Title:	 	  
	 		 	Date:	 	  

		 		 		 		 	
					
		 		 		 	Verified:	 	  

		 		 		 	AUTHORIZED SIGNER
		 		 		 	Date:	 	  

									
				
		 		 		 	Compliance Status:     Yes    No

  

	1 	See Minimum Net Product Revenue Schedule for required amount 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	4	  	

 EXHIBIT C 

CREDIT EXTENSION FORM 

DEADLINE IS NOON E.S.T. 

Date:             , 201     

LOAN ADVANCE: 

Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire. 

 

									
	From Account #	 	  
	 		 	To Account #	 	  

		 	(Loan Account #)	 		 		 	(Deposit Account #)

 Amount of Advance $         

All Borrower’s representations and warranties in the Credit, Guaranty and Security Agreement are true, correct and complete in all
material respects on the date of the request for an advance; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text
thereof; and provided, further, that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date: 

 

									
	Authorized Signature:	 	  
	 		 	Phone Number:	 	  

	Print Name/Title:	 	  
	 		 		 	

 OUTGOING WIRE REQUEST: 

Complete only if all or a portion of funds from the loan advance above is to be wired. 

 

											
	Beneficiary Name:	 	  

		 		 		 	Amount of Wire: $	 	  

	Beneficiary Lender:	 	  
	 		 		 	
		 		 		 	Account Number:	 	  

	City and State:	 	  
	 		 		 		 	
					
	Beneficiary Lender Transit (ABA) #:	 	  
	 		 	Beneficiary Lender Code (Swift, Sort, Chip, etc.):	 	  

	(For International Wires Only)	 		 		 		 		 	
	Intermediary Lender:	 	  
	 		 	Transit (ABA) #:	 	  

		
	For Further Credit to:	 	  

	Special Instruction:	 	  

 By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in
accordance with and subject to the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me. 

 

									
	Authorized Signature:	 	  
	 		 	2nd Signature (if required):	 	  

	Print Name/Title:	 	  
	 		 	Print Name/Title:	 	  

	Telephone #:	 	  
	 		 	Telephone #:	 	  

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	5	  	

 CREDIT FACILITY SCHEDULE 

The following Credit Facilities are specified on this Credit Facility Schedule: 
  

			
	Credit Facility #1:	  	
		
	Credit Facility and Type:            	  	Term

 Lenders for and their respective Applicable Commitments to this Credit Facility: 

 

					
	 Lender
	  	Applicable
Commitment	 
	 Midcap Funding V, LLC
	  	$	15,000,000	  

 The following defined terms apply to this Credit Facility: 

Applicable Interest Period: means the one-month period starting on the first (1st) day of each month and ending on the last day of such month;
provided, however, that the first (1st) Applicable Interest Period for each Credit Extension under this Facility shall commence on the date that the applicable Credit Extension is made and end on the last day of such month. 

Applicable Floor: means two percent (2.0%) per annum for the Applicable Libor Rate. 

Applicable Margin: a rate of interest equal to six and seven one-tenths percent (6.7%) per annum. 

Applicable Prepayment Fee: means the following amount, calculated as of the date (the “Accrual Date”) that the Applicable Prepayment
Fee becomes payable in the case of prepayments required under the Financing Documents or the date any voluntary prepayment is made: (a) for an Accrual Date on or after the Closing Date through and including the date which is twelve
(12) months after the Closing Date, five percent (5.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of
the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this
Agreement); (b) for an Accrual Date on or after the date which is twelve (12) months after the Closing Date through and including the date which is twenty-four (24) months after the Closing Date, three percent (3.0%) multiplied
by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the
principal amount of Credit Extensions being prepaid or required to be prepaid (whichever is greater) divided by the aggregate amount of the Credit Extensions made under this Agreement); and (c) for an Accrual Date on or after the date which is
twenty-four (24) months after the Closing Date through and including the date immediately preceding the Maturity Date one percent (1.0%) multiplied by the aggregate amount of the Credit Extensions made under this Agreement (or, in the case
of a partial prepayment, multiplied by the product of the aggregate amount of the Credit Extensions made under this Agreement and a fraction equal to the principal amount of Credit Extensions being prepaid or required to be prepaid (whichever is
greater) divided by the aggregate amount of the Credit Extensions made under this Agreement). 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	6	  	

 Commitment Commencement Date: Closing Date. 

Commitment Termination Date:
                    the close of the Business Day following the Closing Date. 

Minimum Credit Extension Amount: $15,000,000 

Permitted Purpose: means general working capital needs of the Borrower and to finance the repayment of existing inter-company loans made by the other
credit parties to the Borrower and the making of intercompany loans by Borrower to the other Credit Parties to fund the general working capital needs of the other Credit Parties 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	7	  	

 AMORTIZATION SCHEDULE (FOR EACH CREDIT FACILITY) 

Credit Facility #1 
 Commencing on the first day of the
nineteenth full calendar month following the Closing Date, and continuing on the first day of each calendar month thereafter, an amount equal to $500,000 per month. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	8	  	

 POST CLOSING OBLIGATIONS SCHEDULE 

Borrower shall satisfy and complete each of the following obligations, or provide Agent each of the items listed below, as applicable, on or
before the date indicated below, all to the satisfaction of Agent in its sole and absolute discretion: 
  

	1.	The Borrower shall, within 10 days of the Closing Date, establish the Wells Account. 

  

	2.	The Borrower shall, within 20 days of the establishment of the Wells Account, deliver one or more Control Agreements with Wells Fargo Bank N.A., in form and substance reasonably acceptable to Agent, duly executed by the
applicable Credit Parties and Wells Fargo Bank N.A., for each deposit and securities account with Wells Fargo Bank N.A. to the extent required pursuant to Section 6.6(a) herein. 

 

	3.	The Borrower shall, within 50 days of the Closing Date, deliver an Access Agreement in respect of Borrower’s property held by UPS, in form and substance reasonably acceptable to Agent, duly executed by UPS and the
applicable Credit Parties. 

  

	4.	The Borrower shall, within 30 days of the Closing Date, deliver an Access Agreement in respect of Borrower’s property facilities in Newtown, Pennsylvania. 

 

	5.	The Borrower shall, within 30 days of the Closing Date, deliver endorsements to Borrower’s insurance policies reasonably satisfactory to Agent. 

Borrower’s failure to complete and satisfy any of the above obligations on or before the date indicated above, or Borrower’s failure
to deliver any of the above listed items on or before the date indicated above, shall constitute an immediate and automatic Event of Default. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	9	  	

 CLOSING DELIVERIES SCHEDULE 

 

	1.	duly executed original signatures to the Financing Documents to which Borrower is a party; 

  

	2.	duly executed original Secured Promissory Notes in favor of each Lender with a face amount equal to such Lender’s Applicable Commitment under each Credit Facility; 

 

	3.	the Operating Documents of each Credit Party and good standing certificates (or, to the extent applicable, the equivalent in the relevant jurisdiction of organization of such Credit Party) of each Credit Party certified
by the Secretary of State of the state(s) of organization of such Credit Party or another applicable government official, if customary, as of a date no earlier than thirty (30) days prior to the Closing Date; 

 

	4.	good standing certificates dated as of a date no earlier than thirty (30) days prior to the Closing Date to the effect that each Credit Party is qualified to transact business in all states in which the nature of
such Credit Party’s business so requires; 

  

	5.	duly executed original signatures to the completed Borrowing Resolutions for each Credit Party; 

  

	6.	a payoff letter, or other appropriate evidence of payoff and release of liens, from Haemonetics Limited; 

  

	7.	evidence that (i) the Liens securing Indebtedness owed by the Credit Parties to Haemonetics Limited will be terminated and (ii) the documents and/or filings evidencing the perfection of such Liens, including
without limitation any financing statements and/or control agreements, have or will, concurrently with the initial Credit Extension, be terminated; 

  

	8.	certified copies, dated as of a recent date, of financing statement searches, as Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such
financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released; 

  

	9.	the Perfection Certificate executed by Borrower; 

  

	10.	a legal opinion of Borrower’s counsel dated as of the Closing Date together with the duly executed original signatures thereto; 

 

	11.	evidence satisfactory to Agent that the insurance policies required by Article 6 are in full force and effect, together with appropriate evidence showing loss payable and/or additional insured clauses or endorsements in
favor of Agent, for the ratable benefit of the Lenders; 

  

	12.	payment of the fees and expenses of Agent and Lenders then accrued, including pursuant to the Fee Letters; 

  

	13.	a duly executed original Secretary’s Certificate for each Credit Party dated as of the Closing Date which includes copies of the completed Borrowing Resolutions for such Credit Party; 

 

	14.	timely receipt by the Agent of an executed disbursement letter; 

  

	15.	a certificate executed by a Responsible Officer of Borrower, in form and substance satisfactory to Agent, which shall certify as to certain conditions to the funding of the Credit Extensions on the Closing Date;

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	10	  	

	16.	Lenders shall have received warrants to purchase shares of Borrower’s fully registered common stock equal to $600,000 divided by the exercise price, which shall be US$3.00 per share, each in form and substance
satisfactory to Agent and Lenders (the “Warrants”); 

  

	17.	evidence that Borrower shall have received net cash proceeds of not less than Two Million Dollars ($2,000,000) (subject to no clawback, escrow or other terms limiting Borrower’s ability to freely use such proceeds)
from the sale of Borrower’s equity securities after October 9, 2013 and on or prior to the Closing Date; 

  

	18.	evidence reasonably satisfactory to Agent that all outstanding intercompany loans of the Borrower have been retired; 

  

	19.	duly executed stock transfer form in respect of the shares held by Quotient Limited in Alba Bioscience Limited, and a share certificate and updated register of members showing the Agent as the registered holder of the
shares in Alba Bioscience Limited; 

  

	20.	a copy of the consent of the Jersey Financial Services Commission to the issue of shares in that company pursuant to the Control of Borrowing (Jersey) Order 1958 of Quotient Limited and QBD (QS IP) Limited;

  

	21.	a certified copy of the register of members and the register of directors of Quotient Limited and QBD (QS IP) Limited; 

  

	22.	original share certificates, duly executed stock transfer forms and the updated register of members of QBD (QS IP) Limited, endorsed to show the interests of the Lender in the shares of QBD (QS IP) Limited;

  

	23.	all notices and acknowledgements required under the Jersey Security Document being a notice to QBD (QS IP) Limited substantially in the relevant form set out in the Jersey Security Document; 

 

	24.	a signed and dated directors’ certificate to be given by two directors of each of Quotient Limited and QBD (QS IP) Limited to accompany the legal opinion of Bedell Cristin Jersey Partnership; 

 

	25.	a search by Bedell Cristin Jersey Partnership, at the Jersey Financial Services Commission and the Viscount’s Department in relation to each of Quotient Limited and QBD (QS IP) Limited. 

  

					
	 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

 

	 Quotient Credit Agreement
	  	11	  	

 DISCLOSURE SCHEDULE 

Scheduled Permitted Liens 
  

									
	 Debtor
	  	 Secured Party
	  	 Collateral
	  	 State and Jurisdiction
	  	 Filing Date and Number
(include original file date and
continuations, amendments,
etc.)

	None	  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

 Scheduled Permitted Indebtedness 
  

							
	 Debtor
	  	 Creditor
	  	 Amount of Indebtedness outstanding
as of October 31, 2013
	  	 Maturity Date

	Alba Bioscience Limited	  	Lombard, 3 Princess Way, Redhill, Surrey RH1 1NP	  	 Hire purchase facility amounting to £700,000 (Seven hundred thousand pounds sterling). Amounts outstanding at October 31, 2013 are:

Agreement number A001159239 - £17,121 Agreement number P001325225 - £151,413 Agreement number P001411643 - £96,137
	  	Agreement number A001159239 – 31 May 2014 Agreement number P001325225 – 30 November 2015 Agreement number P001411643 – 31 March 2016
	Alba Bioscience Limited	  	Premium Credit Limited	  	Installment plan for payment of insurance premium - £17,042 outstanding at October 31, 2013	  	December 31, 2013
	Alba Bioscience Limited	  	Moneycorp, 100 Brompton Road, Knightsbridge, London SW3 1ER	  	Eight forward contracts maturing at monthly intervals from November 2013 through June 2014 each to sell USD 300,000 and to purchase GBP 198,675	  	 Maturity dates for the eight contracts are:

November 25, 2013 December 24, 2013
 January 24, 2014

February 25, 2014
 March 25, 2014

April 23, 2014
 May 25, 2014

June 23, 2014

	Alba Bioscience Limited	  	Royal Bank of Scotland, St Andrew Square, Edinburgh	  	Corporate credit card facility of £76,000. Balance utilized at October 28, 2013 was £38,843	  	Indefinite facility
	Alba Bioscience Limited	  	The Common Services Agency (acting through Scottish National Blood Transfusion Service)	  	Deferred consideration as ultimately payable for the 2007 purchase of the Alba business. The amount	  	

 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.

							
		  		  	concerned is the subject of a dispute and is described in more detail under scheduled litigation below. Alba believes that no amount is due.	  	
	Alba Bioscience Limited	  	Scottish Enterprise Atrium Court 50 Waterloo Street Glasgow G2 6HQ	  	Contingent liability relating to grants of £1,791,000 from Scottish Enterprise for the development of the MosaiQ project (formerly known as Q Screen). The terms of the grant provide for the full amount received to be repayable
in the event that Scottish Enterprise are not satisfied with the progress of the project. Alba considers it unlikely that any amounts will be repayable.	  	
	Quotient Biodiagnostics Inc	  	American Express PO Box 1270 Newark NJ 07101-1270	  	Corporate credit card facility. Account: 3767 4110 0035 2009. No formal credit limit.	  	Indefinite facility

 Schedule Permitted Investments 
  

							
	 Debtor
	  	 Type of Investment
	  	 Date
	  	 Amount Outstanding as of             

	See below.	  		  		  	
		  		  		  	
		  		  		  	
		  		  		  	

 An Investment of 100,000 Swiss Francs by the Credit Parties, in Quotient Suisse SA, occurring on or about December 3,
2013. 
 Scheduled Material Agreements 
 1. Master
Development Agreement between the Technology Partnership PLC and Alba Bioscience Limited dated 4 January 2010. 
 2. Umbrella Supply Agreement between
Ortho Clinical Diagnostics and Alba Bioscience Limited dated 1 December 2004 as amended and updated. 
 Scheduled Litigation 

1. Dispute with SNBTS – detailed description attached 

Scheduled ownership interest in any Chattel Paper, letter of credit rights, commercial tort claims, Instruments, documents or investment property 

1. None 
 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED
SEPARATELY WITH THE COMMISSION. 

 INTELLECTUAL PROPERTY SCHEDULE 

See the exhibits to the Intellectual Property Security Agreement, all of which are incorporated by reference herein. Please note that the applicable Credit
Party owner/licensee of all the Intellectual Property mentioned in this Intellectual Property Schedule is Alba Bioscience Limited, unless otherwise stated. 

All Intellectual Property referenced below is owned, not licensed, unless otherwise noted below. 

Licenses & Registrations - USA 

US Establishment Registration 
  

											
	 Registered
	  	 Number
	  	 Jurisdiction
	  	 Market
	  	 Owner

Name
	  	 Scope

	US FDA	  	 FEI
 3003580203
	  	 Regulatory
 Authority
	  	USA	  	Alba Bioscience Limited	  	 21 CFR, Part 600, Biological products gen
 21
CFR, Part 800, Medical devices
 21 CFR, Part 820, Quality system regulations - Facility and red cell manufacturing processes last inspected February
2011

 US Agent 
  

									
	 Contact Name
	  	 Company
	  	 Address
	  	 Tel.
	  	 Email Address

	Jeremy Stackawitz	  	 Quotient
 Biodiagnostics Inc.
	  	301 South State
Street, Suite S-204
Newtown, PA 18940	  	1-888-284-1901	  	jeremy.stackawitz@
 quotientbd.com

 US Licensed Products 
  

											
	 License

Number
	  	 Products
	  	 License

Applicant
	  	 Intended

Use
	  	 Contract

Type
	  	 Approval

Date

	1807	  	Monoclonal blood grouping reagents, Anti-A Z001U, Anti-B Z015U, Anti-A,B Z023U, Anti-D alpha Z031U, Anti-D beta Z036U, Anti-D delta Z039U, Anti-D blend Z041U, Anti-E Z073U, Anti-c Z083U, Anti-k Z137U, Anti-M Z171U, Anti-N Z176U,
Anti-Lea Z212U, Anti- Leb Z217U, Anti-Lub Z223U	  	Alba
 Bioscience
 Limited
	  	Detection and
identification
of human
group A, B,
AB, RhD, c, E,
k, Lea, Leb,
Lub, M, N red
blood cells by

directagglutination
	  	Alba Manufacturer
/ QBD Distributor	  	16 October
2009
		  	2-3% Reagent Red Blood Cells, A1 Z401U, A2Z406U, B Z411U and Orr Z421U for Reverse Grouping, Antibody Screen (untreated)
Z451U, Antibody Identification Panels (papain-treated and untreated) Z471U and Z472U	  	Alba
 Bioscience
 Limited
	  	Reverse
 grouping,

detection/
identification
of
 unexpected

antibodies
	  	Alba Manufacturer
/ QBD Distributor	  	13 January
2012
		  	Polyclonal blood grouping reagents, Anti-K Z131, Anti-Fya Z151, Anti-Fyb Z153, Anti-s Z186, Anti-Wra Z231	  	Alba
 Bioscience
 Limited
	  	blood grouping
reagents for
the in vitro
 detection andidentification
of human
group K, Fya,
Fyb, Wra and
s
positive red
blood cells by
the indirect
antiglobulin
test
	  	Alba Manufacturer
/ QBD Distributor	  	27
 September
 2012

 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 US Licensed Products - OEM 
  

							
	 License

Number
	  	 Products
	  	 License Applicant
	  	 Contract Type

	1798	  	Anti-k finished bulk, product code Z649, Anti-Lea finished bulk, product code Z680	  	Biotest Medical Diagnostics GmbH (now BioRad)	  	 Contract
 Manufacturing

Agreement

 510(k) Clearances 
  

									
	 510(k)

Number
	  	 Products
	  	 Intended Use
	  	 Contract

Type
	  	 510(k)

Clearance Date

	BK050005	  	Quant-Rho® FITC Anti-D, product code Z499	  	For the estimation of FMH by in vitro labelling of RhD positive cells for analysis by flow cytometry.	  	Alba Manufacturer / QBD Distributor	  	27 September 2005
					
	BK070033	  	AlbaQ-Chek® Kit (whole blood controls), product code Z498	  	For use as controls of blood grouping reagents in column agglutination techniques.	  	Alba Manufacturer / OCD Distributor	  	18 June 2007

  

									
	 510(k)

Number
	  	 Products
	  	 Intended Use
	  	 Contract

Type
	  	 510(k)

Clearance Date

	BK080027	  	Anti-D Control, product code Z271	  	For use as a negative control in conjunction with Alba Bioscience monoclonal Anti-D reagents.	  	Alba Manufacturer / QBD Distributor	  	29 July 2008
	BK080051	  	Fetalscreen II, product code Z488	  	Qualitative Screening Test for RhD (Rh0) positive fetal red blood cells in the maternal circulation.	  	Alba Manufacturer / OCD Distributor	  	8 April 2009
	BK090030	  	ALBAcheck® Simulated Whole Blood Control, product code Z489	  	For ABO, Rh and Kell and antibody screening controls on the Immucor Galileo and Echo blood typing systems.	  	Alba Manufacturer / QBD Distributor	  	14 June 2010
	BK100005	  	ALBAcyte® IgG Sensitized Red Blood Cells, product code Z441U	  	For the control of the Indirect Antiglobulin Test (IAT) and Direct Antiglobulin Test (DAT).	  	Alba Manufacturer / QBD Distributor	  	26 August 2010

 510(k) Exempt/RUO/Non-IVD Products 
  

									
	 Category
	  	 Products
	  	 Intended Use
	  	 Contract

Type
	  	 Marketing Date
(First Shipment to
US)

	Non-IVD	  	Competency Training Kit, product code Z275U	  	For use as an internal, self assessment of both individual operators and of antibody screening testing platforms.	  	Alba Manufacturer / QBD Distributor	  	October 2008
					
	RUO	  	ALBAclone® Advanced Partial RhD Typing Kit, product code Z293U	  	For the in vitro classification of human partial RhD and weak D types 1 and 2 by indirect agglutination. The product is not suitable for routine RhD typing.	  	Alba Manufacturer / QBD Distributor	  	October 2004
					
	510(k) Exempt	  	ALBAlect Anti-A1 Lectin, product code Z241U	  	For the in vitro detection and identification of human A1 red blood cells by direct agglutination.	  	Alba Manufacturer / QBD Distributor	  	December 2007
					
	510(k) Exempt	  	BSA 22%, product code Z305U	  	For the potentiation of agglutination reactions in blood group serology tests.	  	Alba Manufacturer / QBD Distributor	  	October 2009
					
	510(k) Exempt	  	ALBAhance PEG 4000, product code Z312U	  	Potentiating reagent for the detection of red cell antibodies in human serum or plasma.	  	Alba Manufacturer / QBD Distributor	  	June 2010
					
	510(k) Exempt	  	LISS Additive Reagent, product code Z333U	  	For use as a potentiator in antibody detection, antibody identification and compatibility test procedures.	  	Alba Manufacturer / QBD Distributor	  	June 2010
					
	Evaluation Kit	  	QBD Evaluation Kit (A,B,AB,D), product code ZEVL1	  	Detection and identification of human group A, B, AB, RhD red blood cells by direct agglutination	  	Alba Manufacturer / QBD Distributor	  	October 2009

 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 Licenses - Canada 

Health Canada Licences – Class III 
  

									
	 Classification
	  	 Products
	  	 License

Number
	  	 Applicant
	  	 Approval Date

	III	  	Monoclonal ABO Typing Serums Z001, Z011, Z015, Z021, Z023	  	Licence 74799	  	Alba Bioscience Limited	  	29 August 2007
	III	  	Monoclonal Rhesus Antisera Z031, Z036, Z039, Z041, Z063, Z073, Z083, Z113	  	Licence 76758	  	Alba Bioscience Limited	  	04 April 2008
	III	  	Rare Monoclonal Antisera Z137, Z171, Z176, Z212, Z217, Z223, Z244	  	Licence 77736	  	Alba Bioscience Limited	  	06 August 2008
	III	  	Rare Polyclonal Antisera Z103, Z131, Z139, Z151, Z153, Z186, Z191, Z221, Z231, Z248	  	Licence 77539	  	Alba Bioscience Limited	  	09 July 2008
	III	  	Anti-Human Globulin Reagents Z350, Z356	  	Licence 76757	  	Alba Bioscience Limited	  	04 April 2008
	III	  	A1 and B (Reverse Grouping) Red Cells (3%) Z401/Z411	  	Licence 75911	  	Alba Bioscience Limited	  	17 December 2007
	III	  	Anti-Human Globulin Control Serums Z251, Z261, Z262, Z263, Z264, Z265, Z271	  	Licence 75975	  	Alba Bioscience Limited	  	31 December 2007
	III	  	ALBAclone® Advanced Partial RhD Typing Kit Z293	  	Licence 77927	  	Alba Bioscience Limited	  	10 June 2008
	III	  	Anti-A1 Lectin Dolichos biflorus blood grouping serum Z241	  	Licence 76468	  	Alba Bioscience Limited	  	04 March 2008
	III	  	O Adult I Cells (2-3%) Z431	  	Licence 76469	  	Alba Bioscience Limited	  	04 March 2008
	III	  	IgG Sensitised Cells (5%) Z441	  	Licence 76470	  	Alba Bioscience Limited	  	04 March 2008
	III	  	3 Cell Antibody Screening Z451/Z452	  	Licence 76471	  	Alba Bioscience Limited	  	04 March 2008
	III	  	10 Cell Antibody Identification Z471/Z472	  	Licence 76472	  	Alba Bioscience Limited	  	04 March 2008
	III	  	Red Cells used for Controls of Serological Testing – Not Rhesus grouping Z406, Z413, Z414, Z415, Z435	  	Licence 77363	  	Alba Bioscience Limited	  	13 June 2008
	III	  	Red Cells for Control of Rhesus Grouping Procedures Z416, Z417, Z421, Z427	  	Licence 77364	  	Alba Bioscience Limited	  	13 June 2008
	III	  	AlbaQ-Chek Simulated Whole Blood Controls Z489	  	Licence 76004	  	Alba Bioscience Limited	  	10 January 2008
	III	  	Fetalscreen II Z488	  	Licence 82903	  	Alba Bioscience Limited	  	10 January 2008

 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 Health Canada Licences Class II 
  

									
	 Classification
	  	 Products
	  	 License

Number
	  	 Applicant
	  	 Approval Date

	II	  	PBS Concentrate Z332	  	Licence 73171	  	Alba Bioscience Limited	  	23 January 2007
	II	  	ALBAcheck®- BGS AB Serum Z281	  	Licence 73172	  	Alba Bioscience Limited	  	23 January 2007
	II	  	ALBAcheck®- BGS Proficiency Test Z275	  	Licence 73173	  	Alba Bioscience Limited	  	23 January 2007
	II	  	Quant-RhoTM FITC Anti-D Z499	  	Licence 73175	  	Alba Bioscience Limited	  	23 January 2007
	II	  	Anti-Human C3 Z360	  	Licence 73609	  	Alba Bioscience Limited	  	20 March 2007
	II	  	Enzyme Control Glycine soja Z256	  	Licence 73610	  	Alba Bioscience Limited	  	20 March 2007
	II	  	0.5% Bromelin Z311	  	Licence 73611	  	Alba Bioscience Limited	  	20 March 2007
	II	  	1% Papain Z316	  	Licence 73612	  	Alba Bioscience Limited	  	20 March 2007

  

									
	 MATERIAL LICENSE AGREEMENT(S)
	  	 
	 Name and Address

of Licensor
	  	 Name and Date of
License Agreement
	  	 Exclusive License?

(Yes/No)
	  	 Restrictions

to grant a
 lien?

(Yes/No)
	  	 Default or

Termination
 affect
Agent’s
 ability to sell

or assign?

(Yes/No)

	 The Technology Partnership PLC (“TTP”) located at Melbourn Science Park, Melbourn,

Hertfordshire, SG8 6EE
	  	Master Development Agreement dated January 4, 2010	  	Partially exclusive.	  	N	  	No, so long as the license was granted prior to default or termination.
					
	*Please note that all Intellectual Property arising out of this TTP Master Development Agreement is licensed Intellectual Property.	  		  		  		  	

 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 PRODUCTS SCHEDULE 

See the products in the above Intellectual Property Schedule, all of which are incorporated by reference herein. 

See the “Marked Products” section of Exhibit C to the Intellectual Property Security Agreement, all of which are incorporated by reference herein.

 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 REQUIRED PERMITS SCHEDULE 

See the following sections of the Intellectual Property Schedule: US Establishment Registration, US Agent, 510(k) Clearances, 510(k) Exempt/RUO/Non-IVD
Products, Health Canada Licenses – Class III, and Health Canada Licenses Class II; all of which are incorporated by reference herein. 
 [***]:
CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION. 

 MINIMUM NET PRODUCT REVENUE SCHEDULE 

 

					
	 TESTING DATE
	  	MINIMUM NET
PRODUCT REVENUES
($000s)	 	 TESTING PERIOD

	 January 15, 2014
	  	$[***]	 	December 2012-November 2013
	 February 15, 2014
	  	$[***]	 	January 2013-December 2013
	 March 15, 2014
	  	$[***]	 	February 2013-January 2014
	 April 15, 2014
	  	$[***]	 	March 2013-February 2014
	 May 15, 2014
	  	$[***]	 	April 2013-March 2014
	 June 15, 2014
	  	$[***]	 	May 2013-April 2014
	 July 15, 2014
	  	$[***]	 	June 2013-May 2014
	 August 15, 2014
	  	$[***]	 	July 2013-June 2014
	 September 15, 2014
	  	$[***]	 	August 2013 - July 2014
	 October 15, 2014
	  	$[***]	 	September 2013 - August 2014
	 November 15, 2014
	  	$[***]	 	October 2013 - September 2014
	 December 15, 2014
	  	$[***]	 	November 2013 - October 2014
	 January 15, 2015
	  	$[***]	 	December 2013 - November 2014
	 February 15, 2015
	  	$[***]	 	January 2014- December 2014
	 March 15, 2015
	  	$[***]	 	February 2014 - January 2015
	 April 15, 2015
	  	$[***]	 	March 2014 - February 2015
	 May 15, 2015
	  	$[***]	 	April 2014- March 2015
	 June 15, 2015
	  	$[***]	 	May 2014 - April 2015
	 July 15, 2015
	  	$[***]	 	June 2014- May 2015
	 August 15, 2015
	  	$[***]	 	July 2014 - June 2015
	 September 15, 2015
	  	$[***]	 	August 2014 - July 2015
	 October 15, 2015
	  	$[***]	 	September 2014 - August 2015
	 November 15, 2015
	  	$[***]	 	October 2014 - September 2015
	 December 15, 2015
	  	$[***]	 	November 2014- October 2015
	 January 15, 2016
	  	$[***]	 	December 2014 - November 2015
	 February 15, 2016
	  	$[***]	 	January 2015- December 2015
	 March 15, 2016
	  	$[***]	 	February 2015- January 2016
	 April 15, 2016
	  	$[***]	 	March 2015- February 2016
	 May 15, 2016
	  	$[***]	 	April 2015-March 2016
	 June 15, 2016
	  	$[***]	 	May 2015- April 2016
	 July 15, 2016
	  	$[***]	 	June 2015- May 2016
	 August 15, 2016
	  	$[***]	 	July 2015- June 2016
	 September 15, 2016
	  	$[***]	 	August 2015- July 2016
	 October 15, 2016
	  	$[***]	 	September 2015 - August 2016
	 November 15, 2016
	  	$[***]	 	October 2015- September 2016
	 December 15, 2016
	  	$[***]	 	November 2015-0ctober 2016
	 January 15, 2017
	  	$[***]	 	December 2015-November 2016
	 February 15, 2017
	  	$[***]	 	January 2016-December 2016

 [***]: CONFIDENTIAL PORTIONS OMITTED AND FILED SEPARATELY WITH THE COMMISSION.EX-10.2

 Exhibit 10.2 

Dated 16 February 2012 
 QUOTIENT BIODIAGNOSTICS
HOLDINGS LIMITED 
 and 
 PAUL COWAN 

 

	
	   

 SERVICE AGREEMENT 
  

	
	   

 Speechly Bircham LLP 
 6 New
Street Square 
 London 
 EC4A 3LX 

Tel: +44 (0)20 7427 6400 
 Fax: +44 (0)20 7427 6600 

Ref         344087 

 Contents 
  

							
	 	  	 	  	Page	 
			
	1.	  	DEFINITIONS AND INTERPRETATION	  	 	1	  
			
	2.	  	APPOINTMENT	  	 	2	  
			
	3.	  	TERM	  	 	3	  
			
	4.	  	DUTIES OF THE EXECUTIVE	  	 	3	  
			
	5.	  	HOURS OF WORK	  	 	3	  
			
	6.	  	PRINCIPAL PLACE OF WORK	  	 	4	  
			
	7.	  	SALARY	  	 	4	  
			
	8.	  	EXPENSES	  	 	4	  
			
	9.	  	MOBILE PHONE	  	 	4	  
			
	10.	  	HOLIDAYS	  	 	5	  
			
	11.	  	SICKNESS OR INJURY	  	 	5	  
			
	12.	  	TERMINATION OF AND SUSPENSION FROM EMPLOYMENT	  	 	5	  
			
	13.	  	OBLIGATIONS DURING EMPLOYMENT	  	 	9	  
			
	14.	  	OBLIGATIONS AFTER EMPLOYMENT	  	 	11	  
			
	15.	  	DISCIPLINARY AND GRIEVANCE PROCEDURE	  	 	13	  
			
	16.	  	COLLECTIVE AGREEMENTS	  	 	13	  
			
	17.	  	DEDUCTIONS	  	 	13	  
			
	18.	  	ENTIRE AGREEMENT	  	 	13	  
			
	19.	  	DATA PROTECTION	  	 	14	  
			
	20.	  	RETIREMENT	  	 	14	  
			
	21.	  	E-MAIL/TELEPHONE CALLS	  	 	14	  
			
	22.	  	RELEASES AND WAIVERS	  	 	14	  
			
	23.	  	GOVERNING LAW AND JURISDICTION	  	 	15	  

 THIS AGREEMENT is made the 16 day of February 2012 

BETWEEN: 
  

	1.	QUOTIENT BIODIAGNOSTICS HOLDINGS LIMITED (company number 109886) whose registered office is at PO Box 1075, Elizabeth House, 9 Castle, Jersey JE4 2QP (“the Company”); and

  

	2.	PAUL COWAN of Chalet Cléa, Route des Sapins 4, 3963 Crans Montana, Switzerland (“the Executive”). 

IT IS AGREED as follows: 
  

	1.	DEFINITIONS AND INTERPRETATION 

  

	1.1	In this Agreement, unless the context otherwise requires, the following expressions have the following meanings: 

“Agreement” means this Agreement (including any schedule or annexure to it and any document referred to in it or in agreed
form); 
 “Board” means the board of directors of the Company from time to time and includes any committee of the Board duly
appointed by it; 
 “Business” means scientific research and development and any trade or other commercial activity which is
carried on by the Company, or which the Company shall have determined to carry on with a view to profit in the immediate or foreseeable future; 

“Confidential Information” any trade secrets or other information which is confidential, commercially sensitive and is not in
the public domain relating or belonging to the Company including but not limited to information relating to the business methods, corporate plans, management systems, finances, new business opportunities, research and development projects, marketing
or sales of any past, present or future product or service, secret formulae, processes, inventions, designs, know-how discoveries, technical specifications and other technical information relating to the creation, production or supply of any past,
present or future product or service of the Company, lists or details of clients, potential clients or suppliers or the arrangements made with any client or supplier and any Information in respect of which the Company owes an obligation of
confidentiality to any third party; 
 “Duties” means the duties of the Executive as set out in clause 4; 

“Employment” means the Executive’s employment under this Agreement; 

“Relevant Period” means the period of 12 months ending with the Termination Date; 

  
 1 

 “Restricted Business” means any part of the Business in which the Executive
shall have been directly concerned in the course of the Employment at any time in the Relevant Period; 
 “Termination Date”
means the date on which the Employment terminates. 
  

	1.2	In this Agreement, unless the context otherwise requires: 

  

	 	1.2.1	words in the singular include the plural and vice versa and words in one gender include any other gender; 

  

	 	1.2.2	a reference to a statute or statutory provision includes: 

  

	 	(a)	any subordinate legislation (as defined in Section 21(1), Interpretation Act 1978) made under it; 

  

	 	(b)	any statute or statutory provision which modifies, consolidates, re-enacts or supersedes it; 

  

	 	1.2.3	a reference to: 

  

	 	(a)	a “person” includes any individual, firm, body corporate, association or partnership, government or state (whether or not having a separate legal personality); 

 

	 	(b)	clauses and schedules are to clauses and schedules of this Agreement and references to sub-clauses and paragraphs are references to sub-clauses and paragraphs of the clause or schedule in which they appear;

  

	1.3	The table of contents and headings are for convenience only and shall not affect the interpretation of this Agreement. 

  

	1.4	Except where otherwise stated, words and phrases defined in the City Code on Take-overs and Mergers or in the Companies Act 1985 have the same meaning in this Agreement. 

 

	2.	APPOINTMENT 

  

	2.1	The Company appoints the Executive and the Executive agrees to serve as Chairman of the Company or in such other capacity as the Company may from time to time require on the terms set out in this Agreement.

  

	2.2	The Executive warrants that he is free to enter into this Agreement and is not bound by, nor subject to any court order, arrangement, obligation, restriction or undertaking (contractual or otherwise) which prohibits or
restricts the Executive from entering into this Agreement or performing the Duties. 

  
 2 

	3.	TERM 

 The Employment commenced on      February 2012 and
unless terminated in accordance with clause 12, shall, subject to clause 20, continue until terminated by either party giving to the other not less than twelve months’ prior written notice. 

 

	4.	DUTIES OF THE EXECUTIVE 

  

	4.1	The Executive shall carry out such duties as may be agreed between the Executive and the Board from time to time and exercise the powers consistent with such duties. 

 

	4.2	The Executive shall at all times during the Employment 

  

	 	4.2.1	devote the whole of his time, attention, skill and ingenuity during working hours to his duties under this Agreement; 

  

	 	4.2.2	faithfully and using his best endeavours carry out all work consistent with his position which may be required of him; 

  

	 	4.2.3	comply with all the Company’s rules, regulations, policies and procedures from time to time in force; 

  

	 	4.2.4	perform the Duties faithfully and diligently; 

  

	 	4.2.5	obey all lawful and reasonable directions of the Board, observe such restrictions or limitations as may from time to time be imposed by the Board upon the Executive’s performance of the Duties and implement and
abide by any relevant Company policy which may be promulgated or operated in practice from time to time; 

  

	 	4.2.6	use best endeavours to promote the interests of the Company and shall not do or willingly permit to be done anything which is harmful to those interests; and 

 

	 	4.2.7	keep the Board fully informed (in writing if so requested) of the Executive’s conduct of the business or affairs of the Company and provide such explanations as the Board may require. 

 

	5.	HOURS OF WORK 

  

	5.1	The Executive shall devote 150 full-time equivalent days per annum to fulfilling his Duties, such days to be set as necessary to fulfil the Duties set out in clause 4. The Executive shall not be entitled to receive any
additional remuneration should he be required to work more than 150 full-time equivalent days per annum. 

  

	5.2	The Executive’s hours of work shall be the Company’s normal office hours of 9.00 am to 5.15 p.m and such further hours as may be necessary for the proper discharge of the Duties, The Executive shall not be
entitled to receive any additional remuneration for work outside the Company’s normal office hours. 

  
 3 

	5.3	The Executive acknowledges that he may work in excess of an average of 48 hours in any one period of 7 calendar days if so requested by the Company and consents to do so. The Executive shall give the Company 3
months’ prior notice if he wishes the limit on weekly working time specified in the Working Time Regulations 1998 to apply to the Employment. 

  

	6.	PRINCIPAL PLACE OF WORK 

  

	6.1	The Executive’s principal place of work shall be from home or anywhere else within the United Kingdom or abroad as shall be agreed between the parties. 

 

	6.2	The Executive shall travel to and work on a temporary basis from such locations within the UK and abroad as the Board may reasonably require for the performance of his Duties. 

 

	6.3	There is no current requirement, as at the date of this agreement, for the Executive to work in or outside the United Kingdom for any consecutive period of one month or more. 

 

	7.	SALARY 

  

	7.1	During the Employment the Company shall pay to the Executive a basic salary at the rate of £150,000 per annum. This salary shall accrue from day to day, be payable by equal monthly instalments in arrears on
or before the last day of each month. 

  

	7.2	The Executive’s basic salary shall be reviewed by the Board from time to time. Any increase in the Executive’s salary consequent upon such review will be effective from the effective date specified by the
Board. 

  

	8.	EXPENSES 

  

	8.1	The Company shall reimburse to the Executive all expenses reasonably and properly incurred by the Executive in the performance of the Duties subject to the production of such receipts or other evidence of expenditure as
the Company may reasonably require. 

  

	8.2	Any credit card or charge card supplied to the Executive by the Company shall be used solely for expenses incurred by the Executive in carrying out the Duties. Any such card must be returned by the Executive to the
Company immediately upon the Company’s request. 

  

	9.	MOBILE PHONE 

  

	9.1	For the better performance of the Executive’s Duties he will be provided with a work mobile telephone. The Company will pay the monthly subscription fees and for any work related calls. Please note that the Company
will not pay for any personal calls and payment of any personal calls will be the Executive’s responsibility. 

  
 4 

	9.2	The mobile telephone will remain the property of the Company and the Executive will be required to return it to the Company on request and upon the termination of his employment. 

 

	10.	HOLIDAYS 

  

	10.1	The Company’s holiday year runs from 1 April to 31 March, 

  

	10.2	The Executive shall not be entitled to any paid holiday in each holiday year provided that this shall not affect his entitlement to statutory holidays 

 

	11.	SICKNESS OR INJURY 

  

	11.1	If unable to perform the Duties due to sickness or injury the Executive shall report this fact as soon as possible on the first working day of incapacity to the Board, and provide, so far as practicable, an expected
date of return to work. 

  

	11.2	To be eligible for sick pay under clause 11.3, the Executive must supply the Company with such certification of sickness or injury as the Company may require. 

 

	11.3	If the Executive shall be absent due to sickness or injury duly certified in accordance with the Company’s requirements the Executive shall be paid full basic salary for up to 13 weeks’ absence in any period
of 12 consecutive months. 

  

	11.4	Any remuneration paid under sub-clause 11.3 shall be inclusive of any Statutory Sick Pay to which the Executive is entitled or other benefits recoverable by the Executive (whether or not recovered) which may be deducted
from it. 

  

	11.5	The Executive accepts that with his consent (such consent not to be unreasonably withheld or delayed) at any time during the Employment, the Executive shall, at the request and expense of the Company: 

 

	 	11.5.1	consent to an examination by a doctor to be selected by the Company; and 

  

	 	11.5.2	authorise this doctor to disclose to and discuss with the Company’s medical adviser, or other nominated officer of the Company, the results of or any matter arising out of this examination. 

 

	12.	TERMINATION OF AND SUSPENSION FROM EMPLOYMENT 

  

	12.1	Subject to the remainder of this clause 12, the Company may terminate the Executive’s employment by serving notice upon him in accordance with clause 3. 

  
 5 

	12.2	Immediate dismissal 

  

	 	12.2.1	The Company may by written notice terminate the Employment without notice or pay in lieu of notice if the Executive: 

  

	 	(a)	commits any act of gross misconduct or is guilty of any conduct which may in the reasonable opinion of the Board, bring the Company into disrepute or is calculated or likely prejudicially to affect the interests of the
Company, whether or not the conduct occurs during or in the context of the Executive’s Employment; 

  

	 	(b)	is convicted of any criminal offence punishable with imprisonment (other than an offence under road traffic legislation in the United Kingdom or elsewhere for which he is not sentenced to any term of imprisonment
whether immediate or suspended); 

  

	 	(c)	commits any act of dishonesty relating to the Company, any of its employees or otherwise; 

  

	 	(d)	commits a material breach of the terms and conditions of this Agreement or repeats or continues (after a written warning) any other breach of such terms and conditions, including any failure to carry out the Duties
efficiently, diligently or competently; 

  

	 	(e)	becomes prohibited by law from being a director, is removed from office pursuant to the Company’s articles of association, or, except at the request of the Company or pursuant to clause 12.7.1, resigns as a
director; 

  

	 	(f)	becomes of unsound mind or a patient within the meaning of the Mental Health Act 1983 so that in the opinion of the Board he is unable to perform the Duties; 

 

	 	(g)	becomes bankrupt or makes any arrangement or composition with his creditors generally; or 

  

	 	(h)	is the subject of or causes the Company to be the subject of a penalty or reprimand imposed by any regulatory authority by which the Company is governed or to which its activities are subject. 

 

	12.3	Suspension 

 In order to investigate a complaint against the Executive of misconduct the Company
may suspend the Executive on full pay for so long as may be necessary to carry out a proper investigation and hold any appropriate disciplinary hearing. 
  

	12.4	Dismissal due to ill-health 

 If the Executive is incapable of performing the Duties due to ill
health or accident for a period or periods aggregating at least 28 weeks in any period of 12 months the Company may, by not less than 1 month’s prior written notice (or the statutory minimum notice if longer) given at any time whilst such
incapacity continues and terminate the Employment. 

  
 6 

	12.5	Pay in lieu 

 On either party serving notice for any reason to terminate the Employment or at
any time during the currency of such notice, the Company may elect (but shall not be obliged) to terminate the Employment with immediate effect by notifying the Executive in writing that the Employment is being terminated pursuant to this clause and
undertaking to pay to the Executive a sum equivalent to the Executive’s basic salary for the unexpired portion of the Executive’s contractual notice entitlement. The Company will pay the salary due and payable under this sub-clause
(subject to deduction of tax and national insurance contributions at source) within 14 days of the Termination Date. 
  

	12.6	Garden leave 

  

	 	12.6.1	After notice to terminate the Employment has been given by the Executive or the Company, the Company may for all or part of the duration of the notice period in its absolute discretion: 

 

	 	(a)	require the Executive not to perform any of the Duties; 

  

	 	(b)	require the Executive to undertake any alternative duties or special projects outside the scope of his normal duties and may appoint any other person to undertake the Duties; 

 

	 	(c)	require the Executive not to have any contact with clients of the Company; 

  

	 	(d)	require the Executive not to have any contact with such employees or suppliers of the Company as the Company shall determine; 

  

	 	(e)	require the Executive to disclose any attempted contact with him made by any client, employee or supplier with whom the Executive has been required to have no contact pursuant to this clause; 

 

	 	(f)	require the Executive to take any accrued holiday entitlement or prohibit the Executive from taking any accrued holiday entitlement; 

 

	 	(g)	provided always that throughout the period of any such action and subject to the other provisions of this Agreement the Executive’s salary and contractual benefits shall not cease to accrue or be paid.

  

	 	12.6.2	The Executive acknowledges that such action taken on the part of the Company shall not constitute a breach of this Agreement of any kind whatsoever nor shall the Executive have any claim against the Company in respect
of any such action. 

  
 7 

	 	12.6.3	The Executive acknowledges that during any such period of garden leave, the terms of this Agreement and the obligations owed by the Executive generally to the Company, including without limitation the Executive’s
duties of good faith and fidelity to the Company shall continue. 

  

	 	12.6.4	During any such period of garden leave the Executive must not work for any other person or on his own account and shall remain readily contactable and available to work for the Company. Should the Executive fail to be
available for work at any time having been requested by the Company to do so, the Executive’s right to salary and contractual benefits in respect of such period of non-availability shall be forfeit notwithstanding any other provision of this
Agreement. 

  

	12.7	Effect of termination 

  

	 	12.7.1	On the Termination Date or at any time after notice is given by the Company or the Executive to terminate the Employment, the Executive shall, at the request of the Board: 

 

	 	(a)	resign (without prejudice to any claims which he may have against the Company arising out of the Employment or its termination) from all and any offices which he may hold as a director of the Company and from all other
appointments or offices which he holds as nominee of representative of the Company; and 

  

	 	(b)	transfer without payment to the Company or as the Company may direct any shares held by him for the purposes only of fulfilling any requirement in the Company’s articles of association that a director holds shares
in the Company and any shares held by him on trust for the Company. 

  

	 	12.7.2	If the Executive should fail to do so within 7 days the Company is irrevocably authorised to appoint some person in his name and on his behalf to sign any documents or do any things necessary or requisite to effect such
resignation(s). 

  
 8 

	13.	OBLIGATIONS DURING EMPLOYMENT 

  

	13.1	Assignment of Intellectual Property Rights 

  

	 	13.1.1	It is agreed that the Executive is in a position of special responsibility and under a special obligation to further the interests of the Company. Accordingly, any discovery, invention, secret process or improvement in
procedure discovered, invented, developed or devised by the Executive during his employment with the Company (and whether or not in conjunction with a third party) affecting or relating to the business of the Company or capable of being used or
adapted for use in it, shall immediately be disclosed by the Executive to the Board of the Company and subject to such rights as the Executive may have under the Patents. Act 1977, will belong to, and be the absolute property of the Company.

  

	 	13.1.2	The Executive acknowledges that the Company is the sole owner of any and all Intellectual Property Rights and, insofar as any of the Intellectual Property Rights are not vested in the Company and in consideration of the
salary payable to the Executive by the Company the Executive assigns to the Company with full title guarantee the entire copyright (including future copyright) and all other rights and interests of whatsoever nature in and to the Intellectual
Property Rights and relating to the Company together with the right to take proceedings and recover damages and obtain all other remedies for past infringements in respect thereof throughout the world for the full period of copyright (and of any
analogous rights) and all revivals, renewals, extensions and novations thereof and thereafter (so far as possible) in perpetuity together with the right to the same in any manner and through any media as the Company shall in its absolute discretion
decide. 

  

	 	13.1.3	The Executive shall transfer to the Company all relevant lending and rental rights arising out of the Intellectual Property Rights throughout the world and the Executive irrevocably and unconditionally confirms that the
remuneration payable to him under the terms of this Contract of Employment includes equitable remuneration, for the right to exploit all rental rights. 

  

	 	13.1.4	The Executive unconditionally and irrevocably waives all moral rights conferred by the Copyright Designs and Patents Act 1988 and all other moral and author’s rights of a similar nature under the laws of any other
jurisdiction. 

  

	 	13.1.5	For the purposes of this clause 13 “Intellectual Property Rights” shall mean all copyrights, patents, utility models, trademarks, rights in designs, database rights, goodwill, in each case whether
registered or unregistered or the subject of a pending application for registration, all legal rights protecting the confidentiality of any information or materials and all other rights of a similar nature anywhere in the world in any work created
by the Executive during his employment by the Company and in respect of the Company. 

  
 9 

	 	13.1.6	The Executive shall, at the expense of the Company and upon its request (during his employment by the Company) execute all such document as may be necessary to vest such rights, title and interest in the Company.

  

	 	13.1.7	The Executive shall, at the expense of the Company and upon its request (during his employment by the Company) executive all such documents as may be necessary to vest such rights, title and interest in the Company.

  

	13.2	Power of attorney 

 The Executive irrevocably appoints the Company as his attorney in his name
and on his behalf to execute documents, to use his name and to do all things which may be necessary or desirable for the Company to obtain for itself or its nominee the full benefit of the provisions of clause 13 and a certificate in writing signed
by any director or the Company Secretary that any instrument or act falls within the authority conferred by this paragraph shall be conclusive evidence that such is the case so far as any third party is concerned. 

 

	13.3	Conflict of Interest 

  

	 	13.3.1	During the Employment, the Executive shall not: 

  

	 	(a)	other than in the proper performance of his duties directly or indirectly disclose divulge or communicate to any person or persons whatsoever or make use of any Confidential Information to which he has or may in the
course of his employment become aware of relating to the business of the Company; and 

  

	 	(b)	at any time (whether during or outside normal working hours) take any preparatory steps to become engaged or interested in any capacity whatsoever in any business or venture which is in or is intended to enter into
competition with the Business. 

  

	 	13.3.2	The Executive shall promptly disclose in writing to the Board all his interests (including but not limited to shareholdings and directorships) in any businesses, whether or not of a commercial or business nature.

  
 10 

	 	13.3.3	The Executive shall not, at any time during the Employment, whether directly or indirectly be employed, engaged or concerned in any capacity whatsoever in the conduct of any activity or business which is similar to or
competes with any activity or business carried on by the Company (except as a representative of the Company or with the written consent of the Board.) 

  

	 	13.3.4	The Executive shall, at any time during the Employment or following its termination at the request of the Company return to the Company or at the Company’s request, shall destroy: 

 

	 	(a)	any documents, drawings, designs, computer files or software, visual or audio tapes or other materials containing information (including, without limitation, Confidential Information) relating to the Company’s
business created by in the possession of or under the control of the Executive; and 

  

	 	(b)	any other property of the Company in his possession or under his control. 

  

	 	13.3.5	The Executive shall not make or keep or permit any person to make or keep on his behalf any copies or extracts of the items referred to in sub-clause 13.3.4 in any medium or form. 

 

	14.	OBLIGATIONS AFTER EMPLOYMENT 

  

	14.1	The Executive shall not directly or indirectly, whether on the Executives own behalf or on behalf of another person: 

  

	 	14.1.1	for the period of 9 months following the Termination Date: 

  

	 	(a)	so as to compete with the Company in any part of the Restricted Business solicit or entice away or seek to solicit or entice away or deal with any person who was at any time during the Relevant Period a client of the
Company with whom: 

  

	 	(i)	the Executive shall have had material dealing in the course of the Employment at any time in the Relevant Period; 

  

	 	(ii)	any employee of the Company who is under the Executives control shall have had material dealing in the course of their employment with the Company during the Relevant Period; 

 

	 	(iii)	the Executive shall have had material dealings in the course of the Employment at any time in the Relevant Period and who, to the Executives knowledge, was at the Termination Date negotiating with the Company with a
view to dealing with that company as a client; 

  
 11 

	 	(b)	solicit or entice away or seek to solicit or entice away from the Company any person who is and was at the Termination Date employed or engaged by the Company in any part of the Restricted Business in a senior
managerial, technical, supervisory, sales, marketing or risk assessment capacity and was a person with whom the Executive had material dealings in the course of the Employment during the Relevant Period; 

 

	 	(c)	employ or engage any person who is and was at the Termination Date employed or engaged by the Company in any part of the Restricted Business in a senior managerial, technical, supervisory, sales, marketing or risk
assessment capacity and was a person with whom the Executive had material dealings in the course of the Employment during the Relevant Period; or 

  

	 	(d)	so as to compete with the Company in any part of the Restricted Business seek to entice away from the Company or otherwise solicit or interfere with the relationship between the Company and any supplier of such company
with whom the Executive shall have had material dealings in the course of the Employment during the Relevant Period; 

  

	 	14.1.2	at any time after the Termination Date: 

  

	 	(a)	induce or seek to induce by any means involving the disclosure or use of Confidential Information any customer to cease dealing with the Company or to restrict or vary the terms upon which it deals with the Company;

  

	 	(b)	be held out or represented by the Executive or any other person, as being in any way connected with or interested in the Company; or 

 

	 	(c)	disclose, divulge, print, publish or communicate to any person or persons whatsoever or make use of any Confidential Information. 

  

	14.2	Any period of Garden Leave served by the Executive pursuant to clause 12.6 shall reduce the 9 month period referred to in clause 14.1.1 by an equal period of time. 

 

	14.3	In the event that any one or any part of the restrictions set out in this clause shall be rendered or judged invalid or unenforceable such restriction or part shall be deemed to be severed from this agreement and such
invalidity or unenforceability shall not in any way affect the validity of the remaining restrictions. 

  
 12 

	14.4	The Executive acknowledges that the restrictions contained in this clause shall operate for the benefit of any business carried on by the Company and such restrictions shall be enforceable against the Executive by any
subsequent owner of the business carried on by the Company. 

  

	15.	DISCIPLINARY AND GRIEVANCE PROCEDURE 

  

	15.1	There are no specific disciplinary rules or procedures applicable to the Executive. Any matters concerning the Executive’s unsatisfactory conduct or performance will be dealt with by the Board. An appeal against
any disciplinary decision should be made by the Executive in writing to the Board, whose decision will be final. The Board will however observe all statutory requirements in all disciplinary matters. 

 

	15.2	If the Executive has any grievance relating to his Employment (other than one relating to a disciplinary decision) he should refer such grievance to the Board and if the grievance is not resolved by discussion with him
it will be referred for resolution to the Board, whose decision shall be final. Again, the Company will observe all statutory requirements in all grievance matters. 

 

	16.	COLLECTIVE AGREEMENTS 

 There are no collective agreements which affect the terms and
conditions of the Executives employment. 
  

	17.	DEDUCTIONS 

 The Executive consents to the deduction at any time from any salary or other
sum due from the Company to the Executive including any payment on termination of employment, of sums owed by the Executive to the Company either by way of a loan, overpaid salary with respect to holiday where the Executive has taken more holiday
than his accrued entitlement at the date of termination of employment or expenses. 
  

	18.	ENTIRE AGREEMENT 

 This Agreement together with any documents referred to in this
Agreement sets out the entire agreement and understanding between the parties and supersedes all prior agreements, understandings or arrangements (oral or written) in respect of the employment or engagement of the Executive by the Company. No
purported variation of this Agreement shall be effective unless it is in writing and signed by or on behalf of each of the parties. 

  
 13 

	19.	DATA PROTECTION 

  

	19.1	For the purposes of complying with the Data Protection Act 1998 the Executive agrees to provide the Company or any Associated Company with any personal data and sensitive personal data relating to him that either may
request and he further consents to the holding and processing (in manual, electronic or any other form) of such data by the Company and/or any Associated Company and/or any agent or third party nominated by the Company and bound by a duty of
confidentiality, for the purpose of: 

  

	 	19.1.1	employee related administration; 

  

	 	19.1.2	processing his file and management of its business; 

  

	 	19.1.3	compliance with applicable procedures, laws and regulations: 

  

	 	(a)	providing data to external suppliers for the provision and administration of his remuneration and any benefits and any benefits; and/or 

 

	 	(b)	to evaluate the efficiency of the Company’s and any Associated Companies’ business systems. 

The Executive recognises his responsibilities for compliance with data protection legislation and that failure to comply with such legislation
may result in personal criminal liability as well as disciplinary action. 
  

	20.	RETIREMENT 

 The Company’s normal retirement age is 65. 

 

	21.	E-MAIL/TELEPHONE CALLS 

 The Company has the right to intercept, monitor and review all
telephone calls, e-mails and attachments which are at any time on or within its telephone or email systems. 
  

	22.	RELEASES AND WAIVERS 

  

	22.1	The Company may, in whole or in part, release, compound, compromise, waive or postpone, in its absolute discretion, any liability owed to it or right granted to it in this Agreement by the Executive without in any way
prejudicing or affecting its rights in respect of any part of that liability or any other liability or right not so released, compounded, compromised, waived or postponed. 

 

	22.2	No single or partial exercise, or failure or delay in exercising any right, power or remedy by the Company shall constitute a waiver by it of, or impair or preclude any further exercise of, that or any right, power or
remedy arising under this Agreement or otherwise. 

  
 14 

	23.	GOVERNING LAW AND JURISDICTION 

  

	23.1	This Agreement shall be governed by and construed in accordance with English law. 

  

	23.2	Each of the parties irrevocably submits for all purposes in connection with this Agreement to the exclusive jurisdiction of the English courts. 

This Agreement has been executed and delivered as a Deed on the date appearing at the head of page 1 

 

					
	EXECUTED as a DEED by	  	)	  	
	QUOTIENT BIODIAGNOSTICS	  	)	  
	HOLDINGS LIMITED	  	)	  
	acting by	  	)	  
	a Director, in the presence of:	  	)	  
	
	Signature of Witness: /s/ Erin O’Brien
		
	Name: Erin O’Brien	  	
		
	Address: San Diego, CA	  	
		
	Occupation: Paralegal	  	
			
	EXECUTED as a DEED by	  	        )	  	
	PAUL COWEN	  	        )	  
	acting by	  	        )	  
	a Director, in the presence of:	  	        )	  
	
	Signature of Witness: /s/ Erin O’Brien
			
	Name: Erin O’Brien	  		  	
		
	Address: San Diego, CA	  	
	
	Occupation: Paralegal

  
 15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]